New concepts: present in TDEByNameForProduction-06.12d.xml but not in TDEByNameForProduction-06.11d2.xml name kind FACT-BR_Questionnaire NCI_Kind Utricle-Associated_Mucosal_Gland_Hyperplasia Findings_and_Disorders_Kind Affy_Constant_Normalization Activity_Kind Affy_Contrasts_Normalization Activity_Kind Affy_Invariant_Set_Normalization Activity_Kind Affy_Loess_Normalization Activity_Kind Affy_Q-Spline_Normalization Activity_Kind Affy_Quantiles_Normalization Activity_Kind Affy_Quantiles_Robust_Normalization Activity_Kind N_4-Ethoxyphenyl_Retinamide Chemicals_and_Drugs_Kind Nitrosulindac Chemicals_and_Drugs_Kind NO-Releasing_Ibuprofen Chemicals_and_Drugs_Kind _4-Fluoro-3-Nitroflavone Chemicals_and_Drugs_Kind _4-Hydroxy-3-Nitroflavone Chemicals_and_Drugs_Kind _4-Methoxy-3-Nitroflavone Chemicals_and_Drugs_Kind _3_4-Dinitroflavone Chemicals_and_Drugs_Kind Cyclopamine Chemicals_and_Drugs_Kind Cicloxolone Chemicals_and_Drugs_Kind _2-Hydroxyestrone Chemicals_and_Drugs_Kind Hydroxyflutamide Chemicals_and_Drugs_Kind Glycitein Chemicals_and_Drugs_Kind Methdilazine_Hydrochloride Chemicals_and_Drugs_Kind Allixin Chemicals_and_Drugs_Kind Dimethylselenoxide Chemicals_and_Drugs_Kind Temarotene Chemicals_and_Drugs_Kind Plomestane Chemicals_and_Drugs_Kind _3-Nitroflavone Chemicals_and_Drugs_Kind Licofelone Chemicals_and_Drugs_Kind Resiquimod Chemicals_and_Drugs_Kind Adenocarcinoma_of_the_Rat_Clitoral_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Oviduct EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Clitoral_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Oviduct EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Adenosquamous_Carcinoma_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Adenosquamous_Carcinoma_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Benign_Granulosa_Cell_Tumor_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Benign_Mixed_Muellerian_Tumor_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Benign_Mixed_Muellerian_Tumor_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Benign_Sertoli_Cell_Tumor_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Benign_Thecoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Choriocarcinoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Choriocarcinoma_of_the_Rat_Oviduct EO_Findings_and_Disorders_Kind Choriocarcinoma_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Choriocarcinoma_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Cystadenocarcinoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Cystadenoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Decidual_Reaction_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Decidual_Reaction_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Endometrial_Stromal_Polyp_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Endometrial_Stromal_Polyp_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Endometrial_Stromal_Sarcoma_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Endometrial_Stromal_Sarcoma_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Keratoacanthoma_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Keratoacanthoma_of_the_Rat_Vagina EO_Findings_and_Disorders_Kind Malignant_Granulosa_Cell_Tumor_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Malignant_Mixed_Muellerian_Tumor_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Malignant_Mixed_Muellerian_Tumor_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Malignant_Sertoli_Cell_Tumor_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Malignant_Thecoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Clitoral_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Vagina EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Clitoral_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Uterus_ EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Vagina EO_Findings_and_Disorders_Kind Tubulostromal_Adenocarcinoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Tubulostromal_Adenoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Yolk_Sac_Carcinoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Yolk_Sac_Carcinoma_of_the_Rat_Oviduct EO_Findings_and_Disorders_Kind Yolk_Sac_Carcinoma_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Yolk_Sac_Carcinoma_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Adenocarcinoma_Arising_In_Fibroadenoma_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Coagulating_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Extraorbital_Lacrimal_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Harderian_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Intraorbital_Lacrimal_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Lacrimal_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Prostate EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Seminal_Vesicle EO_Findings_and_Disorders_Kind Adenolipoma_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Coagulating_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Extraorbital_Lacrimal_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Harderian_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Intraorbital_Lacrimal_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Lacrimal_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Prostate EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Rete_Testis EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Seminal_Vesicle EO_Findings_and_Disorders_Kind Basal_Cell_Carcinoma_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Benign_Astrocytoma_of_the_Rat_Brain EO_Findings_and_Disorders_Kind Benign_Astrocytoma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Benign_Ependymoma_of_the_Rat_Brain EO_Findings_and_Disorders_Kind Benign_Ependymoma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Benign_Granulosa_Cell_Tumor_of_the_Rat_Testis EO_Findings_and_Disorders_Kind Benign_Meningioma_of_the_Rat_Cerebral_Meninx EO_Findings_and_Disorders_Kind Benign_Meningioma_of_the_Rat_Spinal_Meninx EO_Findings_and_Disorders_Kind Benign_Mixed_Glioma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Benign_Mixed_Tumor_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Benign_Oligodendroglioma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Carcinoma_of_the_Rat_Choroid_Plexus EO_Findings_and_Disorders_Kind Carcinoma_of_the_Rat_Rete_Testis EO_Findings_and_Disorders_Kind Carcinosarcoma_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Fibroadenoma_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Keratoacanthoma_of_the_Rat_External_Ear EO_Findings_and_Disorders_Kind Malignant_Astrocytoma_of_the_Rat_Brain EO_Findings_and_Disorders_Kind Malignant_Astrocytoma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Malignant_Ependymoma_of_the_Rat_Brain EO_Findings_and_Disorders_Kind Malignant_Ependymoma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Malignant_Glioma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Malignant_Intraocular_Schwannoma_of_the_Rat_Eyeball EO_Findings_and_Disorders_Kind Malignant_Melanoma_of_the_Rat_Cerebral_Meninx EO_Findings_and_Disorders_Kind Malignant_Melanoma_of_the_Rat_Spinal_Meninx EO_Findings_and_Disorders_Kind Malignant_Mixed_Glioma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Malignant_Mixed_Tumor_of_the_Rat_Mammary_Gland EO_Findings_and_Disorders_Kind Malignant_Neuromyoblastoma_of_the_Rat_Brain EO_Findings_and_Disorders_Kind Malignant_Neuromyoblastoma_of_the_Rat_Cranial_Nerve EO_Findings_and_Disorders_Kind Malignant_Oligodendroglioma_of_the_Rat_Brain EO_Findings_and_Disorders_Kind Malignant_Oligodendroglioma_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Malignant_Reticulosis_of_the_Rat_Brain EO_Findings_and_Disorders_Kind Malignant_Reticulosis_of_the_Rat_Spinal_Cord EO_Findings_and_Disorders_Kind Malignant_Sertoli_Cell_Tumor_of_the_Rat_Testis EO_Findings_and_Disorders_Kind Malignant_Uveal_Melanoma_of_the_Rat_Eyeball EO_Findings_and_Disorders_Kind Meningeal_Sarcoma_of_the_Rat_Cerebral_Meninx EO_Findings_and_Disorders_Kind Meningeal_Sarcoma_of_the_Rat_Spinal_Meninx EO_Findings_and_Disorders_Kind Ocular_Dermoid_of_the_Rat_Eyeball EO_Findings_and_Disorders_Kind Papilloma_of_the_Rat_Choroid_Plexus EO_Findings_and_Disorders_Kind Rat_Basophilic_Leukemia EO_Findings_and_Disorders_Kind Rat_Eosinophilic_Leukemia EO_Findings_and_Disorders_Kind Rat_Large_Granular_Lymphocyte_Leukemia EO_Findings_and_Disorders_Kind Rat_Lymphoblastic_Lymphoma EO_Findings_and_Disorders_Kind Rat_Lymphocytic_Lymphoma EO_Findings_and_Disorders_Kind Rat_Malignant_Glioma EO_Findings_and_Disorders_Kind Rat_Neutrophilic_Leukemia EO_Findings_and_Disorders_Kind Rat_Pilomatricoma_Type_Benign_Follicle_Hair_Tumor EO_Findings_and_Disorders_Kind Rat_Plasmacytic_Lymphoma EO_Findings_and_Disorders_Kind Rat_Pleomorphic_Lymphoma EO_Findings_and_Disorders_Kind Rat_Trichoepithelioma_Type_Benign_Follicle_Hair_Tumor EO_Findings_and_Disorders_Kind Rat_Trichofolliculoma_Type_Benign_Follicle_Hair_Tumor EO_Findings_and_Disorders_Kind Rat_Tricholemmoma_Type_Benign_Follicle_Hair_Tumor EO_Findings_and_Disorders_Kind Sebaceous_Cell_Adenoma_of_the_Rat_Zymbal_Gland EO_Findings_and_Disorders_Kind Sebaceous_Cell_Carcinoma_of_the_Rat_Zymbal_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Conjunctiva EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_External_Ear EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Eyelid EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Zymbal_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Conjunctiva EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_External_Ear EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Eyelid EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Bronchiole EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Bronchus EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Adenocarcinoma_of_the_Rat_Urinary_Bladder EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Kidney EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Adenoma_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Adenosquamous_Carcinoma_of_the_Rat_Lung EO_Findings_and_Disorders_Kind Adenosquamous_Carcinoma_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Adenosquamous_Carcinoma_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Adenosquamous_Carcinoma_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Amelanotic_Malignant_Melanoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Basal_Cell_Carcinoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Benign_Mesothelioma_of_the_Rat_Pericardium EO_Findings_and_Disorders_Kind Benign_Mesothelioma_of_the_Rat_Peritoneum EO_Findings_and_Disorders_Kind Benign_Mesothelioma_of_the_Rat_Pleura EO_Findings_and_Disorders_Kind Benign_Basal_Cell_Tumor_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Benign_Basosquamous_Tumor_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Carcinoma_of_the_Rat_Kidney EO_Findings_and_Disorders_Kind Carcinoma_of_the_Rat_Lung EO_Findings_and_Disorders_Kind Epithelioid_Mesothelioma_of_the_Rat_Pericardium EO_Findings_and_Disorders_Kind Keratinizing_Cystic_Epithelioma_of_the_Rat_Lung EO_Findings_and_Disorders_Kind Keratoacanthoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Lipoma_of_the_Rat_Kidney EO_Findings_and_Disorders_Kind Liposarcoma_of_the_Rat_Kidney EO_Findings_and_Disorders_Kind Malignant_Mesenchymal_Tumor_of_the_Rat_Kidney EO_Findings_and_Disorders_Kind Malignant_Mesothelioma_of_the_Rat_Pericardium EO_Findings_and_Disorders_Kind Malignant_Mesothelioma_of_the_Rat_Peritoneum EO_Findings_and_Disorders_Kind Malignant_Mesothelioma_of_the_Rat_Pleura EO_Findings_and_Disorders_Kind Malignant_Neuroendocrine_Cell_Tumor_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Malignant_Melanoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Melanotic_Malignant_Melanoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Non-Keratinizing_Epithelioma_of_the_Rat_Lung EO_Findings_and_Disorders_Kind Olfactory_Neuroblastoma_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Papilloma_of_the_Rat_Bronchiole EO_Findings_and_Disorders_Kind Papilloma_of_the_Rat_Bronchus EO_Findings_and_Disorders_Kind Papilloma_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Papilloma_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Rat_Angiolipomatous_Lipoma EO_Findings_and_Disorders_Kind Rat_Myxolipomatous_Lipoma EO_Findings_and_Disorders_Kind Sebaceous_Cell_Adenoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Sebaceous_Cell_Carcinoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Bronchiole EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Bronchus EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Lung EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Renal_Pelvis EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Ureter EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Urethra EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Urinary_Bladder EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Bronchiole EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Bronchus EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Urethra EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Urinary_Bladder EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Skin EO_Findings_and_Disorders_Kind Transitional_Cell_Carcinoma_of_the_Rat_Renal_Pelvis EO_Findings_and_Disorders_Kind Transitional_Cell_Carcinoma_of_the_Rat_Ureter EO_Findings_and_Disorders_Kind Transitional_Cell_Carcinoma_of_the_Rat_Urethra EO_Findings_and_Disorders_Kind Transitional_Cell_Carcinoma_of_the_Rat_Urinary_Bladder EO_Findings_and_Disorders_Kind Transitional_Cell_Papilloma_of_the_Rat_Renal_Pelvis EO_Findings_and_Disorders_Kind Transitional_Cell_Papilloma_of_the_Rat_Ureter EO_Findings_and_Disorders_Kind Transitional_Cell_Papilloma_of_the_Rat_Urethra EO_Findings_and_Disorders_Kind Transitional_Cell_Papilloma_of_the_Rat_Urinary_Bladder EO_Findings_and_Disorders_Kind Squamous_Cell_Papilloma_of_the_Rat_Tongue EO_Findings_and_Disorders_Kind Squamous_Cell_Carcinoma_of_the_Rat_Tongue EO_Findings_and_Disorders_Kind Perillic_Acid Chemicals_and_Drugs_Kind Farnesol Chemicals_and_Drugs_Kind Glabridin Chemicals_and_Drugs_Kind Anticonvulsant_Therapy Activity_Kind Ro_19-2968 Chemicals_and_Drugs_Kind Ro_16-9100 Chemicals_and_Drugs_Kind Thiolutin Chemicals_and_Drugs_Kind Atreleuton Chemicals_and_Drugs_Kind Teratoma_of_the_Rat_Ovary EO_Findings_and_Disorders_Kind Androst-5-en-17-one Chemicals_and_Drugs_Kind Prolinethiuramdisulfide Chemicals_and_Drugs_Kind Gramine Chemicals_and_Drugs_Kind Myristyl_Nicotinate Chemicals_and_Drugs_Kind Acolbifene Chemicals_and_Drugs_Kind Butoxamine_Hydrochloride Chemicals_and_Drugs_Kind Prolinedithiocarbamate Chemicals_and_Drugs_Kind Allylisopropylacetamide Chemicals_and_Drugs_Kind Juvenile_Hormone_III Chemicals_and_Drugs_Kind Chaetomellic_Acid_A_Disodium Chemicals_and_Drugs_Kind N-Desmethyltamoxifen Chemicals_and_Drugs_Kind CISCA_Regimen Chemotherapy_Regimen_Kind IFL-FOLFIRI_Regimen Chemotherapy_Regimen_Kind Waist Anatomy_Kind Hip Anatomy_Kind Processor_Core Equipment_Kind Streaming_SIMD_Extensions Equipment_Kind Graphics_Processing_Unit Equipment_Kind Consensus Properties_or_Attributes_Kind Comparative_Marker_Selection NCI_Kind Consensus_Clustering Activity_Kind log2 Properties_or_Attributes_Kind Preprocess Activity_Kind Smoothing Activity_Kind Neighborhood Properties_or_Attributes_Kind Performing_Laboratory NCI_Kind Central_Laboratory NCI_Kind Concept_Descriptor_Data_Type NCI_Kind PROM1_Gene Gene_Kind Protocol_Identifier_Assigning_Organization NCI_Kind Change-Point_Analysis Activity_Kind Perfect_Match_Probe NCI_Kind Mismatch_Probe NCI_Kind False_Discovery_Rate Activity_Kind Family_Wise_Error_Rate Activity_Kind maxT Activity_Kind Q-Value NCI_Kind Balanced_Permutation Activity_Kind Permutation Activity_Kind Random_Seed NCI_Kind Probe_Summary_Method Activity_Kind Affy_Average_DIfference_Probe_Summary_Method Activity_Kind Affy_Li_Wong_Probe_Summary_Method Activity_Kind Affy_MAS_Probe_Summary_Method Activity_Kind Affy_Median_Polish_Probe_Summary_Method Activity_Kind Affy_Player_Out_Probe_Summary_Method Activity_Kind Remove_Extremes Activity_Kind Remove_Extremes_by_Mean_Criterion Activity_Kind Remove_Extremes_by_Variance_Criterion Activity_Kind Affy_Probe_Correction_Method Activity_Kind MAS_Probe_Correction_Method Activity_Kind PM_Only_Probe_Correction_Method Activity_Kind Subtract_MM_Probe_Correction_Method Activity_Kind Affy_Background_Correction_Method Activity_Kind RMA_Background_Correction_Method Activity_Kind RMA2_Background_Correction_Method Activity_Kind MAS_Background_Correction_Method Activity_Kind Affy_Baseline_Removal_Method Activity_Kind Mean_Baseline_Removal_Method Activity_Kind Median_Baseline_Removal_Method Activity_Kind Pseudo_Median_Baseline_Removal_Method Activity_Kind Pseudo_Mean_Baseline_Removal_Method Activity_Kind No_Pressure_Medical_Device_Problem Properties_or_Attributes_Kind caExpresso_Analytic_Service NCI_Kind DNAcopy_Analytic_Service NCI_Kind caPROcess NCI_Kind Inoperable Properties_or_Attributes_Kind Orthodontic_Treatment Activity_Kind Pervasive Properties_or_Attributes_Kind Removable Properties_or_Attributes_Kind Left_Ventricular_Systolic_Dysfunction Findings_and_Disorders_Kind Survey_Administration Activity_Kind Questionnaire_Administration Activity_Kind Chart_Review Activity_Kind Informational_Intervention Activity_Kind Therapy_Preparation Activity_Kind Non-negative_Matrix_Factorization NCI_Kind Bone_Marrow_Donation Activity_Kind Systemic_Chemotherapy Activity_Kind Biologic_Sample_Preservation_Procedure Activity_Kind Laboratory_Biomarker_Analysis Activity_Kind Imaging_Biomarker_Analysis Activity_Kind Circumference Properties_or_Attributes_Kind Merge Activity_Kind Two-Sided_Test Activity_Kind All-Pairs_Comparison Activity_Kind One-Versus-All_Comparison Activity_Kind Discretize Activity_Kind Basal_Cell_Hyperplasia_of_the_Rat_Esophagus EO_Findings_and_Disorders_Kind Basal_Cell_Hyperplasia_of_the_Rat_Forestomach EO_Findings_and_Disorders_Kind Acinar_Cell_Hyperplasia_of_the_Rat_Clitoral_Gland EO_Findings_and_Disorders_Kind Acinar_Cell_Hyperplasia_of_the_Rat_Pancreas EO_Findings_and_Disorders_Kind Acinar_Cell_Hyperplasia_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Endometrial_Stromal_Hyperplasia_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Endometrial_Stromal_Hyperplasia_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Bronchiole EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Bronchus EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Lacrimal_Gland_NOS EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Thymus EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_with_Cellular_Atypia_of_the_Rat_Nasal_Cavity EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_with_Cellular_Atypia_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Epithelial_Hyperplasia_with_Cellular_Atypia_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Glandular_Hyperplasia_of_the_Rat_Harderian_Gland EO_Findings_and_Disorders_Kind Glandular_Hyperplasia_of_the_Rat_Uterine_Cervix EO_Findings_and_Disorders_Kind Glandular_Hyperplasia_of_the_Rat_Uterus EO_Findings_and_Disorders_Kind Mesothelial_Hyperplasia_of_the_Rat_Pericardium EO_Findings_and_Disorders_Kind Mesothelial_Hyperplasia_of_the_Rat_Peritoneum EO_Findings_and_Disorders_Kind Mesothelial_Hyperplasia_of_the_Rat_Pleura EO_Findings_and_Disorders_Kind Mucus_Cell_Hyperplasia_of_the_Rat_Bronchiole EO_Findings_and_Disorders_Kind Mucus_Cell_Hyperplasia_of_the_Rat_Bronchus EO_Findings_and_Disorders_Kind Mucus_Cell_Hyperplasia_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Mucus_Cell_Hyperplasia_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Sebaceous_Cell_Hyperplasia_of_the_Rat_Zymbal_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Clitoral_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Esophagus EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_External_Ear EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Forestomach EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Skin_Subcutaneous_Tissue EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Tongue EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Vagina EO_Findings_and_Disorders_Kind Squamous_Cell_Hyperplasia_of_the_Rat_Zymbal_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Bronchiole EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Bronchus EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Clitoral_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Larynx EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Lung EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Nasopharynx EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Paranasal_Sinus EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Preputial_Gland EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Renal_Pelvis EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Trachea EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Ureter EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Urethra EO_Findings_and_Disorders_Kind Squamous_Cell_Metaplasia_of_the_Rat_Urinary_Bladder EO_Findings_and_Disorders_Kind Transitional_Cell_Hyperplasia_of_the_Rat_Renal_Pelvis EO_Findings_and_Disorders_Kind Transitional_Cell_Hyperplasia_of_the_Rat_Ureter EO_Findings_and_Disorders_Kind Transitional_Cell_Hyperplasia_of_the_Rat_Urethra EO_Findings_and_Disorders_Kind Transitional_Cell_Hyperplasia_of_the_Rat_Urinary_Bladder EO_Findings_and_Disorders_Kind Failure_to_Form_Staple_Medical_Device_Problem Properties_or_Attributes_Kind Deleted concepts: present in TDEByNameForProduction-06.11d2.xml but not in TDEByNameForProduction-06.12d.xml No deleted concepts found. Concepts retired in TDEByNameForProduction-06.12d.xml (retirements from merges are not flagged). name old kind BEC-2 Chemicals_and_Drugs_Kind Intervention Activity_Kind Recombinant_Vaccinia-GM-CSF Chemicals_and_Drugs_Kind Rat_Malignant_Glioma_NOS EO_Findings_and_Disorders_Kind Fluoroethyltyrosine_F_18 Chemicals_and_Drugs_Kind Gene_Expression_Profiling Activity_Kind Screening_and_Diagnostic_Assessment Activity_Kind Underdelivery_Medical_Device_Problem Properties_or_Attributes_Kind Shed_Medical_Device_Material Properties_or_Attributes_Kind Overdelivery_Medical_Device_Problem Properties_or_Attributes_Kind Medical_Device_Plugged Properties_or_Attributes_Kind Medical_Device_Battery_Shift Properties_or_Attributes_Kind Incomplete_Aspiration_Medical_Device_Problem Properties_or_Attributes_Kind Image_Reversal_Left_or_Right_Medical_Device_Problem Properties_or_Attributes_Kind Failure_to_Diagnose_Rhythm_Medical_Device_Problem Properties_or_Attributes_Kind Excessive_Aspiration_Medical_Device_Problem Properties_or_Attributes_Kind Entrapment_Medical_Device_Problem Properties_or_Attributes_Kind Device-Device_Connection_Issue Properties_or_Attributes_Kind Device_Problem_Related_to_Medical_Gas_or_Vacuum Properties_or_Attributes_Kind Cross_Connection_Medical_Device_Problem Properties_or_Attributes_Kind Device-Patient_Connection_Issue Properties_or_Attributes_Kind Inactive_Medical_Device_Failure_or_Malfunction_Code_CDRH Properties_or_Attributes_Kind Pars_Distalis_Adenoma_of_the_Rat_Pituitary_Gland EO_Findings_and_Disorders_Kind Pars_Distalis_Carcinoma_of_the_Rat_Pituitary_Gland EO_Findings_and_Disorders_Kind Pars_Intermedia_Adenoma_of_the_Rat_Pituitary_Gland EO_Findings_and_Disorders_Kind CONCEPTS WITH CHANGED KIND (excluding retirements/unretirements) found in TDEByNameForProduction-06.12d.xml, concepts are name new kind old kind No Kind-changed concepts found. Concepts that have been retreed in TDEByNameForProduction-06.12d.xml relative to TDEByNameForProduction-06.11d2.xml name kind parents in TDEByNameForProduction-06.12d.xml parents in TDEByNameForProduction-06.11d2.xml Di-dgA-RFB4_Immunotoxin Chemicals_and_Drugs_Kind CD22_Immunotoxin | Ricin_Immunoconjugate Ricin_Immunoconjugate Medulloepithelioma Findings_and_Disorders_Kind Embryonal_Neoplasm_of_the_CNS Central_Nervous_System_Primitive_Neuroectodermal_Tumor Childhood_Multilocular_Cystic_Renal_Neoplasm Findings_and_Disorders_Kind Childhood_Renal_Neoplasm Childhood_Wilms_Tumor Cystic_Partially_Differentiated_Nephroblastoma Findings_and_Disorders_Kind Childhood_Multilocular_Cystic_Renal_Neoplasm | Renal_Wilms_Tumor Renal_Wilms_Tumor Anesthesia_Procedure Activity_Kind Therapeutic_Procedure Procedure Bone_Marrow_Transplantation Activity_Kind Transplantation Organ_Transplantation Adoptive_Immunotherapy Activity_Kind Immunotherapy | Passive_Immunization Biological_Immunotherapy | Passive_Immunization Smoking_Cessation_Intervention Activity_Kind Behavioral_Intervention | Preventive_Intervention Behavioral_Intervention Dietary_Intervention Activity_Kind Behavioral_Educational_Psychological_Intervention Intervention Evaluation_of_Cancer_Risk_Factors Activity_Kind Evaluation_of_Risk_Factors | Screening Evaluation_of_Risk_Factors Radioprotection Activity_Kind Therapeutic_Procedure Preventive_Intervention Bone_Metastases_Prevention Activity_Kind Therapeutic_Procedure Cancer_Prevention Intra-Operative_Blood_Salvage Activity_Kind Autotransfusion Intervention Media_Intervention Activity_Kind Behavioral_Educational_Psychological_Intervention Intervention Population_Intervention Activity_Kind Behavioral_Educational_Psychological_Intervention Intervention Preventive_Intervention Activity_Kind Procedure Intervention Alternative_Medical_System Activity_Kind Complementary_and_Alternative_Medicine | Procedure Complementary_and_Alternative_Medicine | Intervention Manipulative_and_Body-Based_Methods Activity_Kind Alternative_Medical_System Alternative_Medical_System | Intervention Cancer_Intervention Activity_Kind Healthcare_Activity Intervention Liquid_Chromatography Activity_Kind Chromatography Column_Chromatography Educational_Intervention Activity_Kind Informational_Intervention Intervention Diagnostic_or_Prognostic_Tests Activity_Kind Diagnostic_Procedure Intervention Preservation_Technique Activity_Kind Test Procedure Observation Activity_Kind Diagnostic_Procedure Intervention Harvest Activity_Kind Therapy_Preparation Intervention Intubation Activity_Kind Therapeutic_Procedure Intervention Catheterization Activity_Kind Therapeutic_Procedure Procedure Dental_Procedure Activity_Kind Therapeutic_Procedure Procedure Lavage Activity_Kind Cytologic_Test Diagnostic_Procedure Polyphenon_E Chemicals_and_Drugs_Kind Antioxidant | Fruit_and_Vegetable_Extracts Green_Tea_Extract Acute_Myeloid_Leukemia_Transient_Myeloproliferative_Disorder_in_Down_Syndrome Findings_and_Disorders_Kind Acute_Myeloid_Leukemia_not_Otherwise_Categorized | Childhood_Acute_Myeloid_Leukemia Acute_Myeloid_Leukemia_not_Otherwise_Categorized Probe NCI_Kind Miscellaneous_Molecular_Biology_Terms Conceptual_Entities Extubation Activity_Kind Therapeutic_Procedure Intervention Autotransfusion Activity_Kind Blood_Transfusion | Reinfusion Reinfusion Bone_Marrow_Purging Activity_Kind Therapeutic_Procedure Cancer_Intervention Rat_Adenocarcinoma_in_Fibroadenoma EO_Findings_and_Disorders_Kind Rat_Integumentary_System_Neoplasms Rat_Adenocarcinoma | Rat_Integumentary_System_Neoplasms Rat_Adenosquamous_Carcinoma EO_Findings_and_Disorders_Kind Rat_Carcinoma Rat_Carcinoma | Rat_Genital_System_Neoplasms | Rat_Respiratory_System_Neoplasms Rat_Basal_Cell_Carcinoma EO_Findings_and_Disorders_Kind Rat_Carcinoma Rat_Carcinoma | Rat_Digestive_System_Neoplasms | Rat_Genital_System_Neoplasms | Rat_Integumentary_System_Neoplasms Rat_Benign_Basal_Cell_Tumor EO_Findings_and_Disorders_Kind Rat_Neoplasms_by_Morphology Rat_Digestive_System_Neoplasms | Rat_Integumentary_System_Neoplasms Rat_Benign_Mixed_Tumor EO_Findings_and_Disorders_Kind Rat_Neoplasms_by_Morphology Rat_Digestive_System_Neoplasms | Rat_Integumentary_System_Neoplasms Rat_Benign_Neuroendocrine_Cell_Tumor EO_Findings_and_Disorders_Kind Rat_Digestive_System_Neoplasms Rat_Soft_Tissue_and_Musculoskeletal_System_Neoplasms Rat_Benign_Teratoma EO_Findings_and_Disorders_Kind Rat_Neoplasms_by_Morphology Rat_Soft_Tissue_and_Musculoskeletal_System_Neoplasms Rat_Bronchiolo-Alveolar_Adenoma EO_Findings_and_Disorders_Kind Rat_Respiratory_System_Neoplasms Rat_Adenoma | Rat_Respiratory_System_Neoplasms Rat_Bronchiolo-Alveolar_Carcinoma EO_Findings_and_Disorders_Kind Rat_Respiratory_System_Neoplasms Rat_Carcinoma | Rat_Respiratory_System_Neoplasms Rat_C-Cell_Adenoma EO_Findings_and_Disorders_Kind Rat_Endocrine_System_Neoplasms Rat_Adenoma | Rat_Endocrine_System_Neoplasms Rat_C-Cell_Carcinoma EO_Findings_and_Disorders_Kind Rat_Endocrine_System_Neoplasms Rat_Carcinoma | Rat_Endocrine_System_Neoplasms Rat_Cholangiocarcinoma EO_Findings_and_Disorders_Kind Rat_Hepatic_Neoplasm Rat_Carcinoma | Rat_Hepatic_Neoplasm Rat_Choriocarcinoma EO_Findings_and_Disorders_Kind Rat_Carcinoma Rat_Carcinoma | Rat_Genital_System_Neoplasms Rat_Choroid_Plexus_Carcinoma EO_Findings_and_Disorders_Kind Rat_Nervous_System_and_Sensory_Organs_Neoplasms Rat_Carcinoma | Rat_Nervous_System_and_Sensory_Organs_Neoplasms Rat_Cortical_Adenoma EO_Findings_and_Disorders_Kind Rat_Endocrine_System_Neoplasms Rat_Adenoma | Rat_Endocrine_System_Neoplasms Rat_Cortical_Carcinoma EO_Findings_and_Disorders_Kind Rat_Endocrine_System_Neoplasms Rat_Carcinoma | Rat_Endocrine_System_Neoplasms Rat_Cystadenocarcinoma EO_Findings_and_Disorders_Kind Rat_Adenocarcinoma Rat_Adenocarcinoma | Rat_Female_Genital_System_Neoplasms Rat_Cystadenoma EO_Findings_and_Disorders_Kind Rat_Adenoma Rat_Adenoma | Rat_Female_Genital_System_Neoplasms Rat_Ductal_Cell_Adenocarcinoma EO_Findings_and_Disorders_Kind Rat_Adenocarcinoma Rat_Adenocarcinoma | Rat_Digestive_System_Neoplasms Rat_Ductal_Cell_Adenoma EO_Findings_and_Disorders_Kind Rat_Adenoma Rat_Adenoma | Rat_Digestive_System_Neoplasms Rat_Embryonal_Carcinoma EO_Findings_and_Disorders_Kind Rat_Female_Genital_System_Neoplasms Rat_Carcinoma | Rat_Genital_System_Neoplasms Rat_Fibroadenoma EO_Findings_and_Disorders_Kind Rat_Integumentary_System_Neoplasms Rat_Adenoma | Rat_Integumentary_System_Neoplasms Rat_Follicular_Cell_Adenoma EO_Findings_and_Disorders_Kind Rat_Adenoma Rat_Adenoma | Rat_Endocrine_System_Neoplasms Rat_Follicular_Cell_Carcinoma EO_Findings_and_Disorders_Kind Rat_Carcinoma Rat_Carcinoma | Rat_Endocrine_System_Neoplasms Rat_Glandular_Metaplasia EO_Findings_and_Disorders_Kind Rat_Hyperplasia Rat_Hyperplasia | Rat_Urinary_System_Disorder Rat_Goblet_Cell_Metaplasia EO_Findings_and_Disorders_Kind Rat_Respiratory_System_Disorder Rat_Hyperplasia | Rat_Respiratory_System_Disorder Rat_Hepatocellular_Adenoma EO_Findings_and_Disorders_Kind Rat_Hepatic_Neoplasm Rat_Adenoma | Rat_Hepatic_Neoplasm Rat_Hepatocellular_Carcinoma EO_Findings_and_Disorders_Kind Rat_Hepatic_Neoplasm Rat_Carcinoma | Rat_Hepatic_Neoplasm Rat_Hepatocholangiocellular_Adenoma EO_Findings_and_Disorders_Kind Rat_Hepatic_Neoplasm Rat_Adenoma | Rat_Hepatic_Neoplasm Rat_Hepatocholangiocellular_Carcinoma EO_Findings_and_Disorders_Kind Rat_Hepatic_Neoplasm Rat_Carcinoma | Rat_Hepatic_Neoplasm Rat_Islet_Cell_Adenoma EO_Findings_and_Disorders_Kind Rat_Endocrine_System_Neoplasms Rat_Adenoma | Rat_Endocrine_System_Neoplasms Rat_Islet_Cell_Carcinoma EO_Findings_and_Disorders_Kind Rat_Endocrine_System_Neoplasms Rat_Carcinoma | Rat_Endocrine_System_Neoplasms Rat_Keratoacanthoma EO_Findings_and_Disorders_Kind Rat_Neoplasms_by_Morphology Rat_Female_Genital_System_Neoplasms | Rat_Integumentary_System_Neoplasms Rat_Leydig_Cell_Adenoma EO_Findings_and_Disorders_Kind Rat_Male_Genital_System_Neoplasms Rat_Adenoma | Rat_Male_Genital_System_Neoplasms Rat_Leydig_Cell_Carcinoma EO_Findings_and_Disorders_Kind Rat_Male_Genital_System_Neoplasms Rat_Carcinoma | Rat_Male_Genital_System_Neoplasms Rat_Malignant_Craniopharyngioma EO_Findings_and_Disorders_Kind Rat_Nervous_System_and_Sensory_Organs_Neoplasms Rat_Endocrine_System_Neoplasms Rat_Malignant_Mixed_Tumor EO_Findings_and_Disorders_Kind Rat_Neoplasms_by_Morphology Rat_Digestive_System_Neoplasms Rat_Malignant_Neuroendocrine_Cell_Tumor EO_Findings_and_Disorders_Kind Rat_Neoplasms_by_Morphology Rat_Digestive_System_Neoplasms | Rat_Respiratory_System_Neoplasms Rat_Malignant_Sertoli_Cell_Tumor EO_Findings_and_Disorders_Kind Rat_Genital_System_Neoplasms Rat_Female_Genital_System_Neoplasms | Rat_Male_Genital_System_Neoplasms Rat_Papilloma EO_Findings_and_Disorders_Kind Rat_Neoplasms_by_Morphology Rat_Digestive_System_Neoplasms Rat_Pars_Distalis_Carcinoma EO_Findings_and_Disorders_Kind Rat_Carcinoma Rat_Carcinoma | Rat_Endocrine_System_Neoplasms Rat_Respiratory_Epithelial_Metaplasia EO_Findings_and_Disorders_Kind Rat_Respiratory_System_Disorder Rat_Hyperplasia | Rat_Respiratory_System_Disorder Rat_Rete_Testis_Adenoma EO_Findings_and_Disorders_Kind Rat_Male_Genital_System_Neoplasms Rat_Adenoma | Rat_Male_Genital_System_Neoplasms Rat_Rete_Testis_Carcinoma EO_Findings_and_Disorders_Kind Rat_Male_Genital_System_Neoplasms Rat_Carcinoma | Rat_Male_Genital_System_Neoplasms Rat_Sebaceous_Cell_Adenoma EO_Findings_and_Disorders_Kind Rat_Adenoma Rat_Adenoma | Rat_Integumentary_System_Neoplasms Rat_Sebaceous_Cell_Carcinoma EO_Findings_and_Disorders_Kind Rat_Carcinoma Rat_Carcinoma | Rat_Integumentary_System_Neoplasms Rat_Transitional_Cell_Carcinoma EO_Findings_and_Disorders_Kind Rat_Carcinoma Rat_Carcinoma | Rat_Urinary_System_Neoplasms Rat_Tubulostromal_Adenocarcinoma EO_Findings_and_Disorders_Kind Rat_Adenocarcinoma Rat_Adenocarcinoma | Rat_Female_Genital_System_Neoplasms Rat_Tubulostromal_Adenoma EO_Findings_and_Disorders_Kind Rat_Adenoma Rat_Adenoma | Rat_Female_Genital_System_Neoplasms Rat_Yolk_Sac_Carcinoma EO_Findings_and_Disorders_Kind Rat_Female_Genital_System_Neoplasms Rat_Carcinoma | Rat_Genital_System_Neoplasms Fluoroethyl-L-tyrosine_F_18 Chemicals_and_Drugs_Kind Diagnostic_Reagent | Radioconjugate Diagnostic_Reagent Recombinant_Human_Hyaluronidase Chemicals_and_Drugs_Kind Adjuvant | Glycosaminoglycan Adjuvant Oligofructose-Enriched_Inulin Chemicals_and_Drugs_Kind Immunostimulant | Protective_Agent Pharmacologic_Substance Dinoprostone Chemicals_and_Drugs_Kind Adjuvant | Prostaglandin Adjuvant | Eicosanoid Bowel_Preparation Activity_Kind Therapeutic_Procedure Intervention Gerson_Therapy Activity_Kind Dietary_Intervention Nutritional_Supplementation Exercise_Intervention Activity_Kind Behavioral_Educational_Psychological_Intervention | Preventive_Intervention Behavioral_Educational_Psychological_Intervention Comparison_of_Screening_Methods Activity_Kind Screening Intervention Unstable_Connection_Medical_Device_Problem Properties_or_Attributes_Kind Unintended_Movement_Medical_Device_Problem Medical_Device_or_Device_Component_Connection_Issue Unexpected_Therapeutic_Result Properties_or_Attributes_Kind Result_Incorrect_Medical_Device_Problem Therapeutic_or_Diagnostic_Output_Failure_Associated_with_Medical_Device Obstruction_within_Medical_Device Properties_or_Attributes_Kind Infusion_or_Flow_Issue_Associated_with_Medical_Device Medical_Device_Mechanical_Issue Migration_of_Medical_Device_or_Device_Component Properties_or_Attributes_Kind Unintended_Movement_Medical_Device_Problem Medical_Device_Mechanical_Issue Medical_Device_Failure_to_Shut_Off Properties_or_Attributes_Kind Medical_Device_Electronic_Property_Issue Medical_Device_Charging_or_Battery_Issue Medical_Device_Difficult_to_Open_or_Close Properties_or_Attributes_Kind Medical_Device_Difficult_to_Use_or_Set_Up Medical_Device_Difficult_to_Use_or_Set_Up | Reportable_Event Medical_Device_Calibration_Issue Properties_or_Attributes_Kind Medical_Device_Operational_Issue Medical_Device_Protective_Measure_Issue Improper_Gas_Output_Medical_Device_Problem Properties_or_Attributes_Kind Improper_Medical_Device_Output Delivery_System_Failure_Medical_Device_Problem Biomarker_Analysis Activity_Kind Procedure Intervention Interventional_Radiology_Procedure Activity_Kind Therapeutic_Procedure Intervention Surgical_Wound_Closure Activity_Kind Surgical_Procedure Intervention Behavioral_Educational_Psychological_Intervention Activity_Kind Procedure Intervention Hematopoietic_Stem_Cell_Mobilizer_Therapy Activity_Kind Therapy_Preparation Intervention Nitroflurbiprofen Chemicals_and_Drugs_Kind Cyclooxygenase_Inhibitor | Nitric_Oxide-Releasing_Compound Cyclooxygenase_Inhibitor Neuroendocrine_Cell_Hyperplasia_of_the_Rat_Glandular_Stomach EO_Findings_and_Disorders_Kind Rat_Neuroendocrine_Cell_Hyperplasia Rat_Intestinal_Neoplasm Concepts with new/changed/deleted definitions in TDEByNameForProduction-06.12d.xml relative to TDEByNameForProduction-06.11d2.xml name kind def in TDEByNameForProduction-06.12d.xml def in TDEByNameForProduction-06.11d2.xml Antithymocyte_Globulin Chemicals_and_Drugs_Kind A purified gamma immunoglobulin with immunosuppressive properties. Obtained from rabbits that have been immunized with human thymocytes, anti-thymocyte globulin specifically recognizes and destroys T lymphocytes. Although the exact mechanism of action is not completely understood, it appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering anti-thymocyte globulin with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease. (NCI04) A purified gamma immunoglobulin with immunosuppressive properties. Obtained from rabbits that have been immunized with human thymocytes, antithymocyte globulin specifically recognizes and destroys T lymphocytes. Although the exact mechanism of action is not completely understood, it appears to involve T lymphocyte clearance from the circulation and modulation of T lymphocyte activity. Administering antithymocyte globulin with chemotherapy prior to stem cell transplantation may reduce the risk of graft-versus-host disease. (NCI04) Dapsone Chemicals_and_Drugs_Kind A synthetic derivative of diamino-sulfone with anti-inflammatory and anti-bacterial properties. As a structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Although the exact mechanism through which dapsone exerts its anti-inflammatory activity has yet to be fully elucidated, this agent interferes with the activation and oxidative damage of myeloperoxidase in neutrophils and inhibits the integrin-mediated adherence and chemotaxis of neutrophils. Dapsone's anti-inflammatory activities may contribute to the effects seen upon topical administration. A synthetic derivative of diamino-sulfone, usually formulated as a 5% (w/w) dapsone gel, with anti-bacterial properties. A structural analog of p-aminobenzoic acid (PABA), dapsone inhibits dihydropteroate synthase (DHPS), an enzyme important in folate synthesis, resulting in a depletion of the folate pool and a reduction in the amount of thymidylate available for DNA synthesis. Isotretinoin Chemicals_and_Drugs_Kind A naturally-occurring retinoic acid with potential antineoplastic activity and teratogenic properties. Isotretinoin binds to and activates nuclear retinoic acid receptors (RAR), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization. (NCI04) A naturally-occurring retinoic acid with potential antineoplastic activity and teratogenic properties. 13-cis retinoic acid binds to and activates nuclear retinoic acid receptors (RAR), thereby regulating cell proliferation and differentiation. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization. (NCI04) Novobiocin Chemicals_and_Drugs_Kind An aminocoumarin antibiotic, produced by the actinomycete Streptomyces nivens, with antibacterial proeprty. Novobiocin, as well as other aminocoumarin, inhibits bacterial DNA synthesis by targeting at the bacteria DNA gyrase and the related enzyme DNA topoisomerase IV. This antibiotic was used to treat infections by gram-positive bacteria. Novobiocin is one of aminocoumarin antibiotics that were produced by the actinomycete Streptomyces nivens. Novobiocin as well as other aminocoumarin inhibit bacterial DNA synthesis by targeting the enzyme DNA gyrase; and the related enzyme DNA topoisomerase IV is a secondary target of these compounds. It was used to treat infections by gram-positive bacteria. (NCI) Coenzyme-Q Chemicals_and_Drugs_Kind A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme Q10 functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme Q10 may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04) A naturally occurring benzoquinone important in electron transport in mitochondrial membranes. Coenzyme-Q functions as an endogenous antioxidant; deficiencies of this enzyme have been observed in patients with many different types of cancer and limited studies have suggested that coenzyme-Q may induce tumor regression in patients with breast cancer. This agent may have immunostimulatory effects. (NCI04) Bryostatin-1 Chemicals_and_Drugs_Kind A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity. Bryostatin 1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04) A macrocyclic lactone isolated from the bryozoan Bugula neritina with antineoplastic activity. Bryostatin-1 binds to and inhibits the cell-signaling enzyme protein kinase C, resulting in the inhibition of tumor cell proliferation, the promotion of tumor cell differentiation, and the induction of tumor cell apoptosis. This agent may act synergistically with other chemotherapeutic agents. (NCI04) Sialyl_Tn_Antigen Chemicals_and_Drugs_Kind A tumor-associated core-region carbohydrate antigen of epithelial mucin, expressed in most colon carcinoma, mucinous carcinoma, pancreatic cancer, gastric, lung, breast, and ovarian carcinoma. Sialosyl-Tn (STn) antigen has been shown to be highly sensitive and specific marker of colorectal cancer, associated with more aggressive diseases and poor prognosis. STn antigen and its immediate precursor, Tn antigen, are mucin type glycoprotein structures associated with the earliest steps of mucin O-linked glycosylation. When combined with a carrier molecule, keyhole limpet hemocyanin (KLH), this antigen maybe co-administer with oral cyclophosphamide as an immune modulator. Sialyl Tn antigen (SRn) is a carcinoma-associated core-region carbohydrate antigen of epithelial mucin, expressed in most colon carcinoma, mucinous carcinoma, pancreatic cancer, gastric, lung, breast, and ovarian carcinoma. Has been shown to be highly sensitive and specific marker of colorectal cancer, associated with more aggressive diseases and poor prognosis. Sialosyl-Tn antigen and its immediate precursor, Tn antigen, are mucin type glycoprotein structures associated with the earliest steps of mucin O- linked glycosylation. The vaccine is designed to stimulate a T cell response to STn. The synthetic antigen is combined with a carrier molecule, keyhole limpet hemocyanin (KLH), and is administered with oral cyclophosphamide as an immune modulator. O_6_Benzylguanine Chemicals_and_Drugs_Kind A guanine analogue with antineoplastic activity. O6-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04) A guanine analogue with antineoplastic activity. O(6)-benzylguanine binds the DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), transferring the benzyl moiety to the active-site cysteine and resulting in inhibition of AGT-mediated DNA repair. Co-administration of this agent potentiates the effects of other chemotherapeutic agents that damage DNA. (NCI04) Clodronate_Disodium Chemicals_and_Drugs_Kind The sodium salt form of clodronate, a nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate disodium binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain. A nitrogen-free bisphosphonate analog of naturally occurring pyrophosphate. Clodronate disodium binds to calcium and inhibits osteoclastic bone resorption and hydroxyapatite crystal formation and dissolution, resulting in a reduction of bone turnover. This agent may control malignancy-associated hypercalcemia, inhibit osteolytic bone metastasis and decrease pain. Re_186_Hydroxyethylidene_Diphosphonate Chemicals_and_Drugs_Kind A synthetic compound containing the radioisotope rhenium 186 and a chelator, hydroxyethylidene diphosphonate (HEDP). Re-HEDP functions as a bone-seeking radiopharmaceutical when it is mixed with bioactive material, hydroxyapatite (calcium phosphate ceramic) via intravenous infusion. Re-186 is a beta emitter, with a short half life, which provides local effects with limited distribution to extramedullary bone marrow tissues. Re-HEDP can be used to treat pain associated with primary and metastatic bone lesions. A synthetic compound containing the radioisotope rhenium 186 and a chelator, hydroxyethylidene diphosphonate (HEDP). Re-HEDP functions as a bone-seeking radiopharmaceutical when it is mixed with bioactive material, hydroxyapatite (calcium phosphate ceramic) via intravenous infusion. Re 186 is a beta emitter, with a short half life, which provides local effects with limited distribution to extramedullary bone marrow tissues. Re-HEDP can be used to treat pain associated with primary and metastatic bone lesions. Nolatrexed Chemicals_and_Drugs_Kind The hydrochloride salt form of nolatrexed, a water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity. (NCI04) A water-soluble lipophilic quinazoline folate analog with antineoplastic activity. Nolatrexed occupies the folate binding site of thymidylate synthase, resulting in inhibition of thymidylate synthase activity and thymine nucleotide synthesis with subsequent inhibition of DNA replication, DNA damage, S-phase cell cycle arrest, and caspase-dependent apoptosis. This agent also exhibits radiosensitizing activity. (NCI04) Rebeccamycin_Analogue Chemicals_and_Drugs_Kind A synthetic diethylaminoethyl analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin. Becatecarin intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04) A synthetic diethylaminoethyl analogue of the indolocarbazole glycoside antineoplastic antibiotic rebeccamycin. The rebeccamycin analogue intercalates into DNA and stabilizes the DNA-topoisomerase I complex, thereby interfering with the topoisomerase I-catalyzed DNA breakage-reunion reaction and initiating DNA cleavage and apoptosis. (NCI04) Ibandronate Chemicals_and_Drugs_Kind The sodium salt form of ibandronate, a synthetic nitrogen-containing bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. (NCI04) A synthetic nitrogen-containing bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain. (NCI04) CI-1033 Chemicals_and_Drugs_Kind An orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib dihydrochloride binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents. An orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. Canertinib binds to the intracellular domains of epidermal growth factor receptor tyrosine kinases (ErbB family), irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation. This agent also acts as a radiosensitizing agent and displays synergistic activity with other chemotherapeutic agents. Monoclonal_Antibody_BC8 Chemicals_and_Drugs_Kind A murine IgG1 anti-CD45 monoclonal antibody (MoAb) with immunotherapeutic activity. CD45 antigen, a receptor protein-tyrosine phosphatase essential for T cell development and lymphocyte activation, is expressed on virtually all leukocytes. MoAb BC8 has specificity for hematopoietic tissues and maybe used in targeted immunotherapy. An anti-CD45 antibody (BC8) that has specificity for hematopoietic tissues and used in targeted immunotherapy. (NCI) Borocaptate_Sodium Chemicals_and_Drugs_Kind A boron-carrying compound. After parenteral administration, sodium borocaptate accumulates preferentially in tumor cells. When exposed to neutron irradiation, borocaptate absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues. (NCI04) A boron-carrying compound. After parenteral administration, borocaptate sodium accumulates preferentially in tumor cells. When exposed to neutron irradiation, borocaptate absorbs neutrons and self-destructs releasing short-range alpha radiation and 'recoil' lithium in tumor cells, resulting in alpha radiation-induced tumor cell death. This highly selective, localized radiotargeting of tumor cells, known as boron neutron capture therapy (BNCT), spares adjacent normal tissues. (NCI04) Monoclonal_Antibody_4B5_Anti-Idiotype_Vaccine Chemicals_and_Drugs_Kind A humanized anti-idiotypic (anti-Id) monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id 4B5 IgG was capable of eliciting both cellular and humoral immune responses against GD2 expression tumor cells. A vaccine comprised of the monoclonal antibody 4B5, an anti-GD2 anti-idiotypic antibody, mimicking the GD2 antigen, causing an immune response. (NCI) Y_90_Monoclonal_Antibody_MN-14 Chemicals_and_Drugs_Kind A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. (NCI04) A radioimmunotherapeutic monoclonal antibody (MN-14) directed against tumor-associated carcinoembryonic antigen (CEA) and chelated to the radioisotope yttrium-90 (Y 90). Y 90 monoclonal antibody MN-14 binds to tumor cell expressing CEA, delivering a cytotoxic dose of beta radiation. (NCI04) Di-dgA-RFB4_Immunotoxin Chemicals_and_Drugs_Kind An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to two deglycosylated ricin toxin A-chain (Di-dgA), can be extracted from cator beans. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This Di-dgA conjugated MoAb RFB4 delivers 7 folds more cytotoxicity, than the single dgA immunotoxin, against CD22-positive malignant cells. Di-dgA-RFB4 Immunotoxin is produced from deglycosylated A chain of plant toxin ricin (dgA) conjugated to murine monoclonal antibodies directed against CD22 (RFB4-dgA) antigen. The combination of Di-dgA-RFB4 Immunotoxin with another immunotoxin CD19 (HD37-dgA; Combotox) was demonstrated to have significant antitumor activity in mouse model of lymphoma and is supposed to be useful in the treatment of human refractory B cell lymphoma. (NCI) IgG-RFB4-SMPT-dgA_Immunotoxin Chemicals_and_Drugs_Kind An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to a single deglycosylated ricin toxin A-chain (dgA), originated from castor bean. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This agent limits specific cytotoxicity of ricin toxin to CD22-positive malignant cells. An immunotoxin comprised of a SMPT stabilized anti-CD22 murine monoclonal antibody, RFB4, linked with a deglycosylated A chain of ricin, a toxin, selectively targeting and poisoning CD22 expressing tumor cells. Monoclonal_Antibody_T101 Chemicals_and_Drugs_Kind A murine monoclonal antibody (MoAb) with application in Immunotherapy and radioimmunodetection in T-cell malignancies. MoAb T101 recognizes a 65kD glycoprotein, CD5 antigen, on the surface of T-cells. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against CD5+ T cells. An anti-T-cell monoclonal antibody used in Immunotherapy and Radioimmunodetection. (NCI) Monoclonal_Antibody_BEC2 Chemicals_and_Drugs_Kind A murine anti-idiotypic monoclonal antibody (anti-Id MoAb) that directed against an idiotype mimicking a disialoganglioside GD3. GD3 represents a major surface marker on most human melanoma cells. Due to poor immunogenicity of GD3, anti-Id MoAb BEC2 (Ab2) was raised against a mouse anti-GD3 MoAb, R24 (Ab1). This anti-Id MoAb was shown to be functionally mimicking GD3 in stimulating immune response to produce Ab3 that maybe used in combination with other adjuvants for treatment of melanomas. An anti-idiotypic monoclonal antibody that mimics GD3, a tumor antigen for use as an immune stimulant. (NCI) Monoclonal_Antibody_BEC2 Chemicals_and_Drugs_Kind An anti-idiotypic monoclonal antibody that mimics the ganglioside GD3, a tumor antigen on the surface of certain types of tumor cells and stimulates a stronger immune response to cells expressing natural GD3. (NCI) Therapeutic_Hematopoietic_Growth_Factor Chemicals_and_Drugs_Kind Drugs derived from hematopoietic growth factor that promote the development of blood cells. Hematopoietic growth factors promote the development of blood cells. Monoclonal_Antibody_MX35_F_ab_2 Chemicals_and_Drugs_Kind The F(ab)2 fragment of monoclonal antibody (MoAb) MX35 that recognizes a 95 kD glycoprotein with homogeneous distribution on 80% of ovarian tumor specimens. When radiolabeled, this MoAb has potential use in the radioimaging or may induce a cytotoxic T-cell response against tumor cell that express this glycoprotein. Containing only the antigen-binding fragment of the Ig molecule, MoAb MX35 F(ab')2 offers the advantages of smaller size and lower cross-reactivity compared to complete antibodies. The F(ab)2 fragment of monoclonal antibody MX35, an epithelial differentiation antigen, that exhibits reactivity with epithelial ovarian cancers. Monoclonal_Antibody_A1G4_Anti-Idiotype_Vaccine Chemicals_and_Drugs_Kind An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells. A vaccine comprised of an anti-idiotype rat monoclonal antibody A1G4, that targets ganglioside GD2. (NCI) Monoclonal_Antibody_11D10 Chemicals_and_Drugs_Kind A murine monoclonal anti-idiotype antibody (anti-Id). Anti-Id 11D10 mimics a specific epitope of the high molecular weight human milk fat globule (HMFG) glycoprotein primarily expressed by human breast and some other tumor cells at high density. This specific HMFG epitope is identified by mAb BrE1, which was used as the immunizing antibody or Ab1 to generate the anti-Id (Ab2) 11D10. Anti-ID 11D10 reacts specifically with breast tumor cells and with minimal reactivity with normal tissues. Vaccination with anti-Id 11D10 induces anti-anti-idiotype antibodies (Ab3) that may react with breast cancer cell lines expressing the HMFG membrane epitope. An anti-idiotype monoclonal antibody that mimics an epitope of the human milk fat globule, an antigen expressed by breast cancer cells, used in Vaccine Therapy. Monoclonal_Antibody_3622W94 Chemicals_and_Drugs_Kind A humanized murine monoclonal antibody (MoAb) against the 17-1A antigen, with potential adjuvant therapy property in colorectal cancer. 17-1A antigen (EpCAM), a human epithelial cell adhesion molecule, expresses in a variety of carcinoma tissues, such as those of colon and breast carcinomas. Immunization with MoAb 3622W94 may elicit immune responses, which could result in eradicating tumor cells expressing 17-1A antigen. A humanized anti-epithelial cell adhesion molecule (17-1A epithelial antigen) monoclonal antibody. (NCI) Monoclonal_Antibody_muJ591 Chemicals_and_Drugs_Kind A murine IgG monoclonal antibody against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, but over-expression indicates an aggressive phenotype of the prostate cancer. Radiolabelled MoAb muJ591 may be used in prostate cancer diagnosis and therapy. A monoclonal antibody against the external domain of the Prostate Membrane Specific Antigen. Monoclonal_Antibody_F19 Chemicals_and_Drugs_Kind A murine monoclonal antibody (MoAb) against human fibroblast activation protein (FAP). FAP is a 95 kDa cell surface glycoprotein and an inducible tumour stromal antigen of epithelial cancers and of a subset of soft tissue sarcomas. FAP shows a very limited distribution pattern in normal tissues, thereby MoAb F19 has possible diagnostic and therapeutic applications in epithelial cancers. A murine monoclonal antibody directed against fibroblast activation protein, a tumor stroma antigen, with potential antitumor stroma activity. (NCI) Monoclonal_Antibody_CD19 Chemicals_and_Drugs_Kind A mouse anti-human CD19 monoclonal antibody (MoAb). CD19 as well as CD22 are cell surface antigens present on majority of B lymphocytes, including early B progenitor cells. Anti-CD19 MoAb, either alone or in combination with other immunotherapeutic agents, maybe used in management of B-cell malignancies. A monoclonal antibody directed against the CD19 antigen, expressed on human B lymphocytes. (NCI) Y_90_Humanized_Monoclonal_Antibody_LL2 Chemicals_and_Drugs_Kind A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Yttrium 90 humanized epratuzumab binds to tumor cells expressing CD222, delivering a cytotoxic dose of beta radiation. (NCI04) A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD222, delivering a cytotoxic dose of beta radiation. (NCI04) Monoclonal_Antibody_Mono-dgA-RFB4 Chemicals_and_Drugs_Kind An immunotoxin of monoclonal antibody (MoAb) RFB4 covalently linked to a single deglycosylated ricin toxin A-chain (dgA), originated from castor bean. MoAb RFB4 recognizes CD22 antigen, a B-cell adhesion protein expressed on malignant cells in about 70 percent of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Ricin toxin A-chain, a potent protein synthesis inhibitor, was deglycosylated and was used in this immunoconjugate to avoid hepatic entrapment. This agent limits specific cytotoxicity of ricin toxin to CD22-positive malignant cells. An immunotoxin comprised of a monoclonal antibody directed against CD22, an antigen expressed on B lymphocytes, linked to a chemically deglycosylated ricin-A chain toxin. (NCI) Monoclonal_Antibody_ABX-CBL Chemicals_and_Drugs_Kind A murine IgM monoclonal antibody (MoAb) developed for the potential treatment of graft versus host disease (GvHD). MoAb ABX-CBL recognizes human CD147 antigen, weakly expressed on human leukocytes and up-regulated on activated lymphocytes. This MoAb is capable of neutralizing inflammatory reactions via a complement-dependent cytotoxic mechanism. However, MoAb ABX-CBL does not offer an improvement over antithymocyte globulin in the treatment of acute steroid resistant GVHD. A IgM murine monoclonal antibody that targets CD147, an antigen expressed by T-, B-, and Natural Killer (NK) cells, causing immunosuppression. (NCI) CEA_571-579_Peptide Chemicals_and_Drugs_Kind A 9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). Vaccination with carcinoembryonic antigen peptide 1-6D, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA. A 9-residue human leukocyte antigen (HLA)-restricted fragment of carcinoembryonic antigen (CEA). Vaccination with CEA:571-579 peptide, which has the amino acid sequence YLSGANLNL, may elicit a cytotoxic T lymphocyte (CTL) immune response against tumors expressing CEA. Palivizumab Chemicals_and_Drugs_Kind A humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylaxis application of Respiratory Syncytial Virus infections. RSV F protein, a small envelop glycoprotein, not only is required for cytopathic syncytia resulted from cell-to-cell fusion, but also is necessary for viral spreading and evading neutralizing antibody. Palivizumab neutralizes and inhibit fusion activity of RSV, thereby prevent the syncytia formation. Administration of this antibody does not interfere with other immunization. A humanized monoclonal antibody that targets the fusion protein (F protein) of respiratory syncytial virus (RSV), causing neutralization and fusion-inhibition activity against both type A and B RSV isolates. Clinical Use: Respiratory Syncytial Virus-Prophylaxis. Paclitaxel_Liposome Chemicals_and_Drugs_Kind A liposome-encapsulated formulation of paclitaxel, a taxoid compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic property. Paclitaxel binds to tubulin and interferes with the assembly/disassembly dynamics of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis via inactivation of the apoptosis inhibitor, B-cell Leukemia 2 (Bcl-2) protein. Paclitaxel liposome formulation potentially enhances delivery of higher doses of paclitaxel to the target tissues and exhibits lower systemic toxicity. A liposome-encapsulated formulation of paclitaxel. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI) Monoclonal_Antibody_huJ591 Chemicals_and_Drugs_Kind A humanized monoclonal antibody (MoAb) against the external domain of the Prostate-specific membrane antigen (PSMA), overexpressed in malignant prostate and its metastases. Although PSMA is not a biomarker of disease progression, but over-expression indicates an aggressive phenotype of the prostate cancer. This humanized J591 (huJ591) MoAb was generated by replacing murine Ig sequences with human ones, thereby it can be administered to patients on multiple occasions over long time periods without inducing an immune response. Radiolabelled MoAb huJ591 may be used in immunotherapy of prostate cancer. A humanized monoclonal antibody directed against the external domain of the prostate specific membrane antigen (PSMA) for use in Immunotherapy and Immunostaining. (NCI) Herba_Scutellariae_Barbatae Chemicals_and_Drugs_Kind A Chinese herbal extract, isolated from the plant Scutellaria barbata D. Don (Lamiaceae) with potential antineoplastic activity. Containing the antioxidant flavone scutellarin, herba scutellaria barbata has been shown to induce apoptosis of ovarian and breast tumor cells in vitro. A Chinese herbal extract, isolated from the plant Scutellaria barbata D. Don (Lamiaceae) with potential antineoplastic activity. Containing the antioxidant flavone scutellarin, herba scutellariae barbatae has been shown to induce apoptosis of ovarian and breast tumor cells in vitro. Vaccinia-GM-CSF_Vaccine Chemicals_and_Drugs_Kind A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth. (NCI04) A vaccine comprised of a recombinant vaccinia virus encoding the gene for Granulocyte-Macrophage Colony-Stimulating Factor (Sargramostim, GM-CSF). (NCI) Monoclonal_Antibody_D6_12 Chemicals_and_Drugs_Kind A murine IgG2a monoclonal antibody directed against a 48 kDa antigen expressed on the cell surface of normal and malignant gastrointestinal epithelium. MoAb D6.12 has been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC). This MoAb, either alone or in combination with other immunotherapeutic agents, may have possible diagnostic or therapeutic applications in gastrointestinal cancers. A murine monoclonal antibody directed against the Mr 48,000 antigen expressed on the cell surface of normal and malignant gastrointestinal epithelium, resulting in antibody-dependent cell-mediated cytotoxicity. (NCI) Monoclonal_Antibody_C-58 Chemicals_and_Drugs_Kind A human IgM monoclonal antibody (MoAb) directed against a human Cytomegalovirus (CMV) antigen. MoAb C-58 recognizes the p51 protein of viral capsid, thereby might be used for the early detection or treatment of CMV infection. A human IgM monoclonal antibody directed against human Cytomegalovirus. (NCI) Visilizumab Chemicals_and_Drugs_Kind A humanized anti-CD3 monoclonal antibody (MoAb) with potential application in treatment of graft-versus-host disease (GVHD). Visilizumab reacts with the invariant CD3 epsilon, one of the non-covalently associated subunits of T-cell receptors (TCR) on activated T-cells. This MoAb is engineered with substitution at amino acid residues 234 and 237 (Val3Ala) within the IgG2 Fc arm, rendering its inability to bind type II FcRs. Unable to binds to FcRs attributes to less toxicity associated with this MoAb via not activating resting T cells. Binding to TCR/CD3 complex, allows visilizumab to induce apoptosis of the bound cells, thereby potentially produce selective clonal deletion of activated pathogenic T-cells in condition such as GVHD. A humanized anti-CD3 monoclonal antibody targeting activated T-cells, inducing apoptosis. (NCI) ZD-6474 Chemicals_and_Drugs_Kind An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. (NCI04) An orally bioavailable 4-anilinoquinazoline. ZD-6474 selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis. (NCI04) Anal_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the anus. An abnormal growth of cells at or near the anus Coagulation_Disorder Findings_and_Disorders_Kind A condition in which there is a deviation from or interruption of the normal coagulation properties of the blood. Esophageal_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the esophagus. Abnormal growth of the cells of the esophagus, without specification as to whether the cells are benign or have malignant characteristics. Gastrointestinal_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving any part of the gastrointestinal system. Benign or malignant neoplasm affecting the gastrointestinal system. Intestinal_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the small or large intestine. Abnormal growth of the cells of the intestinal tissues. Lymphangiomyoma Findings_and_Disorders_Kind A neoplasm with perivascular epithelioid cell differentiation, often associated with tuberous sclerosis. It is characterized by the presence of smooth muscle and epithelioid cells, and the proliferation of lymphatic vessels. Sites of involvement include the lymph nodes, lung, mediastinum, and retroperitoneum. Medulloblastoma Findings_and_Disorders_Kind Medulloblastoma (WHO grade IV) is a malignant, invasive embryonal tumor of the cerebellum which occurs more often in children. It has a predominantly neuronal differentiation and a tendency to metastasize via CSF pathways. Histologically, classic Medulloblastomas are composed of densely packed cells with round-to-oval or carrot-shaped highly hyperchromatic nuclei surrounded by scanty cytoplasm. Neuroblastic rosettes are a typical but not constant feature. There are four histologic types: Desmoplastic Medulloblastoma, Large Cell Medulloblastoma, Medullomyoblastoma, Melanotic Medulloblastoma. (Adapted from WHO.) Angiomyxoma Findings_and_Disorders_Kind A benign soft tissue neoplasm characterized by the presence of neoplastic spindle and stellate cells in a myxoid stroma. Pancreatic_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the pancreas. Abnormal growth of the cells (either cancerous or non-cancerous) of the pancreas, the gland that secrets insulin. Gastric_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the stomach. Cancerous or non-cancerous tumors of the stomach Atrial_Myxoma Findings_and_Disorders_Kind A cardiac myxoma arising from the atrium. Medullomyoblastoma Findings_and_Disorders_Kind Medullomyoblastoma (WHO grade IV) is a rare embryonal cerebellar neoplasm with both a primitive neuroectodermal and striated muscle component. Histologically, it is a medulloblastoma with focal myogenic differentiation. (Adapted from WHO.) Epithelioid_Sarcoma Findings_and_Disorders_Kind An aggressive malignant neoplasm of uncertain lineage, characterized by the presence of epithelioid cells forming nodular patterns. The nodules often undergo central necrosis, resulting in a pseudogranulomatous growth pattern. It usually occurs in young adults. The most common sites of involvement are the extremities (distal-type epithelioid sarcoma), and less frequently the pelvis, perineum, and genital organs (proximal-type epithelioid sarcoma). Lymphangiomyomatosis Findings_and_Disorders_Kind A multifocal neoplasm with perivascular epithelioid cell differentiation affecting almost exclusively females of child-bearing age. It is characterized by the presence of smooth muscle and epithelioid cells, and the proliferation of lymphatic vessels. Sites of involvement include the lungs, mediastinum, and the retroperitoneum. It usually presents with chylous pleural effusion or ascites. Hepatoblastoma Findings_and_Disorders_Kind A malignant liver neoplasm that occurs almost exclusively in infants, although isolated instances in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component which may be undifferentiated or develop into bone or cartilage. The treatment of choice of hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well. --2002 Hepatoblastoma is a malignant liver neoplasm that occurs almost exclusively in infants, although isolated instances in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component which may be undifferentiated or develop into bone or cartilage. The treatment of choice of hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well. --2002 Angiomyolipoma Findings_and_Disorders_Kind A neoplasm with perivascular epithelioid cell differentiation often associated with tuberous sclerosis. It is characterized by a mixture of epithelioid cells, smooth muscle, vessels, and mature adipose tissue. The kidney is the most common site of involvement. Other sites of involvement include the liver, lung, lymph nodes, and retroperitoneum. The vast majority of cases follow a benign clinical course. However, cases of metastatic angiomyolipomas with sarcomatoid features have been described. Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind A rare malignant neoplasm characterized by the presence of large epithelioid cells with abundant cytoplasm forming nests and pseudoalveolar structures. The groups of the epithelioid cells are separated by thin-walled sinusoidal spaces. It occurs most often in adolescents and young adults. In adults, the most common sites of involvement are the extremities, and in infants and children the head and neck. It usually presents as a slowly growing mass and it frequently metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, bone, and brain. Ganglioneuroblastoma Findings_and_Disorders_Kind Ganglioneuroblastoma is a type of Neuroblastic Tumor. There are two subtypes: Ganglioneuroblastoma, intermixed (Schwannian stroma-rich) and Ganglioneuroblastoma, nodular (composite, Schwannian stroma-rich/stroma-dominant and stroma-poor). (Adapted from WHO.) Renal_Angiomyolipoma Findings_and_Disorders_Kind An angiomyolipoma arising from the kidney. Synovial_Sarcoma_with_Spindle_Cell_Components Findings_and_Disorders_Kind A synovial sarcoma characterized by the presence of a spindle cell component only. Epithelioid_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma characterized by the presence of an epithelial cell component only. The epithelial cells are arranged in glandular or papillary structures. Biphasic_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma characterized by the presence of both an epithelial and a spindle cell component. Medulloepithelioma Findings_and_Disorders_Kind Medulloepithelioma (WHO grade IV) is a rare, highly malignant embryonal brain tumor which affects young children. Histologically, it is characterized by papillary, tubular or trabecular arrangements of neoplastic neuroepithelium mimicking the embryonic neural tube. (Adapted from WHO.) Skin_Lymphangioleiomyomatosis Findings_and_Disorders_Kind Lymphangiomyomatosis involving the dermis. Appendix_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the appendix. Ampulla_of_Vater_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the ampulla of Vater. Benign_Gastrointestinal_Neoplasm Findings_and_Disorders_Kind A benign neoplasm arising from any part of the gastrointestinal system. Benign neoplasms of the gastrointestinal system, which includes the esophagus, stomach, intestines, rectum, anus, pancreas, and liver. Left_Atrial_Myxoma Findings_and_Disorders_Kind A cardiac myxoma arising from the left atrium. Right_Atrial_Myxoma Findings_and_Disorders_Kind A cardiac myxoma arising from the right atrium. Malignant_Gastrointestinal_Neoplasm Findings_and_Disorders_Kind A primary or metastatic malignant neoplasm involving any part of the gastrointestinal system. -- 2003 A primary or metastatic malignant tumor involving any part of the gastrointestinal system. -- 2003 Desmoplastic_Medulloblastoma Findings_and_Disorders_Kind Desmoplastic Medulloblastoma is a variant of Medulloblastoma. Some histologic features of this lesion include nodular, reticulin-free zones ('pale islands') surrounded by densely packed, highly proliferative cells that produce a dense intercellular reticulin fiber network. (Adapted from WHO.) Ovarian_Myxoma Findings_and_Disorders_Kind A myxoma arising from the ovary. Intracranial_Chondrosarcoma Findings_and_Disorders_Kind An extraskeletal myxoid chondrosarcoma arising from the structures within the cranium. Monophasic_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma characterized by the presence of an epithelial or a spindle cell component only. Childhood_Renal_Angiomyolipoma Findings_and_Disorders_Kind An angiomyolipoma occurring in childhood. Myxoma Findings_and_Disorders_Kind A benign soft tissue neoplasm characterized by the presence of spindle and stellate cells, lobulated growth pattern, and myxoid stroma formation. Cutaneous_Myxoma Findings_and_Disorders_Kind A myxoma arising from the dermis. Intramuscular_Myxoma Findings_and_Disorders_Kind A myxoma arising from muscle tissues. Juxtaarticular_Myxoma Findings_and_Disorders_Kind A cellular myxoma arising from the joints. Parachordoma Findings_and_Disorders_Kind A rare, usually benign soft tissue neoplasm characterized by the presence of epithelioid, often vacuolated neoplastic cells. Most patients present with painless swelling in the subcutaneous or subfascial soft tissues of the extremities. Ossifying_Fibromyxoid_Neoplasm Findings_and_Disorders_Kind A rare soft tissue neoplasm of uncertain lineage characterized by the presence of neoplastic spindle to round cells forming cords in a fibromyxoid stroma. The lesions are associated with the formation of metaplastic bone. Most patient s present with painless subcutaneous masses. Recurrences have been reported in the minority of patients. Nonossifying_Fibromyxoid_Neoplasm Findings_and_Disorders_Kind A rare soft tissue neoplasm of uncertain lineage characterized by the presence of neoplastic spindle to round cells forming cords in a fibromyxoid stroma. Metaplastic bone formation is not present. Palisaded_Lymph_Node_Myofibroblastoma Findings_and_Disorders_Kind A myofibroblastoma arising from the inguinal lymph nodes. It is characterized by the presence of nuclear palisading. Extrarenal_Rhabdoid_Tumor Findings_and_Disorders_Kind An aggressive malignant neoplasm characterized by the presence of large atypical cells with large nuclei, prominent nucleoli, and abundant cytoplasm that contains inclusions. It occurs in infants and children. It may arise from various anatomic sites including the liver, heart, gastrointestinal system, neck, and paraspinal regions. The prognosis is usually poor. Benign_Miscellaneous_Mesenchymal_Neoplasm Findings_and_Disorders_Kind A benign soft tissue neoplasm in which the line of differentiation is uncertain. Malignant_Miscellaneous_Mesenchymal_Neoplasm Findings_and_Disorders_Kind A malignant soft tissue neoplasm in which the line of differentiation is uncertain. Mediastinal_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma arising from the mediastinum. Chest_Wall_Parachordoma Findings_and_Disorders_Kind A parachordoma arising from the chest wall. Benign_Glomus_Tumor Findings_and_Disorders_Kind A glomus tumor of small size characterized by the absence of nuclear atypia and mitotic activity. A glomus tumor of small size (less than 2 cm) characterized by the absence of nuclear atypia and mitotic activity. Large_Cell_Medulloblastoma Findings_and_Disorders_Kind Large Cell Medulloblastoma is a variant of Medulloblastoma (about 4% of cases). Some features of the tumor cells are large, round and/or pleomorphic nuclei with prominent nucleoli and a more abundant cytoplasm than that found in the classic medulloblastoma. (Adapted from WHO.) Atypical_Teratoid_Rhabdoid_Tumor Findings_and_Disorders_Kind Atypical teratoid/rhabdoid tumor (WHO grade IV) is a malignant embryonal CNS tumor which occurs in children and is composed of rhabdoid cells, with or without fields resembling a classical primitive neuroectodermal tumor (PNET), epithelial tissue and neoplastic mesenchyme. (Adapted from WHO.) Aggressive_Angiomyxoma Findings_and_Disorders_Kind A locally infiltrating, non-metastasizing angiomyxoma arising from the pelviperineal region. It may recur following resection Neuroblastic_Tumor Findings_and_Disorders_Kind Peripheral Neuroblastic Tumors - Neuroblastic Tumors outside the central nervous system - are clinically important neoplasms. They display a wide range of neuronal differentiation, from highly cellular, immature round cell tumors to lesions with advanced differentiation and formation of mature ganglion cells. (Adapted from WHO.) Embryonal_Neoplasm_of_the_CNS Findings_and_Disorders_Kind Embryonal tumors are a large and important fraction of pediatric brain tumors. The following histologically identifiable entities all develop on the background of an undifferentiated round-cell tumor but show a variety of divergent patterns of differentiation. It has been proposed that they be merged under the term primitive neuroectodermal tumors: Ependymoblastoma, Medulloblastoma and Supratentorial PNETs. Two other entities should be kept separate as they have a distinctly different histology and also appear to evolve by different genetic pathways: Medulloepithelioma and Atypical Teratoid/Rhabdoid Tumor. (Adapted from WHO.) Extraosseous_Ewing_s_Sarcoma Findings_and_Disorders_Kind This is a rare malignant neoplasm of the soft tissue. It is typically a disease of children and young adults. It is characterized by t(11:22) (q24: q12) resulting in the expression of EWS/FLI-1 chimeric transcript. Most commonly occurs in the paravertebral region, chest wall, pelvis and lower extremities. Treatment includes local excision with consideration for post operative chemotherapy and/or radiotherapy. - 2003 This is a rare malignant neoplasm of the soft tissue. It is typically a disease of children and young adults. Characterized by t(11:22) (q24: q12) cytogenic abnormality expressing EWS/FLI-1 chimeric transcript. Most commonly occurs in the paravertebral region, chest wall, pelvis and lower extremities. Treatment includes local excision with consideration for post operative chemotherapy and/or radiotherapy. - 2003 PRETEXT_Stage_1_Hepatoblastoma Findings_and_Disorders_Kind An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves only 1 quadrant; 3 adjoining liver quadrants are free of tumor. (from PDQ 2004) In internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves only 1 quadrant; 3 adjoining liver quadrants are free of tumor. (from PDQ 2004) PRETEXT_Stage_2_Hepatoblastoma Findings_and_Disorders_Kind An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 2 adjoining quadrants; 2 adjoining quadrants are free of tumor. (from PDQ 2004) In internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 2 adjoining quadrants; 2 adjoining quadrants are free of tumor. (from PDQ 2004) PRETEXT_Stage_3_Hepatoblastoma Findings_and_Disorders_Kind An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 3 adjoining quadrants or 2 nonadjoining quadrants; 1 quadrant or 2 nonadjoining quadrants are free of tumor. (from PDQ 2004) In internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves 3 adjoining quadrants or 2 nonadjoining quadrants; 1 quadrant or 2 nonadjoining quadrants are free of tumor. (from PDQ 2004) PRETEXT_Stage_4_Hepatoblastoma Findings_and_Disorders_Kind An internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves all 4 quadrants; there is no quadrant free of tumor. (from PDQ 2004) In internationally developed presurgical anatomic staging system using imaging techniques: Tumor involves all 4 quadrants; there is no quadrant free of tumor. (from PDQ 2004) Miscellaneous_Mesenchymal_Neoplasm Findings_and_Disorders_Kind A benign or malignant soft tissue neoplasm in which the line of differentiation is uncertain. Representative examples include neoplasm with perivascular epithelioid cell differentiation, alveolar soft part sarcoma, desmoplastic small round cell tumor, epithelioid sarcoma, extraskeletal myxoid chondrosarcoma, and synovial sarcoma. Endocardial_Myxoma Findings_and_Disorders_Kind A myxoma arising from the endocardium. Adult_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma occurring in adults. Adult_Extraskeletal_Chondrosarcoma Findings_and_Disorders_Kind An extraskeletal myxoid chondrosarcoma occurring in adults. Adult_Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind An alveolar soft part sarcoma occurring in adults. The most common site of involvement is the extremity, particularly the deep soft tissues of the thigh. Adult_Epithelioid_Sarcoma Findings_and_Disorders_Kind An epithelioid sarcoma occurring in adults. Childhood_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma occurring in childhood. Childhood_Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind An alveolar soft part sarcoma occurring in children. The most common site of involvement is the head and neck, particularly the orbit and tongue. Childhood_Epithelioid_Sarcoma Findings_and_Disorders_Kind An epithelioid sarcoma occurring in childhood. Desmoplastic_Small_Round_Cell_Tumor Findings_and_Disorders_Kind An aggressive malignant neoplasm of uncertain lineage. It is characterized by the presence of small round cells in a desmoplastic stroma. It usually affects children and young adults. The most common site of involvement is the abdomen. Patients usually present with abdominal distention, pain, ascites, and a palpable abdominal mass. The prognosis is usually poor. Hepato-Biliary_Neoplasm Findings_and_Disorders_Kind A benign or malignant neoplasm involving the liver or the biliary tract. Rhabdoid_Tumour_of_the_Kidney Findings_and_Disorders_Kind A primary renal tumor notable for clusters of acidophilic tumor cells separated by vascular septa. It can be seen concurrent with traditional Wilms tumor. This tumor is known to metastasize to lung and brain. It is associated, in the literature, with a slight male predominance. (Pizzo and Poplack, Principles and practice of pediatric oncology, 3rd edition.) Metastatic_Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind An alveolar soft part sarcoma which has spread to another anatomic site. Primary_Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind An alveolar soft part sarcoma presently contained in the anatomical site where it initially manifested. Recurrent_Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind The reemergence of alveolar soft part sarcoma after a period of remission. The reemergence of alveolar soft part sarcoma after a period of remission Metastatic_Epithelioid_Sarcoma Findings_and_Disorders_Kind An epithelioid sarcoma which has spread to another anatomic site. Primary_Epithelioid_Sarcoma Findings_and_Disorders_Kind An epithelioid sarcoma presently contained in the anatomical site where it initially manifested. Recurrent_Extraosseous_Ewing_s_Sarcoma Findings_and_Disorders_Kind Reemergence of extra-osseous Ewing sarcoma after a period of remission. Reemergence of extra-osseous Ewing sarcoma after a period of remission Metastatic_Extraskeletal_Chondrosarcoma Findings_and_Disorders_Kind An extraskeletal myxoid chondrosarcoma which has spread to another anatomic site. Pineoblastoma Findings_and_Disorders_Kind Pineoblastoma (WHO grade IV) is a highly malignant, primitive embryonal neoplasm, which occurs more commonly in children. It is composed of patternless sheets of densely packed small cells with round-to-irregular nuclei and scant cytoplasm, similar to medulloblastoma and related primitive neuroectodermal tumors. A frequent complication is metastasis via cerebrospinal fluid pathways, which is often associated with a fatal outcome. (Adapted from WHO.) Melanotic_Medulloblastoma Findings_and_Disorders_Kind Melanotic Medulloblastoma (WHO grade IV) is a rare tumor of childhood with a predominant element of small round cells closely resembling classic medulloblastoma and a minor component of melanin-forming neuroepithelial cells. (Adapted from WHO.) Waist-Hip_Ratio Properties_or_Attributes_Kind The ratio of the abdominal circumference at the navel to maximum hip and buttocks circumference; looks at the proportion of fat stored on the body around the waist and hip. Carrying extra weight around the waist is a greater health risk than carrying extra weight around the hips or thighs. ratio of the abdominal circumference at the navel to maximum hip and buttocks circumference; looks at the proportion of fat stored on your body around your waist and hip; carrying extra weight around the stomach is riskier for your health than carrying extra weight around the hips or thighs. Hematopoietic_Growth_Factor Gene_Product_Kind Endogenous growth factors which promote the development of blood cells. Growth factors which promote the development of blood cells. Procedure Activity_Kind Activity or measure that produces an effect or that is intended to alter the course of a disease in patient or population. This is a general term encompassing medical, social, behavioral, environmental and other acts that can have preventive and/or therapeutic impact. IDEC-114_Monoclonal_Antibody Chemicals_and_Drugs_Kind A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). (NCI04) A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. IDEC-114 monoclonal antibody binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). (NCI04) Extraosseous_Ewing_s_Sarcoma_Peripheral_Primitive_Neuroectodermal_Tumor Findings_and_Disorders_Kind A spectrum of malignant tumors arising from the soft tissues, characterized morphologically by the presence of small round cells. Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor. Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities. Pain and the presence of a mass are the most common clinical symptoms. -- 2004 Recurrent_Peripheral_Primitive_Neuroectodermal_Tumor_of_Bone Findings_and_Disorders_Kind The reemergence of peripheral primitive neuroectodermal tumor of bone after a period of remission. The reemergence of peripheral neuroepithelioma of bone after a period of remission Childhood_Desmoplastic_Small_Round_Cell_Tumor Findings_and_Disorders_Kind A desmoplastic small round cell tumor occurring in children. Adult_Desmoplastic_Small_Round_Cell_Tumor Findings_and_Disorders_Kind A desmoplastic small round cell tumor occurring in adults. Proximal-Type_Epithelioid_Sarcoma Findings_and_Disorders_Kind An epithelioid sarcoma predominantly involving the pelvis, perineum, and genital organs. It tends to have a more aggressive clinical course as compared to the more frequently seen distal-type epithelioid sarcoma. Distal-Type_Epithelioid_Sarcoma Findings_and_Disorders_Kind An epithelioid sarcoma involving the extremities. It usually presents as nodular masses in the dermis and subcutaneous tissues or in the tendons and fascia. It frequently recurs and metastasizes to other anatomic sites. The most common sites of metastasis are the lungs, lymph nodes, bones, and brain. Hepatic_Angiomyolipoma Findings_and_Disorders_Kind An angiomyolipoma arising from the liver. Well-Differentiated_Extraskeletal_Chondrosarcoma Findings_and_Disorders_Kind A well differentiated extraskeletal myxoid chondrosarcoma. Myxoid_Extraskeletal_Chondrosarcoma Findings_and_Disorders_Kind A rare malignant soft tissue neoplasm of uncertain lineage characterized by the presence of chondroblast-like cells in a myxoid stroma and a multinodular growth pattern. The most common sites of involvement are the deep soft tissues of the extremities, particularly the thigh. It usually presents as an enlarging soft tissue mass. Patients may have long survivals, but local recurrences and metastases occur in approximately half of the cases. The most common site of metastasis is the lungs. Trichogenic_Myxoma Findings_and_Disorders_Kind A cutaneous myxoma arising from the hair follicle. Recombinant_KSA_Glycoprotein Chemicals_and_Drugs_Kind A recombinant counterpart of tumor-associated KSA antigen (Ep-CAM), a type-I transmembrane glycoprotein cellular adhesion molecule with a molecular mass of 40 kDa, overexpressed on the majority of tumor cells of most human epithelia of variety of tumor tissues such as stomach, colon, pancreas, gall bladder, bile duct, mammary gland, breast and lung carcinoma. It has been suggested to be involved in the differentiation, growth and organization of epithelial cells within tissues under normal physiological conditions. The antigen has been used as a target for diagnosis and for passive and active immunotherapy of colorectal cancer. Immunization with KSA Glycoprotein elicits both humoral and Th1-associated cellular immune responses. Recombinant KSA Glycoprotein is a therapeutic counterpart of tumor-associated KSA antigen, a type-I transmembrane glycoprotein cellular adhesion molecule with a molecular mass of 40 kDa, overexpressed on the majority of tumor cells of most human epithelia of variety of tumor tissues such as stomach, colon, pancreas, gall bladder, bile duct, mammary gland, breast and lung carcinoma. It has been suggested to be involved in the differentiation, growth and organization of epithelial cells within tissues under normal physiological conditions. The antigen has been used as a target for diagnosis and for passive and active immunotherapy of colorectal cancer. Immunization with KSA Glycoprotein elicits both humoral and Th1-associated cellular immune responses. M_A_Radiolabeled_T101_Human_T-LYMP Chemicals_and_Drugs_Kind A radiolabeled murine monoclonal antibody (also known as T101) directed against T65, an antigen found on cutaneous T cell lymphoma (CTCL) cells and chronic lymphocytic leukemia (CLL) cells as well as normal T lymphocytes. T101 labeled with 131I, 125I, or 111In has potential use in the radioimaging of CTCL. M A radiolabeled T101 human T-lymph may induce a cytotoxic T-cell response against T65-expressing T cells. (NCI04) A radiolabeled murine monoclonal antibody (also known as T101) directed against T65, an antigen found on cutaneous T cell lymphoma (CTCL) cells and chronic lymphocytic leukemia (CLL) cells as well as normal T lymphocytes. T101 labeled with 131I, 125I, or 111In has potential use in the radioimaging of CTCL. M A radiolabeled T101 human T-lymph may induce a cytotoxic T-cell response response against T65-expressing T cells. (NCI04) Recombinant_Vaccinia-GM-CSF Retired_Kind A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth. A recombinant vaccinia virus that encodes granulocyte-macrophage colony stimulating factor (GM-CSF). By activating T-cells and macrophages, vaccination with recombinant vaccinia GM-CSF may enhance the host immune system response to poorly immunogenic tumors, resulting in decreased tumor growth. (NCI04) Ewing_s_Sarcoma_Peripheral_Primitive_Neuroectodermal_Tumor_of_Bone Findings_and_Disorders_Kind A spectrum of malignant tumors arising from the bone, characterized morphologically by the presence of small round cells. Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor. Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities. Pain and the presence of a mass are the most common clinical symptoms. -- 2004 _17-Allylamino_17-demethoxygeldanamycin Chemicals_and_Drugs_Kind A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells. (NCI04) A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. 17-allylamino 17-demethoxygeldanamycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells. (NCI04) Drug_Route_of_Administration NCI_Kind A part of the body through or into which, or the way in which, the medicinal product is intended to be introduced. In some cases a medicinal product can be intended for more than one route and/or method of administration. The course by which a substance was administered in order to reach the site of action in the body. Neoplasm_with_Perivascular_Epithelioid_Cell_Differentiation Findings_and_Disorders_Kind A soft tissue neoplasm composed of perivascular epithelioid cells. Representative examples include angiomyolipoma, clear cell-sugar-tumor of the lung, and lymphangioleiomyomatosis. Epithelioid_Type_Angiomyolipoma Findings_and_Disorders_Kind An angiomyolipoma composed exclusively or predominantly by polygonal epithelioid cells with eosinophilic cytoplasm, often associated with cytologic atypia. Lung_Lymphangioleiomyomatosis Findings_and_Disorders_Kind Lymphangiomyomatosis involving the lungs and local lymph nodes. Patients usually present with chylous pleural effusion. The clinical course is variable. Patients with resectable lesions usually have a favorable clinical outcome. Patients with diffuse lesions usually have a progressive clinical course. HPV_16E7_86-93_Lipopeptide_Vaccine Chemicals_and_Drugs_Kind A synthetic peptide (sequence: TLGIVCPI) vaccine consisting of amino acids 86 through 93 of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16 E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7. A synthetic peptide (sequence: TLGIVCPI) consisting of amino acids 86 through 93 of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination with HPV-16E7:86-93 peptide, which binds to HLA-A* 0201 molecule, may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 E7. Uterine_Corpus_Perivascular_Epithelioid_Cell_Tumor Findings_and_Disorders_Kind A neoplasm with perivascular epithelioid cell differentiation arising from the uterine corpus wall. Cervical_Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind An alveolar soft part sarcoma arising from the cervix. Vaginal_Deep_Angiomyxoma Findings_and_Disorders_Kind A locally infiltrating, non-metastasizing vaginal angiomyxoma. It may recur following resection. Vulvar_Proximal-Type_Epithelioid_Sarcoma Findings_and_Disorders_Kind An epithelioid sarcoma of the proximal type involving the vulva. Vulvar_Alveolar_Soft_Part_Sarcoma Findings_and_Disorders_Kind An alveolar soft part sarcoma arising from the vulva. Vulvar_Deep_Angiomyxoma Findings_and_Disorders_Kind A locally infiltrating, non-metastasizing vulvar angiomyxoma. It may recur following resection. Superficial_Angiomyxoma Findings_and_Disorders_Kind An angiomyxoma arising from the dermis or subcutaneous tissues. It may recur following resection. Vulvar_Superficial_Angiomyxoma Findings_and_Disorders_Kind A vulvar angiomyxoma arising from the dermis or subcutaneous tissues. It may recur following resection. Vulvar_Angiomyxoma Findings_and_Disorders_Kind A deep or superficial angiomyxoma of the vulva. It may recur following resection. Breast_Myofibroblastoma Findings_and_Disorders_Kind A myofibroblastoma occurring in the breast of both women and men. It presents as a slowly growing mass. Pharmaceutical_Dosage_Form Equipment_Kind A form in which a pharmaceutical product is presented in the medicinal product package as supplied by the marketing authorization holder, manufacturer, or distributor. The key defining characteristics of the pharmaceutical dosage form are the state of matter, delivery method, release characteristics, and the administration site or route for which the product is formulated. The form of the completed pharmaceutical product, e.g. tablet, capsule, injection, elixir, suppository. Vaginal_Angiomyofibroblastoma Findings_and_Disorders_Kind An angiomyofibroblastoma arising from the vagina. Vulvar_Angiomyofibroblastoma Findings_and_Disorders_Kind An angiomyofibroblastoma arising from the vulva. Lung_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma arising from the lungs. Lung_Biphasic_Synovial_Sarcoma Findings_and_Disorders_Kind A biphasic synovial sarcoma arising from the lungs. Lung_Monophasic_Synovial_Sarcoma Findings_and_Disorders_Kind A monophasic synovial sarcoma arising from the lungs. Pleural_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma arising in the pleural cavity. Pleural_Monophasic_Synovial_Sarcoma Findings_and_Disorders_Kind A monophasic synovial sarcoma arising in the pleural cavity. Pleural_Biphasic_Synovial_Sarcoma Findings_and_Disorders_Kind A biphasic synovial sarcoma arising in the pleural cavity. Ventricular_Myxoma Findings_and_Disorders_Kind A cardiac myxoma arising from the ventricle. Cardiac_Synovial_Sarcoma Findings_and_Disorders_Kind A synovial sarcoma arising from the heart. Cardiac_Biphasic_Synovial_Sarcoma Findings_and_Disorders_Kind A biphasic synovial sarcoma arising from the heart. Cardiac_Monophasic_Synovial_Sarcoma Findings_and_Disorders_Kind A monophasic synovial sarcoma arising from the heart. Myofibroblastoma Findings_and_Disorders_Kind A benign, well circumscribed soft tissue neoplasm characterized by the presence of spindle shaped myofibroblasts and mast cells in a collagenous stroma. Angiomyofibroblastoma Findings_and_Disorders_Kind A benign soft tissue neoplasm usually arising in the pelviperineal region, characterized by the presence of neoplastic spindle to round cells, dilated thin walled vessels, and stromal edema. Most patients present with painless circumscribed masses. Renal_Tubule Anatomy_Kind The anatomical segment of the kidney that is comprised of both the nephron and associated collecting tubules. These tubules or tubes contains fluid that has been filtered through the glomerulus. Dose_Not_Changed Activity_Kind An indication that a medication schedule was continued without modification. An indication that a medication schedule was maintained. CETP_wt_Allele Gene_Kind Human CETP wild-type allele is located within 16q21 and is approximately 22 kb in length. This allele, which encodes cholesteryl ester transfer protein, is involved in the regulation of cholesteryl ester transfer, which is critical to the processes of cholesterol metabolism and homeostasis. Aberrations in the gene may affect atherosclerosis susceptibility. Human CETP wild-type allele is located in the vicinity of 16q21 and is approximately 22 kb in length. This allele, which encodes cholesteryl ester transfer protein, is involved in the regulation of cholesteryl ester transfer, which is critical to the processes of cholesterol metabolism and homeostasis. Aberrations in the gene may affect atherosclerosis susceptibility. GC_wt_Allele Gene_Kind Human GC wild-type allele is located within 4q12-q13 and is approximately 42 kb in length. This allele, which encodes vitamin D-binding protein, is involved in the transport of vitamin D and its metabolites to targeted tissues. Human GC wild-type allele is located in the vicinity of 4q12-q13 and is approximately 42 kb in length. This allele, which encodes vitamin D-binding protein, is involved in the transport of vitamin D and its metabolites to targeted tissues. IGFBP2_wt_Allele Gene_Kind Human IGFBP2 wild-type allele is located within 2q33-q34 and is approximately 31 kb in length. This allele, which encodes insulin-like growth factor-binding protein 2, is involved in both insulin-like growth factor regulation and in the specific binding of protein-protein interactions in plasma. Separated from IGFBP5 (opposite orientation) by 20-40-kb, 4-exon 31-kb human IGFBP2 Gene at 2q33-q34 encodes cysteine-rich high molecular weight secreted 328-aa 35-kD Insulin-Like Growth Factor-Binding Protein 2 precursor, containing an IGFBP domain and a thyroglobulin type-I domain. IGF-binding proteins prolong plasma IGF half-life and alter IGF interaction with cell surface receptors. The predominant form in plasma (150-kD) contains IGF-BP53 with apparent molecular mass of 53-kD. IGFBP2 binds IGF-II with high affinity more than IGF-I. (from LocusLink, Swiss-Prot, OMIM, and NCI) IGFBP3_wt_Allele Gene_Kind Human IGFBP3 wild-type allele is located within 7p13-p12 and is approximately 9 kb in length. This allele, which encodes insulin-like growth factor-binding protein 3, plays a role in the regulation of insulin-like growth factor and in inhibition processes in the extravascular tissue compartment. The insulin-like growth factors, their receptors, and their binding proteins play key roles in regulating cell proliferation and apoptosis. Among the several roles of IGFBP3 are its function as the major carrying protein for IGF1 and IGF2 in the circulation, and its action as a modulator of IGF bioactivity and as a direct growth inhibitor in the extravascular tissue compartment, where it is expressed in a highly regulated manner (LocusLink) IGFBP4_wt_Allele Gene_Kind Human IGFBP4 wild-type allele is located within 17q12-q21.1 and is approximately 14 kb in length. This allele, which encodes insulin-like growth factor-binding protein 4, is involved in the regulation of insulin-like growth factor interactions, protein circulation in the plasma and cell surface receptor interactions. IGFBP5_wt_Allele Gene_Kind Human IGFBP5 wild-type allele is located within 2q33-q36 and is approximately 23 kb in length. This allele, which encodes insulin-like growth factor-binding protein 5, plays a role in the regulation of insulin-like growth factor and in protein transport in the circulatory system. The insulin-like growth factors, their receptors, and their binding proteins play key roles in regulating cell proliferation and apoptosis. IGFBP5 may function as a carrying protein for IGF1 and IGF2 in the circulation and it can act as an inhibitor of IGF action. IGFBP6_wt_Allele Gene_Kind Human IGFBP6 wild-type allele is located within 12q13 and is approximately 5 kb in length. This allele, which encodes insulin-like growth factor-binding protein 6, is involved in the regulation of insulin-like growth factor interactions, cellular proliferation and apoptosis. The insulin-like growth factors, their receptors, and their binding proteins play key roles in regulating cell proliferation and apoptosis. Acts as a cell density and Ca+2 dependent inhibitor of cell growth. (LocusLink) NUP214_wt_Allele Gene_Kind Human NUP214 wild-type allele is located in the vicinity of 9q34.1 and is approximately 108 kb in length. This allele, which encodes nuclear pore complex protein Nup214, plays a role in the regulation of nucleocytoplasmic transport and receptor-mediated nuclear import. The 3 prime portion of the gene can form a fusion construct with the DEK gene on chromosome 6 in a t(6,9) translocation. The translocation is associated with acute myeloid leukemia and myelodysplastic syndrome. Expressed in thymus, spleen, bone marrow, kidney, brain, and testis, human NUP214 Gene (FG-Repeat NUP Family) encodes 2090-aa 214-kDa homodimeric Nuclear Pore Complex Protein NUP214, likely glycosylated, containing F-G repeats, and associated with cytoplasmic filaments and the cytoplasmic face of the nuclear pore complex. NUP214 is required for proper cell cycle progression and, as a nuclear pore component, may regulate nucleocytoplasmic transport by serving as a docking site in receptor-mediated nuclear import. NUP214 interacts with DDX19 and NUP88. Involved in some cases of leukemia, chromosomal translocation t(6;9)(p23;q34) results in a DEK-NUP214 fusion gene, while chromosomal translocation t(6;9)(q21;q34.1) involves a NUP214/SET gene fusion. (NCI) NUP98_wt_Allele Gene_Kind Human NUP98 wild-type allele is located in the vicinity of 11p15.5 and is approximately 123 kb in length. This allele, which encodes nuclear pore complex protein Nup98-Nup96 protein, is involved in the regulation of the nuclear pore complex and protein docking. Translocations in several myeloid leukemias contain NUP98 fused to other genes; t(7;11)(p15;p15) generates N-terminal NUP98 fused in-frame to HOXA9. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. Up regulated by interferon, human NUP98 Gene (GLFG Nucleoporin Family) in an imprinted domain at 11p15 encodes Nucleoporin 98 kD in several alternative variants. Proteolytic cleavage of a 186 kD precursor yields NUP98 and NUP96, both located at the multiprotein nuclear pore complex (NPC) nucleoplasmic side. NUP96 and NUP98 targeting to the NPC is dependent on cleavage. NUP98 may function as a docking protein for import. The C-terminal RNA-binding domain of NUP98 contains NPC target sequences, a novel protein fold, and an autocatalytic protease; docking/transport function is located in the N-terminal GLFG/FXFG repeats. Vesicular Stomatitis Virus M Protein targets NUP98. Translocations in several myeloid leukemias fuse NUP98 to other genes; t(7;11)(p15;p15) generates N-terminal NUP98 fused in-frame to HOXA9. (from LocusLink 4928, Swiss-Prot P52948, OMIM 601021, and NCI) POV1_wt_Allele Gene_Kind Human SLC43A1 wild-type allele is located within 11p11.2-p11.1 and is approximately 31 kb in length. This allele, which encodes large neutral amino acids transporter small subunit 3 protein, plays a role in the transport of large neutral amino acids. Alterations in the gene may play a role in the development of human prostate cancer. Expressed (2.6-kb transcript) in a variety of tissues (fetal liver and adult pancreas highest), human POV1 Gene encodes 559-aa L-Type Amino Acid Transporter 3, containing a putative secretory signal peptide and a leucine zipper motif. (NCI) SLC22A1L_wt_Allele Gene_Kind Human SLC22A18 wild-type allele is located in the vicinity of 11p15.5 and is approximately 26 kb in length. This allele, which encodes organic cation transporter-like protein 2, is involved in tumor suppression and may play a role in the transport of organic cations. Preferentially expressed from the maternal chromosome predominantly in fetal and adult liver and kidney as 2 alternative transcripts, 23-kb 11-exon human SLC22A1L Gene (Polyspecific Transporter/MDR Family) in an imprinted gene domain at 11p15.5 encodes 424-aa Tumor Suppressing Subtransferable Candidate 5 Protein (Organic Cation Transporter-Like 2 Protein), a polyspecific organic-cation transporter containing 10 transmembrane segments and involved in excretion of endogenous and exogenous compounds. Divergent SLC22A1L and ORCTL2S genes overlap; ORCTL2S exon 1 shares 31 bp with SLC22A1L exon 2. SLC22A1L translation may begin at the second methionine, which would result in a 408-amino acid protein. (NCI) SLC22A1L_wt_Allele Gene_Kind This gene is one of several tumor-suppressing subtransferable fragments located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene may play a role in malignancies and disease that involve this region as well as the transport of chloroquine- and quinidine-related compounds in the kidney. (LocusLink) SLC25A4_wt_Allele Gene_Kind Human SLC25A4 wild-type allele is located within 4q35 and is approximately 4 kb in length. This allele, which encodes ADP/ATP translocase 1 protein, plays a role in the regulation of cellular dependence on oxidative energy metabolism. Defects in the gene are a cause of progressive external ophthalmoplegia. Expressed as a 1.4 kb mRNA in heart, kidney, liver, skeletal muscle, 6-kb 4-exon human SLC25A4 Gene (Mitochondrial Carrier Family) encodes 298-aa 33-kDa homodimeric Adenine Nucleotide Translocator-1, an integral membrane protein embedded asymmetrically in the inner mitochondrial membrane that catalyzes transmembrane exchange of ADP and ATP and determines the rate of ADP/ATP flux between mitochondrion and cytosol. Strongly similar to murine Ant1, ANT1 contains 3 Solcar repeats and the signature RRRMMM motif of nucleotide carriers; six alpha helices form a compact transmembrane domain. Defects in SLC25A4 are a cause of PEO. (NCI) Yttrium_Y_90_DOTA_Chimeric_Monoclonal_Antibody_cG250 Chemicals_and_Drugs_Kind A radioimmunoconjugate comprised of the chimeric monoclonal antibody cG250 conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting radioisotope yttrium 90. The antibody moiety of yttrium 90 DOTA chimeric monoclonal antibody cG250 binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation. A radioimmunoconjugate comprised of the chimeric monoclonal antibody cG250 conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the beta-emitting radioisotope yttrium Y 90. The antibody moiety of yttrium Y 90 DOTA chimeric monoclonal antibody cG250 binds to renal cell carcinoma cells expressing the G250 antigen, thereby selectively delivering a cytotoxic dose of beta radiation. Cellular_Myxoma Findings_and_Disorders_Kind A myxoma with increased cellularity. Pleomorphic_Hyalinizing_Angiectatic_Tumor_of_Soft_Parts Findings_and_Disorders_Kind A non-metastasizing soft tissue neoplasm characterized by the presence of a neoplastic stroma containing spindle cells, dilated thin-walled vessels lined by fibrin, and a chronic inflammatory infiltrate. The majority of cases develop in the subcutaneous tissues usually in the lower extremities and present as slow growing masses. Recurrences occur in approximately half of the cases. Ectopic_Hamartomatous_Thymoma Findings_and_Disorders_Kind A benign, well circumscribed tumor of the neck occurring in adults. It is characterized by the presence of spindle cells, epithelial islands, and adipose tissue. Intimal_Sarcoma Findings_and_Disorders_Kind A malignant neoplasm arising from the large blood vessels. It is characterized by the presence of tumor cells that grow within the lumen of the blood vessels. The intraluminal tumor growth may result in vascular obstruction and spread of tumor emboli to peripheral organs. The prognosis is usually poor. Fluoroethyl-L-tyrosine_F_18 Chemicals_and_Drugs_Kind An amino acid analog radiolabeled with fluorine F 18, a positron emitting isotope, used as a tracer in positron emission tomography (PET). Reflecting the increased amino acid transport capacity of tumor cells, F-18 fluroethyltyrosine (F-18 FET) is actively taken up in tumor cells via amino acid transport system, but is neither incorporated into proteins nor readily degraded, resulting in high intracellular concentrations of this imaging agent. Radiolabeled amino acid-based agents are useful in PET brain tumor imaging because F-18 fluoro-deoxyglucose (F-18 FDG), commonly used in PET tumor imaging, is relatively insensitive for detecting tumors in the brain due the high levels of glycolytic metabolism in the normal cortex and to a lesser extent in white matter. An amino acid analog radiolabeled with fluorine F 18, a positron emitting isotope, used as a tracer in positron emission tomography (PET). Reflecting the increased amino acid transport capacity of tumor cells, F-18 fluroethyltyrosine (F-18 FET) is actively taken up in tumor cells via amino acid transport system L, but is neither incorporated into proteins nor readily degraded, resulting in high intracellular concentrations of this imaging agent. Radiolableled amino acid-based agents are useful in PET brain tumor imaging because F-18 fluoro-deoxyglucose (F-18 FDG), commonly used in PET tumor imaging, is relatively insensitive for detecting tumors in the brain due the high levels of glycolytic metabolism in the normal cortex and to a lesser extent in white matter. Adenovirus-transduced_HER-2_Autologous_Dendritic_Cell_Vaccine Chemicals_and_Drugs_Kind A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, adenovirus-HER2 transduced autologous dendritic cell vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers. A cell-based cancer vaccine composed of autologous dendritic cells (DCs) transduced with a replication-deficient adenovirus vector encoding HER-2 with potential antineoplastic activity. Upon administration, autologous dendritic cell/adenovirus-expressing HER-2 vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against HER-2-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by some breast, ovarian, and gastric cancers. EM-1421 Chemicals_and_Drugs_Kind A semi-synthetic nordihydroguaiaretic acid (NDGA) derivative and transcriptional inhibitor with potential antiviral and antitumor activity. Tetra-O-methyl nordihydroguaiaretic acid competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In viral-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by this agent interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2) and survivin, both overexpressed in many cancers. By suppressing Sp1-regulated transcription, tetra-O-methyl nordihydroguaiaretic acid inhibits the production of cdc2 and survivin leading to a reduction of tumor cell proliferation and an induction of apoptosis. A small molecule and transcriptional inhibitor with potential antiviral and antitumor activity. EM-1421, a semi-synthetic nordihydroguaiaretic acid (NDGA) derivative, competes with the transcription factor Sp1 for specific Sp1 DNA binding domains within gene promoter regions during DNA synthesis. In viral-infected cells, blocking of the Sp1 binding site suppresses Sp1-regulated viral promoter activity and gene expression, thereby inhibiting viral transcription and replication. In tumor cells, blockage of Sp1 binding sites by EM-1421 interferes with the transcription of the Sp1-dependant genes cyclin-dependant kinase (Cdc2), a protein kinase involved in cell cycle progression, and survivin, an apoptosis inhibitor, both overexpressed in many cancers. By suppressing Sp1-regulated transcription, EM-1421 inhibits the production of cdc2 and survivin leading to a reduction of tumor cell proliferation and an induction of apoptosis. Guanfacine Chemicals_and_Drugs_Kind A centrally acting adrenergic agonist with non-stimulant and antihypertensive property. Guanfacine selectively stimulates alpha-2 adrenergic receptors in the central nervous system, thereby resulting in inhibition of sympathetic nervous system outflow. Used alone or in combination with other drugs, this agent causes reduction of peripheral and renal vascular resistance, and lowers both systolic and diastolic blood pressure and heart rate. A centrally acting adrenergic agonist with non-stimulant and antihypertensive property. Guanfacine selectively stimulates alpha-2 adrenergic receptors in the central nervous system, thereby resulting in inhibition of sympathetic nervous system outflow. Used along or in combination with other drugs, this agent causes reduction of peripheral and renal vascular resistance, and lowers both systolic and diastolic blood pressure and heart rate. NY-ESO-1_Plasmid_DNA_Vaccine Chemicals_and_Drugs_Kind A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 used as a cancer vaccine. NY-ESO-1, a tumor associated antigen found in normal testis and expressed on the surface of various tumors, including melanoma, breast, bladder, prostate, lung, ovarian and hepatocellular cancers. Vaccination with NY-ESO-1 plasmid DNA cancer vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. A plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1 used as a cancer vaccine. NY-ESO-1, a tumor associated antigen found in normal testis and expressed on the surface of various tumors, including melanoma, breast, bladder, prostate, lung, ovarian and hepatocellular cancers. Vaccination with NY-ESO-1 plasmid DNA vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte response against tumor cells expressing the NY-ESO-1 antigen, resulting in tumor cell lysis. CHP-HER-2_Peptide_Vaccine Chemicals_and_Drugs_Kind A peptide vaccine containing nanoparticles of cholesterol-bearing hydrophobized pullulan (CHP) complexed with the tumor-associated antigen HER-2/neu (ErbB-2) with potential antineoplastic activity. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumors, including breast, ovarian and gastric cancers. Vaccination with CHP-HER-2 peptide vaccine may stimulate the host immune system to mount a humoral as well as a cytotoxic T-cell response against tumor cells expressing the HER-2/neu antigen. This results in an inhibition of tumor cell proliferation and tumor cell death. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water. CHP-NY-ESO-1_Peptide_Vaccine Chemicals_and_Drugs_Kind A peptide vaccine containing nanoparticles of cholesterol-bearing hydrophobized pullulan (CHP) complexed with the cancer-testis antigen NY-ESO-1 protein with potential antineoplastic activity. NY-ESO-1, an antigen found in normal testis, is upregulated in various tumors, including bladder, breast, hepatocellular, melanoma, and prostate cancers. Vaccination with CHP-NY-ESO-1 peptide vaccine may stimulate the host immune system to mount a humoral as well as a cytotoxic T-cell response against tumor cells expressing NY-ESO-1 antigen, resulting in tumor cell lysis. The self-aggregating CHP, composed of a pullulan backbone and cholesterol branches, forms stable colloidal nanoparticles in water. _2-Methoxyestradiol_Nanocrystal_Colloidal_Dispersion Chemicals_and_Drugs_Kind An orally bioavailable liquid formulation containing the small molecule 2-methoxyestradiol with potential antineoplastic activity. 2-Methoxyestradiol, a naturally occurring estradiol metabolite, exerts its antitumor effect by inhibiting endothelial cells as well as tumor cells through multiple mechanisms. This agent binds to tubulin and disrupts microtubule formation, thereby preventing mitosis and subsequent cellular proliferation. In addition, 2-methoxyestradiol induces caspase activation resulting in cell cycle arrest in the G2 phase and eventually apoptosis. This agent also down-regulates hypoxia inducible factor-one alpha (HIF-1a). The nanocrystal colloidal dispersion increases the absorption of 2-methoxyestradiol, thereby improving its bioavailability resulting in enhanced drug plasma levels. Gene_Expression_Profiling Retired_Kind Analysis using microarray technology (e.g., cDNA arrays to see gene expression or protein microarrays to profile the pattern of proteins). R-CHOP_Regimen Chemotherapy_Regimen_Kind A chemoimmunotherapy regimen containing rituximab, cyclophosphamide, vincristine and prednisone that is used for the treatment of indolent and aggressive non-Hodgkin's lymphoma; also used for the treatment of mantle cell lymphoma. A regimen containing rituximab, cyclophosphamide, vincristine and prednisone that is used for the treatment of indolent and aggressive non-Hodgkin's lymphoma; also used for the treatment of mantle cell lymphoma. Pegylated_Paclitaxel Chemicals_and_Drugs_Kind An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. Oral_Topotecan_Hydrochloride Chemicals_and_Drugs_Kind An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines. IFL_Regimen Chemotherapy_Regimen_Kind A regimen containing irinotecan, fluorouracil and leucovorin, all administered as bolus doses, and used for the treatment of advanced stage colorectal cancer. FU-LV_Regimen Chemotherapy_Regimen_Kind A regimen containing fluorouracil and leucovorin, given in a variety of doses and schedules, used for the adjuvant treatment of colorectal cancer. Irinotecan-Cetuximab_Regimen Chemotherapy_Regimen_Kind A chemo-immunotherapy regimen containing irinotecan and cetuximab used for the treatment of advanced stage colorectal cancer. IFL-Bevacizumab_Regimen Chemotherapy_Regimen_Kind A chemo-immunotherapy regimen containing irinotecan, fluorouracil, leucovorin and bevacizumab, used for the treatment of advanced stage colorectal cancer. FU-LV-Bevacizumab_Regimen Chemotherapy_Regimen_Kind A chemo-immunotherapy regimen consisting of fluorouracil and leucovorin given with bevacizumab, used for the treatment of advanced stage colorectal cancer. IFL-Douillard_Regimen Chemotherapy_Regimen_Kind A regimen containing irinotecan, infusional fluorouracil and leucovorin, used for the treatment of advanced stage colorectal cancer. This regimen differs from the FOLFIRI regimen with regards to the dose of fluorouracil administered. Concepts with a Contributing_Source and DEFINITION without an ALT-DEFINITION in TDEByNameForProduction-06.12d.xml : code name source kind comment C207 Adenosine FDA Chemicals_and_Drugs_Kind C215 Albuterol FDA Chemicals_and_Drugs_Kind C217 Methanol FDA Chemicals_and_Drugs_Kind C220 Alfentanil_Hydrochloride FDA Chemicals_and_Drugs_Kind C227 Alprazolam FDA Chemicals_and_Drugs_Kind C230 Amikacin FDA Chemicals_and_Drugs_Kind C236 Amiodarone FDA Chemicals_and_Drugs_Kind C239 Ampicillin FDA Chemicals_and_Drugs_Kind C285 Ascorbic_Acid FDA Chemicals_and_Drugs_Kind C300 Diphenhydramine_Hydrochloride FDA Chemicals_and_Drugs_Kind C303 Betamethasone FDA Chemicals_and_Drugs_Kind C317 Bromocriptine FDA Chemicals_and_Drugs_Kind C334 Edetate_Calcium_Disodium FDA Chemicals_and_Drugs_Kind C354 Cefotaxime FDA Chemicals_and_Drugs_Kind C363 Chloramphenicol FDA Chemicals_and_Drugs_Kind C364 Chlorhexidine FDA Chemicals_and_Drugs_Kind C367 Chlorpromazine FDA Chemicals_and_Drugs_Kind C369 Cholesterol FDA Chemicals_and_Drugs_Kind C377 Clindamycin FDA Chemicals_and_Drugs_Kind C378 Clofibrate FDA Chemicals_and_Drugs_Kind C379 Clomiphene FDA Chemicals_and_Drugs_Kind C385 Colchicine FDA Chemicals_and_Drugs_Kind C391 Copper FDA Chemicals_and_Drugs_Kind C398 Diltiazem_Hydrochloride FDA Chemicals_and_Drugs_Kind C415 Dapsone FDA Chemicals_and_Drugs_Kind C417 Deferoxamine_Mesylate FDA Chemicals_and_Drugs_Kind C423 Dextromethorphan FDA Chemicals_and_Drugs_Kind C455 Dopamine FDA Chemicals_and_Drugs_Kind C468 Enalapril FDA Chemicals_and_Drugs_Kind C473 Therapeutic_Epinephrine FDA Chemicals_and_Drugs_Kind C474 Epirubicin FDA Chemicals_and_Drugs_Kind C478 Therapeutic_Estradiol FDA Chemicals_and_Drugs_Kind C480 Estramustine_Phosphate_Sodium FDA Chemicals_and_Drugs_Kind C482 Conjugated_Estrogens FDA Chemicals_and_Drugs_Kind C484 Therapeutic_Estrone FDA Chemicals_and_Drugs_Kind C486 Ethinyl_Estradiol FDA Chemicals_and_Drugs_Kind C499 Flecainide FDA Chemicals_and_Drugs_Kind C507 Fluoxymesterone FDA Chemicals_and_Drugs_Kind C508 Flurbiprofen FDA Chemicals_and_Drugs_Kind C537 Haloperidol FDA Chemicals_and_Drugs_Kind C598 Iron FDA Chemicals_and_Drugs_Kind C600 Isoniazid FDA Chemicals_and_Drugs_Kind C610 Levamisole FDA Chemicals_and_Drugs_Kind C611 Levodopa FDA Chemicals_and_Drugs_Kind C614 Lidocaine FDA Chemicals_and_Drugs_Kind C618 Loperamide FDA Chemicals_and_Drugs_Kind C620 Lovastatin FDA Chemicals_and_Drugs_Kind C627 Nitrogen_Mustard FDA Chemicals_and_Drugs_Kind C636 Mestranol FDA Chemicals_and_Drugs_Kind C646 Methylphenidate FDA Chemicals_and_Drugs_Kind C665 Mitoxantrone FDA Chemicals_and_Drugs_Kind C669 Morphine FDA Chemicals_and_Drugs_Kind C673 Mycophenolic_Acid FDA Chemicals_and_Drugs_Kind C703 Norgestrel FDA Chemicals_and_Drugs_Kind C741 Phenytoin FDA Chemicals_and_Drugs_Kind C775 Prochlorperazine_Maleate FDA Chemicals_and_Drugs_Kind C779 Promethazine FDA Chemicals_and_Drugs_Kind C793 Quinidine FDA Chemicals_and_Drugs_Kind C808 Riboflavin FDA Chemicals_and_Drugs_Kind C817 Ceftriaxone FDA Chemicals_and_Drugs_Kind C831 Etidronate_Disodium FDA Chemicals_and_Drugs_Kind C837 Therapeutic_Growth_Hormone FDA Chemicals_and_Drugs_Kind C855 Tamoxifen FDA Chemicals_and_Drugs_Kind C862 Therapeutic_Testosterone FDA Chemicals_and_Drugs_Kind C863 Testosterone_Propionate FDA Chemicals_and_Drugs_Kind C865 Tetracycline FDA Chemicals_and_Drugs_Kind C888 Therapeutic_Levothyroxine FDA Chemicals_and_Drugs_Kind C904 Trifluoperazine FDA Chemicals_and_Drugs_Kind C931 Vinblastine_Sulfate FDA Chemicals_and_Drugs_Kind C960 Hydroxyprogesterone_Caproate FDA Chemicals_and_Drugs_Kind C992 Monobenzone FDA Chemicals_and_Drugs_Kind C1020 Bismuth_Subsalicylate FDA Chemicals_and_Drugs_Kind C1033 Citrated_Caffeine FDA Chemicals_and_Drugs_Kind C1042 Cetirizine FDA Chemicals_and_Drugs_Kind C1051 Cilostazol FDA Chemicals_and_Drugs_Kind C1058 Cortisone_Acetate FDA Chemicals_and_Drugs_Kind C1090 Estradiol_Valerate FDA Chemicals_and_Drugs_Kind C1093 Etoposide_Phosphate FDA Chemicals_and_Drugs_Kind C1100 Cefixime FDA Chemicals_and_Drugs_Kind C1102 Fludarabine_Phosphate FDA Chemicals_and_Drugs_Kind C1156 Megestrol_Acetate FDA Chemicals_and_Drugs_Kind C1160 Meropenem FDA Chemicals_and_Drugs_Kind C1172 Nandrolone_Decanoate FDA Chemicals_and_Drugs_Kind C1193 Foscarnet FDA Chemicals_and_Drugs_Kind C1202 Prednisolone_Acetate FDA Chemicals_and_Drugs_Kind C1219 Ketorolac FDA Chemicals_and_Drugs_Kind C1222 SC-48334 FDA Chemicals_and_Drugs_Kind C1238 Strontium_Chloride_Sr_89 FDA Chemicals_and_Drugs_Kind C1242 Tazobactam FDA Chemicals_and_Drugs_Kind C1246 Testosterone_Cypionate FDA Chemicals_and_Drugs_Kind C1247 Testosterone_Enanthate FDA Chemicals_and_Drugs_Kind C1317 Bupropion FDA Chemicals_and_Drugs_Kind C1319 Leuprolide FDA Chemicals_and_Drugs_Kind C1326 Doxorubicin_Hydrochloride FDA Chemicals_and_Drugs_Kind C1353 Granisetron FDA Chemicals_and_Drugs_Kind C1362 Dexamethasone_Sodium_Phosphate FDA Chemicals_and_Drugs_Kind C1381 Irinotecan FDA Chemicals_and_Drugs_Kind C1386 Isosulfan_Blue FDA Chemicals_and_Drugs_Kind C1395 Vinorelbine_Ditartrate FDA Chemicals_and_Drugs_Kind C1402 Prednisolone_Sodium_Phosphate FDA Chemicals_and_Drugs_Kind C1417 Goserelin_Acetate FDA Chemicals_and_Drugs_Kind C1507 Prazosin_Hydrochloride FDA Chemicals_and_Drugs_Kind C1579 Eflornithine_Hydrochloride FDA Chemicals_and_Drugs_Kind C1583 Daunomycin FDA Chemicals_and_Drugs_Kind C1587 Idarubicin_Hydrochloride FDA Chemicals_and_Drugs_Kind C1588 Ganciclovir_Sodium FDA Chemicals_and_Drugs_Kind C1658 Warfarin_Sodium FDA Chemicals_and_Drugs_Kind C1735 Sodium_Methotrexate FDA Chemicals_and_Drugs_Kind C1736 Aminobenzoate_Potassium FDA Chemicals_and_Drugs_Kind C1739 Vincristine_Sulfate FDA Chemicals_and_Drugs_Kind C1756 Toremifene_Citrate FDA Chemicals_and_Drugs_Kind C1762 Raloxifene_Hydrochloride FDA Chemicals_and_Drugs_Kind C1779 Atrasentan FDA Chemicals_and_Drugs_Kind C1818 Ursodiol FDA Chemicals_and_Drugs_Kind C1819 Hydrocortisone_Sodium_Succinate FDA Chemicals_and_Drugs_Kind C1820 Mitomycin_C FDA Chemicals_and_Drugs_Kind C1849 Aminolevulinic_Acid_Hydrochloride FDA Chemicals_and_Drugs_Kind C1949 Food_and_Food_Product FDA Chemicals_and_Drugs_Kind C2015 Abarelix FDA Chemicals_and_Drugs_Kind C2095 Lopinavir FDA Chemicals_and_Drugs_Kind C2105 T-20 FDA Chemicals_and_Drugs_Kind C2190 Alcohol FDA Chemicals_and_Drugs_Kind C2194 BAY_43-9006 FDA Chemicals_and_Drugs_Kind C2301 Testolactone FDA Chemicals_and_Drugs_Kind C2328 Cefotaxime_Sodium FDA Chemicals_and_Drugs_Kind C2564 Allopurinol_Sodium FDA Chemicals_and_Drugs_Kind C2581 Liothyronine_Sodium FDA Chemicals_and_Drugs_Kind C2583 Rosiglitazone FDA Chemicals_and_Drugs_Kind C2673 Clopidogrel_Bisulfate FDA Chemicals_and_Drugs_Kind C2744 Atropine_Sulfate FDA Chemicals_and_Drugs_Kind C2827 Verapamil_Hydrochloride FDA Chemicals_and_Drugs_Kind C2828 Topotecan_Hydrochloride FDA Chemicals_and_Drugs_Kind C2829 Fluoxetine_Hydrochloride FDA Chemicals_and_Drugs_Kind C2849 Congenital_Abnormality FDA Findings_and_Disorders_Kind C2867 Amnesia FDA Findings_and_Disorders_Kind C2881 Arrhythmia FDA Findings_and_Disorders_Kind C2902 Coagulation_Disorder FDA Findings_and_Disorders_Kind C2982 Depression FDA Findings_and_Disorders_Kind C2987 Diarrhea FDA Findings_and_Disorders_Kind C2990 Gastrointestinal_Disorder CDISC Findings_and_Disorders_Kind C3003 Effusion FDA Findings_and_Disorders_Kind C3009 Endocrine_Disorder CDISC Findings_and_Disorders_Kind C3036 Fatigue FDA Findings_and_Disorders_Kind C3046 Fracture FDA Findings_and_Disorders_Kind C3079 Heart_Disease CDISC Findings_and_Disorders_Kind C3090 Hematuria FDA Findings_and_Disorders_Kind C3094 Hemoptysis FDA Findings_and_Disorders_Kind C3197 Breast_Lump FDA Findings_and_Disorders_Kind C3245 Fungal_Infection FDA Findings_and_Disorders_Kind C3258 Nausea FDA Findings_and_Disorders_Kind C3303 Pain FDA Findings_and_Disorders_Kind C3327 Skin_Discoloration FDA Findings_and_Disorders_Kind C3344 Pruritus FDA Findings_and_Disorders_Kind C3371 Skin_Disorder CDISC Findings_and_Disorders_Kind C3399 Swelling FDA Findings_and_Disorders_Kind C3442 Vomiting FDA Findings_and_Disorders_Kind C3507 Immune_System_Disorder CDISC Findings_and_Disorders_Kind C3508 Injection_Site_Reaction FDA Biological_Process_Kind C3671 Injury FDA Findings_and_Disorders_Kind C3959 Liver_and_Biliary_Tract_Disorder CDISC Findings_and_Disorders_Kind C4080 Perforation FDA Findings_and_Disorders_Kind C9442 Deposit FDA Findings_and_Disorders_Kind C9445 Rupture FDA Findings_and_Disorders_Kind C12472 Adipose_Tissue CDISC Anatomy_Kind C15986 Pharmacological_Treatment FDA Activity_Kind C16267 Afghanistan CDISC NCI_Kind C16268 Elderly CDISC Properties_or_Attributes_Kind C16271 Albania CDISC NCI_Kind C16274 Algeria CDISC NCI_Kind C16289 Andorra CDISC NCI_Kind C16292 Angola CDISC NCI_Kind C16299 Anticoagulation FDA Biological_Process_Kind C16303 Antigua_and_Barbuda CDISC NCI_Kind C16305 Argentina CDISC NCI_Kind C16306 Armenia CDISC NCI_Kind C16311 Australia CDISC NCI_Kind C16312 Austria CDISC NCI_Kind C16316 Azerbaijan CDISC NCI_Kind C16321 Bahamas CDISC NCI_Kind C16322 Bahrain CDISC NCI_Kind C16323 Bangladesh CDISC NCI_Kind C16324 Barbados CDISC NCI_Kind C16329 Belgium CDISC NCI_Kind C16331 Belize CDISC NCI_Kind C16333 Benin_Republic CDISC NCI_Kind C16336 Bhutan CDISC NCI_Kind C16352 African_American FDA NCI_Kind C16358 Body_Mass_Index CDISC Properties_or_Attributes_Kind C16359 Bolivia CDISC NCI_Kind C16361 Bosnia-Herzegovina CDISC NCI_Kind C16363 Botswana CDISC NCI_Kind C16364 Brazil CDISC NCI_Kind C16365 British_Indian_Ocean_Territory CDISC NCI_Kind C16367 Brunei CDISC NCI_Kind C16368 Bulgaria CDISC NCI_Kind C16369 Burkina_Faso CDISC NCI_Kind C16370 Myanmar CDISC NCI_Kind C16371 Burundi CDISC NCI_Kind C16372 Belarus CDISC NCI_Kind C16378 Cambodia CDISC NCI_Kind C16379 Cameroon CDISC NCI_Kind C16380 Canada CDISC NCI_Kind C16382 Cape_Verde CDISC NCI_Kind C16391 Cayman_Islands CDISC NCI_Kind C16409 Central_African_Republic CDISC NCI_Kind C16412 Chad CDISC NCI_Kind C16427 Chile CDISC NCI_Kind C16428 China CDISC NCI_Kind C16445 Cocos_Keeling_Islands CDISC NCI_Kind C16449 Colombia CDISC NCI_Kind C16458 Comoros CDISC NCI_Kind C16467 Congo CDISC NCI_Kind C16469 Cook_Islands CDISC NCI_Kind C16470 Costa_Rica CDISC NCI_Kind C16474 Croatia CDISC NCI_Kind C16477 Cuba CDISC NCI_Kind C16480 Cyprus CDISC NCI_Kind C16496 Denmark CDISC NCI_Kind C16506 Djibouti CDISC NCI_Kind C16519 Dominica CDISC NCI_Kind C16520 Dominican_Republic CDISC NCI_Kind C16528 Ecuador CDISC NCI_Kind C16530 Egypt CDISC NCI_Kind C16532 El_Salvador CDISC NCI_Kind C16557 Equatorial_Guinea CDISC NCI_Kind C16558 Eritrea CDISC NCI_Kind C16562 Estonia CDISC NCI_Kind C16563 Ethiopia CDISC NCI_Kind C16564 Ethnic_Group CDISC NCI_Kind C16573 Faroe_Islands CDISC NCI_Kind C16576 Female CDISC Properties_or_Attributes_Kind Concept contains multiple Contributing Sources C16582 Fiji CDISC NCI_Kind C16584 Finland CDISC NCI_Kind C16592 France CDISC NCI_Kind C16593 French_Guiana CDISC NCI_Kind C16594 French_Polynesia CDISC NCI_Kind C16596 Gabon CDISC NCI_Kind C16598 Gambia CDISC NCI_Kind C16634 Georgia CDISC NCI_Kind C16636 Germany CDISC NCI_Kind C16638 Gibraltar CDISC NCI_Kind C16639 Kiribati CDISC NCI_Kind C16645 Greece CDISC NCI_Kind C16646 Greenland CDISC NCI_Kind C16647 Grenada CDISC NCI_Kind C16651 Guadeloupe CDISC NCI_Kind C16652 Guam CDISC NCI_Kind C16654 Guatemala CDISC NCI_Kind C16655 Guinea CDISC NCI_Kind C16656 Guinea-Bissau CDISC NCI_Kind C16657 Guyana CDISC NCI_Kind C16660 Haiti CDISC NCI_Kind C16694 Honduras CDISC NCI_Kind C16695 Hong_Kong CDISC NCI_Kind C16696 Hospital FDA NCI_Kind C16699 Hungary CDISC NCI_Kind C16704 Iceland CDISC NCI_Kind C16727 India CDISC NCI_Kind C16728 Indonesia CDISC NCI_Kind C16731 Newborn CDISC Properties_or_Attributes_Kind C16755 Iran CDISC NCI_Kind C16756 Iraq CDISC NCI_Kind C16757 Ireland CDISC NCI_Kind C16760 Israel CDISC NCI_Kind C16761 Italy CDISC NCI_Kind C16762 Cote_dIvoire CDISC NCI_Kind C16763 Jamaica CDISC NCI_Kind C16764 Japan CDISC NCI_Kind C16765 Jordan CDISC NCI_Kind C16769 Kenya CDISC NCI_Kind C16771 Kyrgyzstan CDISC NCI_Kind C16773 North_Korea CDISC NCI_Kind C16774 South_Korea CDISC NCI_Kind C16775 Kuwait CDISC NCI_Kind C16780 Lao_Peoples_Democratic_Republic CDISC NCI_Kind C16783 Latvia CDISC NCI_Kind C16784 Lebanon CDISC NCI_Kind C16787 Lesotho CDISC NCI_Kind C16791 Liberia CDISC NCI_Kind C16793 Libyan_Arab_Jamahiriya CDISC NCI_Kind C16794 Liechtenstein CDISC NCI_Kind C16799 Lithuania CDISC NCI_Kind C16803 Luxembourg CDISC NCI_Kind C16807 Macau CDISC NCI_Kind C16808 Madagascar CDISC NCI_Kind C16813 Malawi CDISC NCI_Kind C16814 Malaysia CDISC NCI_Kind C16815 Maldives CDISC NCI_Kind C16816 Mali CDISC NCI_Kind C16817 Malta CDISC NCI_Kind C16822 Marshall_Islands CDISC NCI_Kind C16823 Martinique CDISC NCI_Kind C16826 Mauritania CDISC NCI_Kind C16827 Mauritius CDISC NCI_Kind C16828 Mayotte CDISC NCI_Kind C16850 Mexico CDISC NCI_Kind C16871 Moldova CDISC NCI_Kind C16874 Monaco CDISC NCI_Kind C16875 Mongolia CDISC NCI_Kind C16876 Montserrat CDISC NCI_Kind C16878 Morocco CDISC NCI_Kind C16882 Mozambique CDISC NCI_Kind C16891 Namibia CDISC NCI_Kind C16896 Nauru CDISC NCI_Kind C16901 Nepal CDISC NCI_Kind C16903 Netherlands CDISC NCI_Kind C16904 Netherlands_Antilles CDISC NCI_Kind C16913 New_Caledonia CDISC NCI_Kind C16914 New_Zealand CDISC NCI_Kind C16915 Nicaragua CDISC NCI_Kind C16916 Niger CDISC NCI_Kind C16917 Nigeria CDISC NCI_Kind C16918 Niue CDISC NCI_Kind C16919 Norfolk_Island CDISC NCI_Kind C16920 Norway CDISC NCI_Kind C16933 Oman CDISC NCI_Kind C16949 Pakistan CDISC NCI_Kind C16951 Panama CDISC NCI_Kind C16952 Papua_New_Guinea CDISC NCI_Kind C16953 Paraguay CDISC NCI_Kind C16960 Patient FDA NCI_Kind C16972 Peru CDISC NCI_Kind C16978 Philippines CDISC NCI_Kind C16993 Pitcairn_Island CDISC NCI_Kind C17000 Pleomorphism FDA NCI_Kind C17002 Poland CDISC NCI_Kind C17006 Portugal CDISC NCI_Kind C17043 Puerto_Rico CDISC NCI_Kind C17045 Qatar CDISC NCI_Kind C17049 Race FDA NCI_Kind C17095 Reunion CDISC NCI_Kind C17108 Romania CDISC NCI_Kind C17111 Russia CDISC NCI_Kind C17112 Rwanda CDISC NCI_Kind C17113 Saint_Lucia CDISC NCI_Kind C17114 Saint_Vincent_and_the_Grenadines CDISC NCI_Kind C17115 San_Marino CDISC NCI_Kind C17116 Sao_Tome_and_Principe CDISC NCI_Kind C17117 Saudi_Arabia CDISC NCI_Kind C17118 School FDA NCI_Kind C17121 Senegal CDISC NCI_Kind C17129 Seychelles CDISC NCI_Kind C17130 Sierra_Leone CDISC NCI_Kind C17134 Singapore CDISC NCI_Kind C17138 Slovenia CDISC NCI_Kind C17148 Solomon_Islands CDISC NCI_Kind C17149 Somalia CDISC NCI_Kind C17151 South_Africa CDISC NCI_Kind C17152 Spain CDISC NCI_Kind C17163 Sri_Lanka CDISC NCI_Kind C17164 Saint_Helena CDISC NCI_Kind C17165 Saint_Pierre_and_Miquelon CDISC NCI_Kind C17170 Sudan CDISC NCI_Kind C17175 Suriname CDISC NCI_Kind C17178 Svalbard_and_Jan_Mayen CDISC NCI_Kind C17179 Swaziland CDISC NCI_Kind C17180 Sweden CDISC NCI_Kind C17181 Switzerland CDISC NCI_Kind C17182 Syria CDISC NCI_Kind C17183 Tajikistan CDISC NCI_Kind C17184 Taiwan CDISC NCI_Kind C17185 Tanzania CDISC NCI_Kind C17192 Thailand CDISC NCI_Kind C17200 East_Timor CDISC NCI_Kind C17202 Togo CDISC NCI_Kind C17205 Tonga CDISC NCI_Kind C17217 Trinidad_and_Tobago CDISC NCI_Kind C17221 Tunisia CDISC NCI_Kind C17222 Turkey CDISC NCI_Kind C17223 Turkmenistan CDISC NCI_Kind C17224 Turks_and_Caicos_Islands CDISC NCI_Kind C17225 Tuvalu CDISC NCI_Kind C17228 Uganda CDISC NCI_Kind C17229 Ukraine CDISC NCI_Kind C17232 United_Arab_Emirates CDISC NCI_Kind C17233 United_Kingdom CDISC NCI_Kind C17234 United_States CDISC NCI_Kind C17244 Uruguay CDISC NCI_Kind C17246 Uzbekistan CDISC NCI_Kind C17247 Vanuatu CDISC NCI_Kind C17249 Vatican_City CDISC NCI_Kind C17250 Venezuela CDISC NCI_Kind C17252 Vietnam CDISC NCI_Kind C17255 United_States_Virgin_Islands CDISC NCI_Kind C17259 Wallis_and_Futuna_Islands CDISC NCI_Kind C17264 Yemen CDISC NCI_Kind C17265 Serbia_and_Montenegro CDISC NCI_Kind C17266 Democratic_Republic_of_the_Congo CDISC NCI_Kind C17267 Zambia CDISC NCI_Kind C17268 Zimbabwe CDISC NCI_Kind C17459 Hispanic CDISC NCI_Kind C17649 Other CDISC Properties_or_Attributes_Kind Concept contains multiple Contributing Sources C17653 British_Virgin_Islands CDISC NCI_Kind C17654 The_Former_Yugoslav_Republic_of_Macedonia CDISC NCI_Kind C17668 Czech_Republic CDISC NCI_Kind C17669 Slovakia CDISC NCI_Kind C17704 Tokelau CDISC NCI_Kind C17733 Palau CDISC NCI_Kind C17739 American_Samoa CDISC NCI_Kind C17740 Samoa CDISC NCI_Kind C17881 Federated_States_of_Micronesia CDISC NCI_Kind C17882 Northern_Mariana_Islands CDISC NCI_Kind C17884 Aruba CDISC NCI_Kind C17885 Saint_Kitts_and_Nevis CDISC NCI_Kind C17954 Falkland_Islands CDISC NCI_Kind C17998 Unknown CDISC NCI_Kind Concept contains multiple Contributing Sources C18002 Home FDA NCI_Kind C18007 Antarctica CDISC NCI_Kind C20104 Bouvet_Island CDISC NCI_Kind C20105 French_Southern_Territories CDISC NCI_Kind C20106 Heard_Island_and_McDonald_Islands CDISC NCI_Kind C20107 Kazakhstan CDISC NCI_Kind C20110 Palestinian_Territory_Occupied CDISC NCI_Kind C20111 South_Georgia_and_the_South_Sandwich_Islands CDISC NCI_Kind C20112 United_States_Minor_Outlying_Islands CDISC NCI_Kind C20113 Western_Sahara CDISC NCI_Kind C20133 Anguilla CDISC NCI_Kind C20188 Social_Concepts CDISC NCI_Kind C20197 Male CDISC Properties_or_Attributes_Kind Concept contains multiple Contributing Sources C20587 Age_Group CDISC Properties_or_Attributes_Kind C20812 Coagulation FDA Biological_Process_Kind C21007 Disability FDA NCI_Kind C21097 Sedation FDA Activity_Kind C25150 Age FDA Properties_or_Attributes_Kind C25157 Body_Surface_Area CDISC Properties_or_Attributes_Kind C25179 Hospitalization FDA Activity_Kind C25182 Inpatient FDA NCI_Kind C25193 Occupation FDA NCI_Kind C25201 Sensitivity FDA NCI_Kind C25206 Temperature CDISC Properties_or_Attributes_Kind C25208 Weight CDISC Properties_or_Attributes_Kind Concept contains multiple Contributing Sources C25218 Procedure CDISC Activity_Kind C25250 Complete CDISC Properties_or_Attributes_Kind C25297 Notification FDA Activity_Kind C25298 Systolic_Pressure CDISC Properties_or_Attributes_Kind C25299 Diastolic_Pressure CDISC Properties_or_Attributes_Kind C25301 Day CDISC Properties_or_Attributes_Kind C25347 Height CDISC Properties_or_Attributes_Kind C25370 Exclusion CDISC NCI_Kind C25376 Small CDISC Properties_or_Attributes_Kind C25464 Country CDISC NCI_Kind Concept contains multiple Contributing Sources C25490 During CDISC Properties_or_Attributes_Kind C25512 Foreign FDA Properties_or_Attributes_Kind C25532 Inclusion CDISC NCI_Kind C25613 Percentage CDISC Properties_or_Attributes_Kind C25629 Prior CDISC Properties_or_Attributes_Kind C25637 Reaction FDA Properties_or_Attributes_Kind C25681 Size CDISC NCI_Kind C25690 Street_Address FDA NCI_Kind C25741 Physician FDA NCI_Kind C25742 Pregnancy CDISC Biological_Process_Kind C25745 Failure FDA NCI_Kind C25746 Recovery CDISC Biological_Process_Kind C25751 Deterioration FDA Biological_Process_Kind C26330 Ghana CDISC NCI_Kind C26641 Buspirone FDA Chemicals_and_Drugs_Kind C26642 Dexmethylphenidate FDA Chemicals_and_Drugs_Kind C26657 Levocarnitine FDA Chemicals_and_Drugs_Kind C26667 Zileuton FDA Chemicals_and_Drugs_Kind C26670 Sildenafil_Citrate FDA Chemicals_and_Drugs_Kind C26696 Anxiety FDA Findings_and_Disorders_Kind C26713 Cataract FDA Findings_and_Disorders_Kind C26767 Eye_Disorder CDISC Findings_and_Disorders_Kind C26780 Gastritis FDA Findings_and_Disorders_Kind C26906 Urinary_Frequency FDA Findings_and_Disorders_Kind C27123 Blurred_Vision FDA Findings_and_Disorders_Kind C27574 Connective_and_Soft_Tissue_Disorder CDISC Findings_and_Disorders_Kind C27669 Respiratory_and_Thoracic_Disorder CDISC Findings_and_Disorders_Kind C27954 Adolescent CDISC Properties_or_Attributes_Kind C27990 Toxicity FDA Findings_and_Disorders_Kind C28322 Cisclomiphene FDA Chemicals_and_Drugs_Kind C28421 Sex CDISC Properties_or_Attributes_Kind Concept contains multiple Contributing Sources C28554 Death CDISC Findings_and_Disorders_Kind Concept contains multiple Contributing Sources C28804 Abacavir FDA Chemicals_and_Drugs_Kind C28806 Acebutolol FDA Chemicals_and_Drugs_Kind C28809 Acetazolamide FDA Chemicals_and_Drugs_Kind C28811 Adefovir FDA Chemicals_and_Drugs_Kind C28818 Amantadine_Hydrochloride FDA Chemicals_and_Drugs_Kind C28819 Amitriptyline FDA Chemicals_and_Drugs_Kind C28820 Amlodipine_Besylate FDA Chemicals_and_Drugs_Kind C28822 Amphetamine FDA Chemicals_and_Drugs_Kind C28824 Amprenavir FDA Chemicals_and_Drugs_Kind C28825 Anagrelide FDA Chemicals_and_Drugs_Kind C28826 Anagrelide_Hydrochloride FDA Chemicals_and_Drugs_Kind C28835 Atazanavir FDA Chemicals_and_Drugs_Kind C28836 Atenolol FDA Chemicals_and_Drugs_Kind C28837 Atorvastatin FDA Chemicals_and_Drugs_Kind C28838 Atovoquone FDA Chemicals_and_Drugs_Kind C28840 Atropine FDA Chemicals_and_Drugs_Kind C28845 Aztreonam FDA Chemicals_and_Drugs_Kind C28858 Baclofen FDA Chemicals_and_Drugs_Kind C28859 Barium_Sulfate FDA Chemicals_and_Drugs_Kind C28862 Benazepril_Hydrochloride FDA Chemicals_and_Drugs_Kind C28864 Benztropine_Mesylate FDA Chemicals_and_Drugs_Kind C28865 Benzylpenicillin_Sodium FDA Chemicals_and_Drugs_Kind C28866 Bethanechol_Chloride FDA Chemicals_and_Drugs_Kind C28870 Bisacodyl FDA Chemicals_and_Drugs_Kind C28871 Bisoprolol_Fumarate FDA Chemicals_and_Drugs_Kind C28875 Bumetanide FDA Chemicals_and_Drugs_Kind C28876 Bupivacaine FDA Chemicals_and_Drugs_Kind C28900 Calcipotriene FDA Chemicals_and_Drugs_Kind C28901 Calcium_Chloride FDA Chemicals_and_Drugs_Kind C28903 Candesartan_Cilexetil FDA Chemicals_and_Drugs_Kind C28904 Carisoprodol FDA Chemicals_and_Drugs_Kind C28905 Carteolol_Hydrochloride FDA Chemicals_and_Drugs_Kind C28906 Carvedilol FDA Chemicals_and_Drugs_Kind C28911 Cefaclor FDA Chemicals_and_Drugs_Kind C28912 Cefadroxil FDA Chemicals_and_Drugs_Kind C28913 Cefazolin FDA Chemicals_and_Drugs_Kind C28914 Cefdinir FDA Chemicals_and_Drugs_Kind C28915 Cefoxitin_Sodium FDA Chemicals_and_Drugs_Kind C28920 Cetirizine_Hydrochloride FDA Chemicals_and_Drugs_Kind C28924 Chlorothiazide FDA Chemicals_and_Drugs_Kind C28925 Chlorpheniramine_Maleate FDA Chemicals_and_Drugs_Kind C28926 Chlorzoxazone FDA Chemicals_and_Drugs_Kind C28932 Citalopram_Hydrobromide FDA Chemicals_and_Drugs_Kind C28934 Clobetasol_Propionate FDA Chemicals_and_Drugs_Kind C28935 Clonazepam FDA Chemicals_and_Drugs_Kind C28936 Clozapine FDA Chemicals_and_Drugs_Kind C28941 Cortrsyn FDA Chemicals_and_Drugs_Kind C28946 Cromolyn_Sodium FDA Chemicals_and_Drugs_Kind C28947 Cyclobenzaprine FDA Chemicals_and_Drugs_Kind C28948 Cyclopentolate_Hydrochloride FDA Chemicals_and_Drugs_Kind C28949 Cyproheptadine_Hydrochloride FDA Chemicals_and_Drugs_Kind C28974 Delavirdine_Mesylate FDA Chemicals_and_Drugs_Kind C28975 Demeclocycline_Hydrochloride FDA Chemicals_and_Drugs_Kind C28979 Desipramine_Hydrochloride FDA Chemicals_and_Drugs_Kind C28981 Dextroamphetamine FDA Chemicals_and_Drugs_Kind C28982 Diazepam FDA Chemicals_and_Drugs_Kind C28985 Diclofenac FDA Chemicals_and_Drugs_Kind C28986 Dicloxacillin FDA Chemicals_and_Drugs_Kind C28987 Dicyclomine_Hydrochloride FDA Chemicals_and_Drugs_Kind C28989 Adapalene FDA Chemicals_and_Drugs_Kind C28990 Digoxin FDA Chemicals_and_Drugs_Kind C28992 Dimenhydrinate FDA Chemicals_and_Drugs_Kind C28995 Diphenoxylate FDA Chemicals_and_Drugs_Kind C28997 Dobutamine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29003 Dorzolamide FDA Chemicals_and_Drugs_Kind C29005 Doxazosin_Mesylate FDA Chemicals_and_Drugs_Kind C29006 Doxepin_Hydrochloride FDA Chemicals_and_Drugs_Kind C29007 Doxycline_Hyclate FDA Chemicals_and_Drugs_Kind C29027 Efavirenz FDA Chemicals_and_Drugs_Kind C29029 Ergocalciferol FDA Chemicals_and_Drugs_Kind C29033 Ethambutol_Hydrochloride FDA Chemicals_and_Drugs_Kind C29044 Famciclovir FDA Chemicals_and_Drugs_Kind C29046 Felodipine FDA Chemicals_and_Drugs_Kind C29047 Fenofibrate FDA Chemicals_and_Drugs_Kind C29050 Fexofenadine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29054 Flunisolide FDA Chemicals_and_Drugs_Kind C29055 Fluocinolone_Acetonide FDA Chemicals_and_Drugs_Kind C29056 Fluocinonide FDA Chemicals_and_Drugs_Kind C29058 Fluorometholone FDA Chemicals_and_Drugs_Kind C29060 Flurazepam FDA Chemicals_and_Drugs_Kind C29061 Fluticasone_Propionate FDA Chemicals_and_Drugs_Kind C29062 Fluvastatin_Sodium FDA Chemicals_and_Drugs_Kind C29063 Fluvoxamine_Maleate FDA Chemicals_and_Drugs_Kind C29070 Gatifloxacin FDA Chemicals_and_Drugs_Kind C29071 Gemfibrozil FDA Chemicals_and_Drugs_Kind C29073 Glimepiride FDA Chemicals_and_Drugs_Kind C29074 Glipizide FDA Chemicals_and_Drugs_Kind C29076 Glyburide FDA Chemicals_and_Drugs_Kind C29077 Glycerin FDA Chemicals_and_Drugs_Kind C29081 Guaifenesin FDA Chemicals_and_Drugs_Kind C29098 Hydrochlorothiazide FDA Chemicals_and_Drugs_Kind C29099 Hydrocodone FDA Chemicals_and_Drugs_Kind C29101 Hydroxychloroquine_Sulfate FDA Chemicals_and_Drugs_Kind C29103 Hydroxyzine FDA Chemicals_and_Drugs_Kind C29104 Hyoscyamine FDA Chemicals_and_Drugs_Kind C29116 Imipramine FDA Chemicals_and_Drugs_Kind C29119 Indapamide FDA Chemicals_and_Drugs_Kind C29123 Lispo_Insulin FDA Chemicals_and_Drugs_Kind C29128 Ipratropium_Bromide FDA Chemicals_and_Drugs_Kind C29130 Irbesartan FDA Chemicals_and_Drugs_Kind C29133 Isoproterenol FDA Chemicals_and_Drugs_Kind C29134 Isosorbide_Dinitrate FDA Chemicals_and_Drugs_Kind C29142 Ketamine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29146 Labetalol FDA Chemicals_and_Drugs_Kind C29150 Lansoprazole FDA Chemicals_and_Drugs_Kind C29151 Latanoprost FDA Chemicals_and_Drugs_Kind C29153 Levobunolol FDA Chemicals_and_Drugs_Kind C29158 Linezolid FDA Chemicals_and_Drugs_Kind C29159 Lisinopril FDA Chemicals_and_Drugs_Kind C29160 Lodoxamide_Tromethamide FDA Chemicals_and_Drugs_Kind C29162 Loratadine FDA Chemicals_and_Drugs_Kind C29165 Losartan_Potassium FDA Chemicals_and_Drugs_Kind C29240 Magnesium_Chloride FDA Chemicals_and_Drugs_Kind C29242 Magnesium_Oxide FDA Chemicals_and_Drugs_Kind C29245 Meclizine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29249 Mesalamine FDA Chemicals_and_Drugs_Kind C29251 Metformin_Hydrochloride FDA Chemicals_and_Drugs_Kind C29252 Methocarbamol FDA Chemicals_and_Drugs_Kind C29254 Metoprolol_Succinate FDA Chemicals_and_Drugs_Kind C29255 Metoprolol_Tartrate FDA Chemicals_and_Drugs_Kind C29257 Miconazole FDA Chemicals_and_Drugs_Kind C29262 Milk_of_Magnesium FDA Chemicals_and_Drugs_Kind C29265 Mirtazapine FDA Chemicals_and_Drugs_Kind C29267 Moexipril_Hydrochloride FDA Chemicals_and_Drugs_Kind C29268 Mometasone_Furoate FDA Chemicals_and_Drugs_Kind C29271 Mupirocin FDA Chemicals_and_Drugs_Kind C29277 Nevirapine FDA Chemicals_and_Drugs_Kind C29281 Nafcillin FDA Chemicals_and_Drugs_Kind C29283 Nefazadone_Hydrochloride FDA Chemicals_and_Drugs_Kind C29285 Nelfinavir FDA Chemicals_and_Drugs_Kind C29290 Nifedipine FDA Chemicals_and_Drugs_Kind C29291 Nisoldipine FDA Chemicals_and_Drugs_Kind C29293 Nitrofurantoin FDA Chemicals_and_Drugs_Kind C29294 Nitroglycerin FDA Chemicals_and_Drugs_Kind C29303 Orlistat FDA Chemicals_and_Drugs_Kind C29305 Oseltamivir FDA Chemicals_and_Drugs_Kind C29306 Oxandrolone FDA Chemicals_and_Drugs_Kind C29307 Oxaprozin FDA Chemicals_and_Drugs_Kind C29308 Oxybutynin_Cloride FDA Chemicals_and_Drugs_Kind C29309 Oxycodone FDA Chemicals_and_Drugs_Kind C29313 Oxymetazoline_Hydrochloride FDA Chemicals_and_Drugs_Kind C29314 Oxymorphone FDA Chemicals_and_Drugs_Kind C29346 Pantoprazole FDA Chemicals_and_Drugs_Kind C29349 Pentamidine_Isethionate FDA Chemicals_and_Drugs_Kind C29355 Perphenazine FDA Chemicals_and_Drugs_Kind C29358 Pheniramine_Maleate FDA Chemicals_and_Drugs_Kind C29361 Phentermine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29363 Phenylephrine FDA Chemicals_and_Drugs_Kind C29367 Pioglitazone FDA Chemicals_and_Drugs_Kind C29368 Podofilox FDA Chemicals_and_Drugs_Kind C29372 Potassium_Citrate FDA Chemicals_and_Drugs_Kind C29374 Pramipexole_Dihydrochloride FDA Chemicals_and_Drugs_Kind C29375 Pravastatin FDA Chemicals_and_Drugs_Kind C29382 Propranolol_Hydrochloride FDA Chemicals_and_Drugs_Kind C29383 Propantheline_Bromide FDA Chemicals_and_Drugs_Kind C29384 Propofol FDA Chemicals_and_Drugs_Kind C29385 Propoxyphene_Hydrochloride FDA Chemicals_and_Drugs_Kind C29386 Propoxyphene_Napsylate FDA Chemicals_and_Drugs_Kind C29390 Pseudoephedrine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29395 Pyrazinamide FDA Chemicals_and_Drugs_Kind C29398 Quinapril FDA Chemicals_and_Drugs_Kind C29410 Rabeprazole FDA Chemicals_and_Drugs_Kind C29411 Ramipril FDA Chemicals_and_Drugs_Kind C29416 Risperidone FDA Chemicals_and_Drugs_Kind C29443 Salmeterol FDA Chemicals_and_Drugs_Kind C29444 Saquinavir FDA Chemicals_and_Drugs_Kind C29446 Scopolamine_Hydrobromide FDA Chemicals_and_Drugs_Kind C29451 Sertraline_Hydrochloride FDA Chemicals_and_Drugs_Kind C29454 Simvastatin FDA Chemicals_and_Drugs_Kind C29457 Sodium_Bicarbonate FDA Chemicals_and_Drugs_Kind C29462 Sorbitol FDA Chemicals_and_Drugs_Kind C29463 Sotalol_Hydrochloride FDA Chemicals_and_Drugs_Kind C29467 Sulfacetamide FDA Chemicals_and_Drugs_Kind C29468 Sulfadiazine FDA Chemicals_and_Drugs_Kind C29469 Sulfasalazine FDA Chemicals_and_Drugs_Kind C29470 Sumatriptan_Succinate FDA Chemicals_and_Drugs_Kind C29486 Tamsulosin_Hydrochloride FDA Chemicals_and_Drugs_Kind C29487 Tazarotene FDA Chemicals_and_Drugs_Kind C29488 Temezepam FDA Chemicals_and_Drugs_Kind C29490 Tenofovir FDA Chemicals_and_Drugs_Kind C29491 Terazosin_Hydrochloride FDA Chemicals_and_Drugs_Kind C29492 Terbinafine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29493 Terconzole FDA Chemicals_and_Drugs_Kind C29497 Thiethylperazine FDA Chemicals_and_Drugs_Kind C29498 Thioridazine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29500 Tioconazole FDA Chemicals_and_Drugs_Kind C29501 Timolol_Maleate FDA Chemicals_and_Drugs_Kind C29502 Tolazamide FDA Chemicals_and_Drugs_Kind C29503 Tolmetin FDA Chemicals_and_Drugs_Kind C29504 Tolterodine FDA Chemicals_and_Drugs_Kind C29506 Torsemide FDA Chemicals_and_Drugs_Kind C29507 Tramadol FDA Chemicals_and_Drugs_Kind C29508 Tramadol_Hydrochloride FDA Chemicals_and_Drugs_Kind C29510 Trazadone FDA Chemicals_and_Drugs_Kind C29519 Triamterene FDA Chemicals_and_Drugs_Kind C29520 Triazolam FDA Chemicals_and_Drugs_Kind C29522 Trimethobenzamide_Hydrochloride FDA Chemicals_and_Drugs_Kind C29523 Triptorelin_Pamoate FDA Chemicals_and_Drugs_Kind C29535 Valacyclovir_Hydrochloride FDA Chemicals_and_Drugs_Kind C29536 Valproic_Acid FDA Chemicals_and_Drugs_Kind C29540 Venlafaxine_Hydrochloride FDA Chemicals_and_Drugs_Kind C29551 Zaleplon FDA Chemicals_and_Drugs_Kind C29553 Zolpidem_Tartrate FDA Chemicals_and_Drugs_Kind C29602 Threonine FDA Chemicals_and_Drugs_Kind C29605 Alanine FDA Chemicals_and_Drugs_Kind C29606 Arginine FDA Chemicals_and_Drugs_Kind C29608 Aspartic_Acid FDA Chemicals_and_Drugs_Kind C29612 Proline FDA Chemicals_and_Drugs_Kind C29613 Serine FDA Chemicals_and_Drugs_Kind C29823 Hydroquinone FDA Chemicals_and_Drugs_Kind C29840 Nicardipine FDA Chemicals_and_Drugs_Kind C29844 Week CDISC Properties_or_Attributes_Kind C29846 Month CDISC Properties_or_Attributes_Kind C29848 Year CDISC Properties_or_Attributes_Kind C29849 Piperonyl_Butoxide FDA Chemicals_and_Drugs_Kind C29865 Zinc_Chloride FDA Chemicals_and_Drugs_Kind C29974 Sodium_Chloride FDA Chemicals_and_Drugs_Kind C34504 Conjunctivitis FDA Findings_and_Disorders_Kind C34582 Endocarditis FDA Findings_and_Disorders_Kind C34830 Cardiomyopathy FDA Findings_and_Disorders_Kind C35053 Syncope FDA Findings_and_Disorders_Kind C35117 Vascular_Disorder CDISC Findings_and_Disorders_Kind C35221 Abortion FDA Findings_and_Disorders_Kind C35481 Atrial_Tachycardia FDA Findings_and_Disorders_Kind C35814 Hematopoietic_System_Disorder CDISC Findings_and_Disorders_Kind C36172 Sweating FDA Findings_and_Disorders_Kind C36292 Test_Result FDA Findings_and_Disorders_Kind C37920 Bradycardia FDA Findings_and_Disorders_Kind C37921 Bruising FDA Findings_and_Disorders_Kind C37928 Confusion FDA Findings_and_Disorders_Kind C37942 Distress FDA Findings_and_Disorders_Kind C37943 Dizziness FDA Findings_and_Disorders_Kind C37965 Hemolysis FDA Biological_Process_Kind C37966 Hiccough FDA Findings_and_Disorders_Kind C37970 Hypernatremia FDA Findings_and_Disorders_Kind C37981 Intubation FDA Activity_Kind C37984 Laboratory FDA NCI_Kind C37999 Palpitations FDA Findings_and_Disorders_Kind C38003 Phlebitis FDA Findings_and_Disorders_Kind C38006 Pneumothorax FDA Findings_and_Disorders_Kind C38029 Tachycardia FDA Findings_and_Disorders_Kind C38038 Tremor FDA Findings_and_Disorders_Kind C38045 Catheterization FDA Activity_Kind C38046 Unspecified FDA Properties_or_Attributes_Kind C38057 Vertigo FDA Findings_and_Disorders_Kind C38114 Drug_Route_of_Administration CDISC NCI_Kind Concept contains multiple Contributing Sources C38275 Intravenous_Infusion CDISC NCI_Kind C38691 Phentolamine FDA Chemicals_and_Drugs_Kind C38693 Paricalcitol FDA Chemicals_and_Drugs_Kind C38696 Moxifloxacin FDA Chemicals_and_Drugs_Kind C38703 Lamotrigine FDA Chemicals_and_Drugs_Kind C39493 Pharmacoeconomic_Study CDISC Activity_Kind C39707 Aluminum_Hydroxide FDA Chemicals_and_Drugs_Kind C40866 Vasoconstriction FDA Findings_and_Disorders_Kind C41132 None CDISC Properties_or_Attributes_Kind C41198 Investigation CDISC Activity_Kind C41219 Native_Hawaiian_or_Other_Pacific_Islander FDA NCI_Kind C41222 Not_Hispanic_or_Latino CDISC NCI_Kind C41259 American_Indian_or_Alaska_Native FDA NCI_Kind C41260 Asian FDA NCI_Kind C41261 White FDA NCI_Kind C41330 EKG_ST_Segment_Depression FDA Findings_and_Disorders_Kind C41331 Adverse_Event CDISC Findings_and_Disorders_Kind Concept contains multiple Contributing Sources C41332 Adverse_Reaction FDA Findings_and_Disorders_Kind C42554 Ohm CDISC Properties_or_Attributes_Kind C42559 Degree_Celsius CDISC Properties_or_Attributes_Kind C42569 Square_Meter CDISC Properties_or_Attributes_Kind C42636 Pharmaceutical_Dosage_Form CDISC Equipment_Kind Concept contains multiple Contributing Sources C42774 Document_Title CDISC NCI_Kind C43164 Drug_Packaging_Device FDA Equipment_Kind C43820 MedDRA CDISC NCI_Kind C44277 Degree_Fahrenheit CDISC Properties_or_Attributes_Kind C44397 Lindane FDA Chemicals_and_Drugs_Kind C44435 Phenoxybenzamine FDA Chemicals_and_Drugs_Kind C44444 Selenium_Sulfide FDA Chemicals_and_Drugs_Kind C44481 Aland_Islands CDISC NCI_Kind C44482 Christmas_Island CDISC NCI_Kind C45907 Promethazine_Hydrochloride FDA Chemicals_and_Drugs_Kind C45908 Intersex CDISC Properties_or_Attributes_Kind C46088 Caesarian_Section FDA Activity_Kind C47380 Acetohexamide FDA Chemicals_and_Drugs_Kind C47381 Acetohydroxamic_Acid FDA Chemicals_and_Drugs_Kind C47382 Acetylcholine_Chloride FDA Chemicals_and_Drugs_Kind C47383 Acrivastine FDA Chemicals_and_Drugs_Kind C47384 Albendazole FDA Chemicals_and_Drugs_Kind C47385 Alclometasone_Dipropionate FDA Chemicals_and_Drugs_Kind C47386 Alosetron_Hydrochloride FDA Chemicals_and_Drugs_Kind C47387 Aluminum_Acetate FDA Chemicals_and_Drugs_Kind C47388 Ambenonium_Chloride FDA Chemicals_and_Drugs_Kind C47389 Amcinonide FDA Chemicals_and_Drugs_Kind C47391 Aminocaproic_Acid FDA Chemicals_and_Drugs_Kind C47392 Aminohippurate_Sodium FDA Chemicals_and_Drugs_Kind C47393 Aminophylline FDA Chemicals_and_Drugs_Kind C47394 Aminosalicylic_Acid FDA Chemicals_and_Drugs_Kind C47395 Amlexanox FDA Chemicals_and_Drugs_Kind C47396 Ammonium_Chloride FDA Chemicals_and_Drugs_Kind C47397 Amoxapine FDA Chemicals_and_Drugs_Kind C47398 Anisindione FDA Chemicals_and_Drugs_Kind C47399 Antazoline_Phosphate FDA Chemicals_and_Drugs_Kind C47400 Apomorphine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47401 Apraclonidine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47402 Aprotinin_Bovine FDA Chemicals_and_Drugs_Kind C47403 Aripiprazole FDA Chemicals_and_Drugs_Kind C47404 Articaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47405 Atomoxetine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47406 Avobenzone FDA Chemicals_and_Drugs_Kind C47407 Azelaic_Acid FDA Chemicals_and_Drugs_Kind C47408 Azelastine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47409 Balsalazide_Disodium FDA Chemicals_and_Drugs_Kind C47410 Bendroflumethiazide FDA Chemicals_and_Drugs_Kind C47411 Benzoyl_Peroxide FDA Chemicals_and_Drugs_Kind C47412 Bepridil_Hydrochloride FDA Chemicals_and_Drugs_Kind C47413 Betaxolol_Hydrochloride FDA Chemicals_and_Drugs_Kind C47414 Bimatoprost FDA Chemicals_and_Drugs_Kind C47415 Bivalirudin FDA Chemicals_and_Drugs_Kind C47416 Boric_Acid FDA Chemicals_and_Drugs_Kind C47417 Bosentan FDA Chemicals_and_Drugs_Kind C47418 Bretylium_Tosylate FDA Chemicals_and_Drugs_Kind C47419 Brimonidine_Tartrate FDA Chemicals_and_Drugs_Kind C47420 Brinzolamide FDA Chemicals_and_Drugs_Kind C47421 Bromodiphenhydramine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47422 Brompheniramine_Maleate FDA Chemicals_and_Drugs_Kind C47423 Bromthymol_Blue FDA Chemicals_and_Drugs_Kind C47424 Buprenorphine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47425 Butalbital FDA Chemicals_and_Drugs_Kind C47426 Butenafine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47427 Butoconazole_Nitrate FDA Chemicals_and_Drugs_Kind C47428 Cabergoline FDA Chemicals_and_Drugs_Kind C47429 Calcium_Acetate FDA Chemicals_and_Drugs_Kind C47430 Carbachol FDA Chemicals_and_Drugs_Kind C47431 Carbidopa FDA Chemicals_and_Drugs_Kind C47432 Carbinoxamine_Maleate FDA Chemicals_and_Drugs_Kind C47433 Carboprost_Tromethamine FDA Chemicals_and_Drugs_Kind C47434 Cefditoren_Pivoxil FDA Chemicals_and_Drugs_Kind C47435 Cefoperazone_Sodium FDA Chemicals_and_Drugs_Kind C47436 Ceforanide FDA Chemicals_and_Drugs_Kind C47437 Cefotetan_Disodium FDA Chemicals_and_Drugs_Kind C47438 Ceftizoxime_Sodium FDA Chemicals_and_Drugs_Kind C47439 Cefuroxime_Sodium FDA Chemicals_and_Drugs_Kind C47440 Cephapirin_Sodium FDA Chemicals_and_Drugs_Kind C47442 Cetyl_Alcohol FDA Chemicals_and_Drugs_Kind C47443 Chlordiazepoxide FDA Chemicals_and_Drugs_Kind C47444 Chloroprocaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47445 Chloroquine_Phosphate FDA Chemicals_and_Drugs_Kind C47446 Chloroxine FDA Chemicals_and_Drugs_Kind C47447 Chlorpropamide FDA Chemicals_and_Drugs_Kind C47448 Chlortetracycline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47449 Chlorthalidone FDA Chemicals_and_Drugs_Kind C47450 Cinacalcet_Hydrochloride FDA Chemicals_and_Drugs_Kind C47451 Cisatracurium_Besylate FDA Chemicals_and_Drugs_Kind C47452 Citric_Acid FDA Chemicals_and_Drugs_Kind C47453 Clavulanate_Potassium FDA Chemicals_and_Drugs_Kind C47454 Clemastine_Fumarate FDA Chemicals_and_Drugs_Kind C47455 Clocortolone_Pivalate FDA Chemicals_and_Drugs_Kind C47456 Clofazimine FDA Chemicals_and_Drugs_Kind C47457 Cloflucarban FDA Chemicals_and_Drugs_Kind C47458 Clomipramine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47459 Clorazepate_Dipotassium FDA Chemicals_and_Drugs_Kind C47460 Cloxacillin_Sodium FDA Chemicals_and_Drugs_Kind C47461 Cobalt_Chloride_Co-57 FDA Chemicals_and_Drugs_Kind C47462 Colfosceril_Palmitate FDA Chemicals_and_Drugs_Kind C47463 Corticorelin_Ovine_Triflutate FDA Chemicals_and_Drugs_Kind C47464 Cyclacillin FDA Chemicals_and_Drugs_Kind C47465 Cyclobenzaprine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47466 Cycloserine FDA Chemicals_and_Drugs_Kind C47467 Cysteamine_Bitartrate FDA Chemicals_and_Drugs_Kind C47468 Dalfopristin FDA Chemicals_and_Drugs_Kind C47469 Dapiprazole_Hydrochloride FDA Chemicals_and_Drugs_Kind C47470 Daptomycin FDA Chemicals_and_Drugs_Kind C47471 Daunorubicin_Citrate FDA Chemicals_and_Drugs_Kind C47472 Desflurane FDA Chemicals_and_Drugs_Kind C47473 Desirudin FDA Chemicals_and_Drugs_Kind C47474 Desloratadine FDA Chemicals_and_Drugs_Kind C47475 Desmopressin_Acetate FDA Chemicals_and_Drugs_Kind C47476 Desogestrel FDA Chemicals_and_Drugs_Kind C47477 Desoximetasone FDA Chemicals_and_Drugs_Kind C47478 Dexchlorpheniramine_Maleate FDA Chemicals_and_Drugs_Kind C47479 Dexmedetomidine FDA Chemicals_and_Drugs_Kind C47480 Dexmethylphenidate_Hydrochloride FDA Chemicals_and_Drugs_Kind C47481 Dexpanthenol FDA Chemicals_and_Drugs_Kind C47482 Dextroamphetamine_Sulfate FDA Chemicals_and_Drugs_Kind C47483 Diatrizoate FDA Chemicals_and_Drugs_Kind C47484 Dibenzothiophene FDA Chemicals_and_Drugs_Kind C47485 Dichlorophen FDA Chemicals_and_Drugs_Kind C47486 Diethylpropion_Hydrochloride FDA Chemicals_and_Drugs_Kind C47487 Difenoxin_Hydrochloride FDA Chemicals_and_Drugs_Kind C47488 Diflorasone_Diacetate FDA Chemicals_and_Drugs_Kind C47489 Diflunisal FDA Chemicals_and_Drugs_Kind C47490 Dihydrocodeine_Bitartrate FDA Chemicals_and_Drugs_Kind C47491 Dihydroergotamine_Mesylate FDA Chemicals_and_Drugs_Kind C47492 Dihydrostreptomycin_Sulfate FDA Chemicals_and_Drugs_Kind C47493 Diltiazem_Malate FDA Chemicals_and_Drugs_Kind C47494 Dimercaprol FDA Chemicals_and_Drugs_Kind C47495 Dipivefrin_Hydrochloride FDA Chemicals_and_Drugs_Kind C47496 Dirithromycin FDA Chemicals_and_Drugs_Kind C47497 Disopyramide_Phosphate FDA Chemicals_and_Drugs_Kind C47498 Docosanol FDA Chemicals_and_Drugs_Kind C47499 Dofetilide FDA Chemicals_and_Drugs_Kind C47500 Doxapram_Hydrochloride FDA Chemicals_and_Drugs_Kind C47501 Doxylamine_Succinate FDA Chemicals_and_Drugs_Kind C47502 Drospirenone FDA Chemicals_and_Drugs_Kind C47503 Dutasteride FDA Chemicals_and_Drugs_Kind C47504 Dyphylline FDA Chemicals_and_Drugs_Kind C47505 Echothiophate_Iodide FDA Chemicals_and_Drugs_Kind C47506 Econazole_Nitrate FDA Chemicals_and_Drugs_Kind C47507 Edrophonium_Chloride FDA Chemicals_and_Drugs_Kind C47508 Eletriptan_Hydrobromide FDA Chemicals_and_Drugs_Kind C47509 Emtricitabine FDA Chemicals_and_Drugs_Kind C47510 Enalaprilat FDA Chemicals_and_Drugs_Kind C47511 Enflurane FDA Chemicals_and_Drugs_Kind C47512 Epinastine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47513 Eplerenone FDA Chemicals_and_Drugs_Kind C47514 Epoprostenol_Sodium FDA Chemicals_and_Drugs_Kind C47515 Eprosartan_Mesylate FDA Chemicals_and_Drugs_Kind C47516 Eptifibatide FDA Chemicals_and_Drugs_Kind C47517 Ergotamine_Tartrate FDA Chemicals_and_Drugs_Kind C47518 Escitalopram_Oxalate FDA Chemicals_and_Drugs_Kind C47519 Esmolol_Hydrochloride FDA Chemicals_and_Drugs_Kind C47520 Estazolam FDA Chemicals_and_Drugs_Kind C47521 Estropipate FDA Chemicals_and_Drugs_Kind C47522 Ethionamide FDA Chemicals_and_Drugs_Kind C47523 Ethosuximide FDA Chemicals_and_Drugs_Kind C47524 Ethotoin FDA Chemicals_and_Drugs_Kind C47525 Ethynodiol_Diacetate FDA Chemicals_and_Drugs_Kind C47526 Etodolac FDA Chemicals_and_Drugs_Kind C47527 Etomidate FDA Chemicals_and_Drugs_Kind C47528 Etonogestrel FDA Chemicals_and_Drugs_Kind C47529 Ezetimibe FDA Chemicals_and_Drugs_Kind C47530 Felbamate FDA Chemicals_and_Drugs_Kind C47531 Fenoldopam_Mesylate FDA Chemicals_and_Drugs_Kind C47532 Ferric_Hexacyanoferrate_II FDA Chemicals_and_Drugs_Kind C47533 Flavoxate_Hydrochloride FDA Chemicals_and_Drugs_Kind C47534 Flumazenil FDA Chemicals_and_Drugs_Kind C47535 Fluorometholone_Acetate FDA Chemicals_and_Drugs_Kind C47536 Fluphenazine FDA Chemicals_and_Drugs_Kind C47537 Flurandrenolide FDA Chemicals_and_Drugs_Kind C47538 Fomepizole FDA Chemicals_and_Drugs_Kind C47539 Fondaparinux_Sodium FDA Chemicals_and_Drugs_Kind C47540 Formoterol_Fumarate FDA Chemicals_and_Drugs_Kind C47541 Fosfomycin_Tromethamine FDA Chemicals_and_Drugs_Kind C47542 Fosinopril_Sodium FDA Chemicals_and_Drugs_Kind C47543 Fosphenytoin_Sodium FDA Chemicals_and_Drugs_Kind C47544 Frovatriptan_Succinate FDA Chemicals_and_Drugs_Kind C47545 Gadoversetamide FDA Chemicals_and_Drugs_Kind C47546 Galantamine_Hydrobromide FDA Chemicals_and_Drugs_Kind C47547 Gallium_Citrate_Ga-67 FDA Chemicals_and_Drugs_Kind C47548 Gemifloxacin_Mesylate FDA Chemicals_and_Drugs_Kind C47549 Gluconolactone FDA Chemicals_and_Drugs_Kind C47550 Guanfacine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47551 Guanidine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47552 Halcinonide FDA Chemicals_and_Drugs_Kind C47553 Halobetasol_Propionate FDA Chemicals_and_Drugs_Kind C47554 Halothane FDA Chemicals_and_Drugs_Kind C47555 Hetacillin FDA Chemicals_and_Drugs_Kind C47556 Hexachlorophene FDA Chemicals_and_Drugs_Kind C47557 Hydroflumethiazide FDA Chemicals_and_Drugs_Kind C47558 Hydroxyamphetamine_Hydrobromide FDA Chemicals_and_Drugs_Kind C47559 Hydroxyzine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47560 Hydroxyzine_Pamoate FDA Chemicals_and_Drugs_Kind C47561 Ibutilide_Fumarate FDA Chemicals_and_Drugs_Kind C47562 Indium_In_111_Chloride FDA Chemicals_and_Drugs_Kind C47563 Insulin_Aspart_Recombinant FDA Chemicals_and_Drugs_Kind C47564 Insulin_Glargine_Recombinant FDA Chemicals_and_Drugs_Kind C47565 Iobenguane_Sulfate_I-131 FDA Chemicals_and_Drugs_Kind C47566 Iodipamide_Meglumine FDA Chemicals_and_Drugs_Kind C47567 Iopamidol FDA Chemicals_and_Drugs_Kind C47568 Iothalamate_Meglumine FDA Chemicals_and_Drugs_Kind C47569 Iothalamate_Sodium FDA Chemicals_and_Drugs_Kind C47570 Iothalamate_Sodium_I-125 FDA Chemicals_and_Drugs_Kind C47571 Ioxaglate_Meglumine FDA Chemicals_and_Drugs_Kind C47572 Ioxaglate_Sodium FDA Chemicals_and_Drugs_Kind C47573 Isocarboxazid FDA Chemicals_and_Drugs_Kind C47575 Isosorbide_Mononitrate FDA Chemicals_and_Drugs_Kind C47576 Isoxsuprine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47577 Isradipine FDA Chemicals_and_Drugs_Kind C47578 Ketoprofen FDA Chemicals_and_Drugs_Kind C47579 Ketotifen_Fumarate FDA Chemicals_and_Drugs_Kind C47580 Levalbuterol_Hydrochloride FDA Chemicals_and_Drugs_Kind C47581 Levetiracetam FDA Chemicals_and_Drugs_Kind C47582 Levocabastine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47583 Levomethadyl_Acetate_Hydrochloride FDA Chemicals_and_Drugs_Kind C47584 Levonordefrin FDA Chemicals_and_Drugs_Kind C47585 Levonorgestrel FDA Chemicals_and_Drugs_Kind C47586 Levorphanol_Tartrate FDA Chemicals_and_Drugs_Kind C47587 Lomefloxacin_Hydrochloride FDA Chemicals_and_Drugs_Kind C47588 Loracarbef FDA Chemicals_and_Drugs_Kind C47589 Loteprednol_Etabonate FDA Chemicals_and_Drugs_Kind C47590 Loxapine_Succinate FDA Chemicals_and_Drugs_Kind C47591 Mafenide_Acetate FDA Chemicals_and_Drugs_Kind C47592 Magnesium_Acetate FDA Chemicals_and_Drugs_Kind C47593 Malathion FDA Chemicals_and_Drugs_Kind C47594 Maprotiline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47595 Mebendazole FDA Chemicals_and_Drugs_Kind C47596 Meclocycline_Sulfosalicylate FDA Chemicals_and_Drugs_Kind C47597 Meclofenamate_Sodium FDA Chemicals_and_Drugs_Kind C47598 Medrysone FDA Chemicals_and_Drugs_Kind C47599 Mefenamic_Acid FDA Chemicals_and_Drugs_Kind C47600 Mefloquine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47601 Memantine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47602 Mepivacaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47603 Meprobamate FDA Chemicals_and_Drugs_Kind C47604 Mequinol FDA Chemicals_and_Drugs_Kind C47605 Metaproterenol_Sulfate FDA Chemicals_and_Drugs_Kind C47606 Metaxalone FDA Chemicals_and_Drugs_Kind C47607 Methacholine_Chloride FDA Chemicals_and_Drugs_Kind C47608 Methacycline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47609 Methamphetamine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47610 Methenamine_Hippurate FDA Chemicals_and_Drugs_Kind C47611 Methicillin_Sodium FDA Chemicals_and_Drugs_Kind C47612 Methscopolamine_Bromide FDA Chemicals_and_Drugs_Kind C47613 Methsuximide FDA Chemicals_and_Drugs_Kind C47614 Methyclothiazide FDA Chemicals_and_Drugs_Kind C47615 Methyl_Methacrylate FDA Chemicals_and_Drugs_Kind C47616 Methyldopa FDA Chemicals_and_Drugs_Kind C47617 Methyldopate_Hydrochloride FDA Chemicals_and_Drugs_Kind C47618 Methylergonovine_Maleate FDA Chemicals_and_Drugs_Kind C47619 Metyrapone FDA Chemicals_and_Drugs_Kind C47620 Midodrine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47622 Minocycline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47623 Minoxidil FDA Chemicals_and_Drugs_Kind C47624 Molindone_Hydrochloride FDA Chemicals_and_Drugs_Kind C47625 Montelukast_Sodium FDA Chemicals_and_Drugs_Kind C47626 Moricizine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47627 Nabumetone FDA Chemicals_and_Drugs_Kind C47628 Naftifine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47629 Nalbuphine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47630 Nalidixic_Acid FDA Chemicals_and_Drugs_Kind C47631 Nalmefene_Hydrochloride FDA Chemicals_and_Drugs_Kind C47632 Naphazoline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47633 Naratriptan_Hydrochloride FDA Chemicals_and_Drugs_Kind C47634 Natamycin FDA Chemicals_and_Drugs_Kind C47635 Nedocromil_Sodium FDA Chemicals_and_Drugs_Kind C47636 Nesiritide FDA Chemicals_and_Drugs_Kind C47637 Nitazoxanide FDA Chemicals_and_Drugs_Kind C47638 Norfloxacin FDA Chemicals_and_Drugs_Kind C47639 Olanzapine FDA Chemicals_and_Drugs_Kind C47640 Olmesartan_Medoxomil FDA Chemicals_and_Drugs_Kind C47641 Orphenadrine_Citrate FDA Chemicals_and_Drugs_Kind C47642 Oxazepam FDA Chemicals_and_Drugs_Kind C47643 Oxcarbazepine FDA Chemicals_and_Drugs_Kind C47644 Oxiconazole_Nitrate FDA Chemicals_and_Drugs_Kind C47645 Oxtriphylline FDA Chemicals_and_Drugs_Kind C47646 Oxybenzone FDA Chemicals_and_Drugs_Kind C47647 Oxybutynin FDA Chemicals_and_Drugs_Kind C47648 Oxymorphone_Hydrochloride FDA Chemicals_and_Drugs_Kind C47649 Oxytetracycline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47650 Palonosetron_Hydrochloride FDA Chemicals_and_Drugs_Kind C47651 Pancuronium_Bromide FDA Chemicals_and_Drugs_Kind C47652 Paromomycin_Sulfate FDA Chemicals_and_Drugs_Kind C47653 Paroxetine_Mesylate FDA Chemicals_and_Drugs_Kind C47654 Pemirolast_Potassium FDA Chemicals_and_Drugs_Kind C47655 Pemoline FDA Chemicals_and_Drugs_Kind C47656 Penciclovir_Sodium FDA Chemicals_and_Drugs_Kind C47657 Penicillin_G_Benzathine FDA Chemicals_and_Drugs_Kind C47658 Penicillin_G_Potassium FDA Chemicals_and_Drugs_Kind C47660 Pentaerythritol_Tetranitrate FDA Chemicals_and_Drugs_Kind C47661 Pentazocine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47662 Pentobarbital_Sodium FDA Chemicals_and_Drugs_Kind C47663 Perflexane FDA Chemicals_and_Drugs_Kind C47664 Perflutren FDA Chemicals_and_Drugs_Kind C47665 Pergolide_Mesylate FDA Chemicals_and_Drugs_Kind C47666 Perindopril_Erbumine FDA Chemicals_and_Drugs_Kind C47667 Phendimetrazine_Tartrate FDA Chemicals_and_Drugs_Kind C47668 Phenelzine_Sulfate FDA Chemicals_and_Drugs_Kind C47669 Phenyltoloxamine FDA Chemicals_and_Drugs_Kind C47670 Phosphoric_Acid FDA Chemicals_and_Drugs_Kind C47671 Pimecrolimus FDA Chemicals_and_Drugs_Kind C47672 Pimozide FDA Chemicals_and_Drugs_Kind C47673 Pindolol FDA Chemicals_and_Drugs_Kind C47674 Piperazine_Citrate FDA Chemicals_and_Drugs_Kind C47675 Pirbuterol_Acetate FDA Chemicals_and_Drugs_Kind C47676 Polythiazide FDA Chemicals_and_Drugs_Kind C47677 Potassium_Acetate FDA Chemicals_and_Drugs_Kind C47678 Potassium_Aminosalicylate FDA Chemicals_and_Drugs_Kind C47679 Potassium_Chloride FDA Chemicals_and_Drugs_Kind C47680 Potassium_Iodide FDA Chemicals_and_Drugs_Kind C47681 Potassium_Perchlorate FDA Chemicals_and_Drugs_Kind C47682 Pramoxine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47683 Praziquantel FDA Chemicals_and_Drugs_Kind C47684 Prednicarbate FDA Chemicals_and_Drugs_Kind C47685 Prilocaine FDA Chemicals_and_Drugs_Kind C47686 Primidone FDA Chemicals_and_Drugs_Kind C47687 Procainamide_Hydrochloride FDA Chemicals_and_Drugs_Kind C47688 Procaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47689 Procyclidine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47690 Proguanil_Hydrochloride FDA Chemicals_and_Drugs_Kind C47691 Promazine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47692 Propafenone_Hydrochloride FDA Chemicals_and_Drugs_Kind C47693 Proparacaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47694 Propylhexedrine FDA Chemicals_and_Drugs_Kind C47695 Protriptyline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47696 Pseudoephedrine_Sulfate FDA Chemicals_and_Drugs_Kind C47697 Pyridostigmine_Bromide FDA Chemicals_and_Drugs_Kind C47698 Pyrithione_Zinc FDA Chemicals_and_Drugs_Kind C47699 Quazepam FDA Chemicals_and_Drugs_Kind C47700 Quetiapine_Fumarate FDA Chemicals_and_Drugs_Kind C47701 Quinupristin FDA Chemicals_and_Drugs_Kind C47702 Remifentanil_Hydrochloride FDA Chemicals_and_Drugs_Kind C47703 Repaglinide FDA Chemicals_and_Drugs_Kind C47704 Riluzole FDA Chemicals_and_Drugs_Kind C47705 Rimexolone FDA Chemicals_and_Drugs_Kind C47706 Ritodrine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47707 Rivastigmine_Tartrate FDA Chemicals_and_Drugs_Kind C47708 Rizatriptan_Benzoate FDA Chemicals_and_Drugs_Kind C47709 Rocuronium_Bromide FDA Chemicals_and_Drugs_Kind C47710 Ropinirole_Hydrochloride FDA Chemicals_and_Drugs_Kind C47711 Rubidium_Chloride_Rb-82 FDA Chemicals_and_Drugs_Kind C47712 Scopolamine FDA Chemicals_and_Drugs_Kind C47713 Secretin_Synthetic_Human FDA Chemicals_and_Drugs_Kind C47714 Selegiline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47715 Sermorelin_Acetate FDA Chemicals_and_Drugs_Kind C47716 Sertaconazole_Nitrate FDA Chemicals_and_Drugs_Kind C47717 Sevoflurane FDA Chemicals_and_Drugs_Kind C47718 Sibutramine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47719 Sincalide FDA Chemicals_and_Drugs_Kind C47720 Sodium_Acetate FDA Chemicals_and_Drugs_Kind C47721 Sodium_Carbonate FDA Chemicals_and_Drugs_Kind C47722 Sodium_Chromate_Cr-51 FDA Chemicals_and_Drugs_Kind C47723 Sodium_Gluconate FDA Chemicals_and_Drugs_Kind C47724 Sodium_Iodide_I-123 FDA Chemicals_and_Drugs_Kind C47725 Sodium_Iodide_I-131 FDA Chemicals_and_Drugs_Kind C47726 Sodium_Lactate FDA Chemicals_and_Drugs_Kind C47727 Sodium_Sulfate FDA Chemicals_and_Drugs_Kind C47728 Spectinomycin_Hydrochloride FDA Chemicals_and_Drugs_Kind C47729 Streptomycin_Sulfate FDA Chemicals_and_Drugs_Kind C47730 Succinylcholine_Chloride FDA Chemicals_and_Drugs_Kind C47731 Sufentanil_Citrate FDA Chemicals_and_Drugs_Kind C47732 Sulbactam_Sodium FDA Chemicals_and_Drugs_Kind C47733 Sulconazole_Nitrate FDA Chemicals_and_Drugs_Kind C47734 Sulfacytine FDA Chemicals_and_Drugs_Kind C47735 Sulfadoxine FDA Chemicals_and_Drugs_Kind C47736 Sulfamethizole FDA Chemicals_and_Drugs_Kind C47737 Sulfamethoxazole FDA Chemicals_and_Drugs_Kind C47738 Sulfanilamide FDA Chemicals_and_Drugs_Kind C47739 Sulfinpyrazone FDA Chemicals_and_Drugs_Kind C47740 Sulfisoxazole FDA Chemicals_and_Drugs_Kind C47741 Sulfisoxazole_Acetyl FDA Chemicals_and_Drugs_Kind C47742 Tacrine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47743 Tadalafil FDA Chemicals_and_Drugs_Kind C47744 Tartaric_Acid FDA Chemicals_and_Drugs_Kind C47745 Technetium_Tc-99m_Apcitide FDA Chemicals_and_Drugs_Kind C47746 Telmisartan FDA Chemicals_and_Drugs_Kind C47747 Tenofovir_Disoproxil_Fumarate FDA Chemicals_and_Drugs_Kind C47748 Terbutaline_Sulfate FDA Chemicals_and_Drugs_Kind C47749 Tetrahydrozoline_Hydrochloride FDA Chemicals_and_Drugs_Kind C47750 Thallous_Chloride_Tl-201 FDA Chemicals_and_Drugs_Kind C47751 Thimerosal FDA Chemicals_and_Drugs_Kind C47752 Thiothixene FDA Chemicals_and_Drugs_Kind C47753 Thiothixene_Hydrochloride FDA Chemicals_and_Drugs_Kind C47754 Thonzonium_Bromide FDA Chemicals_and_Drugs_Kind C47755 Tiagabine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47756 Ticlopidine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47757 Timolol FDA Chemicals_and_Drugs_Kind C47758 Tiopronin FDA Chemicals_and_Drugs_Kind C47759 Tirofiban_Hydrochloride FDA Chemicals_and_Drugs_Kind C47760 Tizanidine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47761 Tocainide_Hydrochloride FDA Chemicals_and_Drugs_Kind C47762 Tolcapone FDA Chemicals_and_Drugs_Kind C47763 Tolnaftate FDA Chemicals_and_Drugs_Kind C47764 Topiramate FDA Chemicals_and_Drugs_Kind C47765 Tranexamic_Acid FDA Chemicals_and_Drugs_Kind C47766 Travoprost FDA Chemicals_and_Drugs_Kind C47767 Trazodone_Hydrochloride FDA Chemicals_and_Drugs_Kind C47768 Tribromsalan FDA Chemicals_and_Drugs_Kind C47769 Trichlormethiazide FDA Chemicals_and_Drugs_Kind C47770 Triclocarban FDA Chemicals_and_Drugs_Kind C47771 Trihexyphenidyl_Hydrochloride FDA Chemicals_and_Drugs_Kind C47772 Trimethadione FDA Chemicals_and_Drugs_Kind C47773 Trimipramine_Maleate FDA Chemicals_and_Drugs_Kind C47774 Tripelennamine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47775 Tromethamine FDA Chemicals_and_Drugs_Kind C47776 Tropicamide FDA Chemicals_and_Drugs_Kind C47777 Tubocurarine_Chloride FDA Chemicals_and_Drugs_Kind C47778 Unoprostone_Isopropyl FDA Chemicals_and_Drugs_Kind C47779 Urea_C-13 FDA Chemicals_and_Drugs_Kind C47780 Urea_C-14 FDA Chemicals_and_Drugs_Kind C47781 Valsartan FDA Chemicals_and_Drugs_Kind C47782 Vecuronium_Bromide FDA Chemicals_and_Drugs_Kind C47783 Vitamin_B5 FDA Chemicals_and_Drugs_Kind C47784 Xenon-133 FDA Chemicals_and_Drugs_Kind C47785 Zafirlukast FDA Chemicals_and_Drugs_Kind C47786 Zanamivir FDA Chemicals_and_Drugs_Kind C47787 Zinc_Acetate FDA Chemicals_and_Drugs_Kind C47789 Zolmitriptan FDA Chemicals_and_Drugs_Kind C47790 Zonisamide FDA Chemicals_and_Drugs_Kind C47791 _2-Hydroxyethyl_Methacrylate FDA Chemicals_and_Drugs_Kind C47956 Acyclovir_Sodium FDA Chemicals_and_Drugs_Kind C47957 Albuterol_Sulfate FDA Chemicals_and_Drugs_Kind C47958 Aminosalicylate_Sodium FDA Chemicals_and_Drugs_Kind C47959 Ampicillin_Sodium FDA Chemicals_and_Drugs_Kind C47960 Ampicillin_Trihydrate FDA Chemicals_and_Drugs_Kind C47961 Azathioprine_Sodium FDA Chemicals_and_Drugs_Kind C47962 Betamethasone_Valerate FDA Chemicals_and_Drugs_Kind C47963 Betamethasone_Dipropionate FDA Chemicals_and_Drugs_Kind C47964 Betamethasone_Sodium_Phosphate FDA Chemicals_and_Drugs_Kind C47965 Cefadroxil_Hemihydrate FDA Chemicals_and_Drugs_Kind C47966 Cefamandole_Nafate FDA Chemicals_and_Drugs_Kind C47967 Cefamandole_Sodium FDA Chemicals_and_Drugs_Kind C47968 Cefazolin_Sodium FDA Chemicals_and_Drugs_Kind C47969 Cephalexin_Hydrochloride FDA Chemicals_and_Drugs_Kind C47970 Cephradine_Dihydrate FDA Chemicals_and_Drugs_Kind C47971 Cephradine_Monohydrate FDA Chemicals_and_Drugs_Kind C47972 Chloramphenicol_Sodium_Succinate FDA Chemicals_and_Drugs_Kind C47973 Chlordiazepoxide_Hydrochloride FDA Chemicals_and_Drugs_Kind C47974 Chlorhexidine_Gluconate FDA Chemicals_and_Drugs_Kind C47975 Chlorpromazine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47976 Ciprofloxacin_Hydrochloride FDA Chemicals_and_Drugs_Kind C47977 Clindamycin_Hydrochloride FDA Chemicals_and_Drugs_Kind C47978 Clindamycin_Phosphate FDA Chemicals_and_Drugs_Kind C47979 Clonidine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47980 Demeclocycline FDA Chemicals_and_Drugs_Kind C47981 Diatrizoate_Sodium FDA Chemicals_and_Drugs_Kind C47982 Diatrizoate_Meglumine FDA Chemicals_and_Drugs_Kind C47983 Diclofenac_Potassium FDA Chemicals_and_Drugs_Kind C47984 Diclofenac_Sodium FDA Chemicals_and_Drugs_Kind C47985 Dicloxacillin_Sodium FDA Chemicals_and_Drugs_Kind C47986 Erythromycin_Estolate FDA Chemicals_and_Drugs_Kind C47987 Erythromycin_Ethylsuccinate FDA Chemicals_and_Drugs_Kind C47988 Erythromycin_Lactobionate FDA Chemicals_and_Drugs_Kind C47989 Erythromycin_Stearate FDA Chemicals_and_Drugs_Kind C47990 Estradiol_Acetate FDA Chemicals_and_Drugs_Kind C47991 Estradiol_Cypionate FDA Chemicals_and_Drugs_Kind C47992 Estradiol_Hemihydrate FDA Chemicals_and_Drugs_Kind C47993 Ethacrynate_Sodium FDA Chemicals_and_Drugs_Kind C47994 Fentanyl_Citrate FDA Chemicals_and_Drugs_Kind C47995 Fluphenazine_Hydrochloride FDA Chemicals_and_Drugs_Kind C47996 Fluphenazine_Decanoate FDA Chemicals_and_Drugs_Kind C47997 Flurbiprofen_Sodium FDA Chemicals_and_Drugs_Kind C47998 Haloperidol_Decanoate FDA Chemicals_and_Drugs_Kind C47999 Indomethacin_Sodium FDA Chemicals_and_Drugs_Kind C48000 Lidocaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C48001 Magnesium_Acetate_Tetrahydrate FDA Chemicals_and_Drugs_Kind C48002 Melphalan_Hydrochloride FDA Chemicals_and_Drugs_Kind C48003 Methylprednisolone_Acetate FDA Chemicals_and_Drugs_Kind C48004 Methylprednisolone_Sodium_Succinate FDA Chemicals_and_Drugs_Kind C48005 Metronidazole_Hydrochloride FDA Chemicals_and_Drugs_Kind C48006 Naproxen_Sodium FDA Chemicals_and_Drugs_Kind C48007 Ondansetron_Hydrochloride FDA Chemicals_and_Drugs_Kind C48008 Oxaprozin_Potassium FDA Chemicals_and_Drugs_Kind C48009 Oxycodone_Terephthalate FDA Chemicals_and_Drugs_Kind C48010 Oxycodone_Hydrochloride FDA Chemicals_and_Drugs_Kind C48011 Phenytoin_Sodium FDA Chemicals_and_Drugs_Kind C48012 Prilocaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C48013 Prochlorperazine_Edisylate FDA Chemicals_and_Drugs_Kind C48014 Quinidine_Sulfate FDA Chemicals_and_Drugs_Kind C48015 Quinidine_Gluconate FDA Chemicals_and_Drugs_Kind C48016 Riboflavin_Phosphate_Sodium FDA Chemicals_and_Drugs_Kind C48017 Sodium_Acetate_Anhydrous FDA Chemicals_and_Drugs_Kind C48018 Sodium_Sulfate_Anhydrous FDA Chemicals_and_Drugs_Kind C48019 Terbinafine FDA Chemicals_and_Drugs_Kind C48021 Epinephrine_Bitartrate FDA Chemicals_and_Drugs_Kind C48022 Hydrocortisone_Butyrate FDA Chemicals_and_Drugs_Kind C48023 Hydrocortisone_Probutate FDA Chemicals_and_Drugs_Kind C48024 Hydrocortisone_Valerate FDA Chemicals_and_Drugs_Kind C48025 Thiamine_Hydrochloride FDA Chemicals_and_Drugs_Kind C48026 Triamcinolone_Hexacetonide FDA Chemicals_and_Drugs_Kind C48027 Triamcinolone_Acetonide FDA Chemicals_and_Drugs_Kind C48028 Trimethoprim_Sulfate FDA Chemicals_and_Drugs_Kind C48029 Valproate_Sodium FDA Chemicals_and_Drugs_Kind C48030 Pyridoxine_Hydrochloride FDA Chemicals_and_Drugs_Kind C48031 Ziprasidone_Hydrochloride FDA Chemicals_and_Drugs_Kind C48032 Ziprasidone_Mesylate FDA Chemicals_and_Drugs_Kind C48060 Spotting FDA NCI_Kind C48194 Cholecalciferol FDA Chemicals_and_Drugs_Kind C48226 Efficacy_Lack CDISC NCI_Kind C48227 Lost_To_Follow_Up CDISC Findings_and_Disorders_Kind C48250 Physician_Decision CDISC NCI_Kind C48251 Protocol_Violation CDISC Activity_Kind C48275 Death_Related_to_Adverse_Event CDISC Findings_and_Disorders_Kind C48281 Trial_Phase CDISC NCI_Kind C48289 Distributor FDA NCI_Kind C48384 Deferasirox FDA Chemicals_and_Drugs_Kind C48441 Table FDA Equipment_Kind C48471 Publication FDA NCI_Kind C48646 Therapeutic_Norepinephrine FDA Chemicals_and_Drugs_Kind C48660 Not_Applicable CDISC Properties_or_Attributes_Kind Concept contains multiple Contributing Sources C49173 Aprepitant FDA Chemicals_and_Drugs_Kind C49399 Congenital_Familial_and_Genetic_Disorder_Class CDISC NCI_Kind C49400 Ear_and_Labyrinth_Disorder_Class CDISC NCI_Kind C49401 General_Disorders_and_Administration_Site_Conditions_Class CDISC NCI_Kind C49402 Injury_Poisoning_and_Procedural_Complication_Class CDISC NCI_Kind C49403 Metabolism_and_Nutrition_Disorder_Class CDISC NCI_Kind C49404 Pregnancy_Puerperium_and_Perinatal_Condition_Class CDISC NCI_Kind C49405 Reproductive_System_and_Breast_Disorder_Class CDISC NCI_Kind C49449 Medical_Dictionary_for_Regulatory_Activities_System_Organ_Class CDISC NCI_Kind C49468 World_Health_Organization_Adverse_Reaction_Terminology CDISC NCI_Kind C49471 Thesaurus_of_Adverse_Reaction_Terms_Coding_Symbols CDISC NCI_Kind C49474 International_Classification_of_Diseases CDISC NCI_Kind C49475 World_Health_Organization_Drug_Dictionary CDISC NCI_Kind C49476 Logical_Observation_Identifiers_Names_and_Codes CDISC NCI_Kind C49480 Category_for_Inclusion_and_or_Exclusion CDISC NCI_Kind C49484 Not_Done CDISC Properties_or_Attributes_Kind C49486 Yes_or_No_Response CDISC NCI_Kind C49487 No CDISC NCI_Kind Concept contains multiple Contributing Sources C49488 Yes CDISC NCI_Kind Concept contains multiple Contributing Sources C49489 Adverse_Event_Outcome CDISC NCI_Kind Concept contains multiple Contributing Sources C49494 Not_Recovered_And_Or_Not_Resolved CDISC Findings_and_Disorders_Kind C49495 Recovered_And_Or_Resolved_With_Sequelae CDISC Findings_and_Disorders_Kind C49496 Recovering_and_or_Resolving CDISC NCI_Kind C49498 Recovered_and_or_Resolved CDISC Findings_and_Disorders_Kind C49499 Action_Taken_with_Study_Treatment CDISC Activity_Kind C49501 Drug_Interrupted CDISC Activity_Kind C49502 Drug_Withdrawn CDISC Activity_Kind C49503 Dose_Increased CDISC Activity_Kind C49504 Dose_Not_Changed CDISC Activity_Kind C49505 Dose_Reduced CDISC Activity_Kind C49507 Medium CDISC Properties_or_Attributes_Kind C49508 Large CDISC Properties_or_Attributes_Kind C49558 Submission_Domain_Abbreviation CDISC NCI_Kind C49576 Disposition_Submission_Domain CDISC NCI_Kind C49588 Family_History_Submission_Domain CDISC NCI_Kind C49627 Reason_for_Non_Completion CDISC NCI_Kind C49631 Non_Compliance_with_Study_Drug CDISC Findings_and_Disorders_Kind C49632 Study_Terminated_by_Sponsor CDISC NCI_Kind C49633 Technical_Problem CDISC NCI_Kind C49634 Withdrawal_by_Subject CDISC NCI_Kind C49636 Both CDISC Properties_or_Attributes_Kind C49639 Status_Post CDISC Properties_or_Attributes_Kind C49640 During_and_or_After CDISC Properties_or_Attributes_Kind C49641 In_Utero CDISC Properties_or_Attributes_Kind C49642 Preterm_Newborn_Infant CDISC Properties_or_Attributes_Kind C49643 Infant_and_Toddler CDISC Properties_or_Attributes_Kind C49648 Placebo_Control CDISC Activity_Kind C49650 Diagnosis_Group CDISC Properties_or_Attributes_Kind C49651 Healthy_Subject CDISC Properties_or_Attributes_Kind C49652 Trial_Indication_Type CDISC Activity_Kind C49653 Diagnosis_Study CDISC Activity_Kind C49654 Cure_Study CDISC Activity_Kind C49655 Adverse_Effect_Mitigation_Study CDISC Activity_Kind C49656 Treatment_Study CDISC Activity_Kind C49657 Prevention_Study CDISC Activity_Kind C49658 Trial_Blinding_Schema CDISC Activity_Kind C49659 Open_Label_Study CDISC Activity_Kind C49660 Trial_Type CDISC Activity_Kind C49661 Pharmacogenomic_Study CDISC Activity_Kind C49662 Pharmacodynamic_Study CDISC Activity_Kind C49663 Pharmacokinetic_Study CDISC Activity_Kind C49664 Bioavailability_Study CDISC Activity_Kind C49665 Therapeutic_Equivalency_Study CDISC Activity_Kind C49666 Efficacy_Study CDISC Activity_Kind C49667 Safety_Study CDISC Activity_Kind C49668 Centimeter CDISC Properties_or_Attributes_Kind C49670 Millimeter_of_Mercury CDISC Properties_or_Attributes_Kind C49671 Kilogram_per_Square_Meter CDISC Properties_or_Attributes_Kind C49672 Vital_Signs_Test_Name CDISC Activity_Kind C49673 Beats_per_Minute CDISC Properties_or_Attributes_Kind C49674 Breaths_per_Minute CDISC Properties_or_Attributes_Kind C49675 Units_for_Vital_Signs_Results CDISC Properties_or_Attributes_Kind C49676 Pulse_Rate CDISC Activity_Kind C49677 Heart_Rate CDISC Activity_Kind C49678 Respiratory_Rate CDISC Activity_Kind C49679 Mean_Arterial_Pressure CDISC Findings_and_Disorders_Kind C49680 Body_Frame_Size CDISC Properties_or_Attributes_Kind C49683 Children_Two_Through_Eleven_Years_Old CDISC Properties_or_Attributes_Kind C49685 Adult_Eighteen_Through_Sixty-five_Years_Old CDISC Properties_or_Attributes_Kind C49686 Phase_IIA_Trial CDISC Activity_Kind C49688 Phase_IIB_Trial CDISC Activity_Kind C49691 Trial_Summary_Parameter CDISC Activity_Kind C49692 Planned_Subject_Number CDISC Properties_or_Attributes_Kind C49693 Planned_Minimum_Age_of_Subjects CDISC Properties_or_Attributes_Kind C49694 Planned_Maximum_Age_of_Subjects CDISC Properties_or_Attributes_Kind C49696 Sex_of_Study_Group CDISC Properties_or_Attributes_Kind C49697 Trial_Length CDISC Activity_Kind C49698 Study_Stop_Rules CDISC Activity_Kind C49700 Adverse_Event_Dictionary CDISC NCI_Kind C49701 Drug_Dictionary CDISC NCI_Kind C49702 Medical_History_Dictionary CDISC NCI_Kind C49704 Common_Toxicity_Criteria_for_Adverse_Event_Grading_System CDISC NCI_Kind C49705 Severity_Intensity_Scale_for_Adverse_Events CDISC NCI_Kind C49802 Trial_Title CDISC NCI_Kind C49838 Barrier_Device_Component FDA Equipment_Kind C49858 Device_Camera_Device_Component FDA Equipment_Kind C49900 Cuff_Device_Component FDA Equipment_Kind C50008 Interface_Device_Component FDA Equipment_Kind C50047 Memory_Device_Component FDA Equipment_Kind C50048 Read_Only_Memory_Device_Component FDA Equipment_Kind C50051 Random_Access_Memory_Device_Component FDA Equipment_Kind C50332 CPU FDA Equipment_Kind C50343 Cannula_Device_Component FDA Equipment_Kind C50399 Dictionary_Name CDISC NCI_Kind C50400 Age_Units CDISC Properties_or_Attributes_Kind C50434 Drainage FDA Activity_Kind C50453 Acoustic_Trauma FDA Findings_and_Disorders_Kind C50474 Bradypnea FDA Findings_and_Disorders_Kind C50494 Choking FDA Findings_and_Disorders_Kind C50501 Complete_Heart_Block FDA Findings_and_Disorders_Kind C50518 Cut FDA Findings_and_Disorders_Kind C50529 Delayed_Union_Fracture FDA Findings_and_Disorders_Kind C50535 Discomfort FDA Findings_and_Disorders_Kind C50553 Exit_Block FDA Findings_and_Disorders_Kind C50554 Expulsion FDA Findings_and_Disorders_Kind C50589 Hyperthermia FDA Findings_and_Disorders_Kind C50623 Irritability FDA Findings_and_Disorders_Kind C50625 Ischemic_Heart_Disease FDA Findings_and_Disorders_Kind C50635 Loss_Of_Consciousness FDA Findings_and_Disorders_Kind C50644 Lung_Overinflation FDA Findings_and_Disorders_Kind C50658 Muscle_Weakness FDA Findings_and_Disorders_Kind C50665 Needlestick_Puncture FDA Findings_and_Disorders_Kind C50685 Pallor FDA Findings_and_Disorders_Kind C50693 Perforation_Of_Esophagus FDA Findings_and_Disorders_Kind C50746 Sneezing FDA Findings_and_Disorders_Kind C50747 Sore_Throat FDA Findings_and_Disorders_Kind C50753 Staining FDA Findings_and_Disorders_Kind C50767 Tachypnea FDA Findings_and_Disorders_Kind C50777 Tooth_Fracture FDA Findings_and_Disorders_Kind C50815 Aortic_Valve_Replacement FDA Activity_Kind C50816 Tricuspid_Valve_Replacement FDA Activity_Kind C50817 Pulmonary_Valve_Replacement FDA Activity_Kind C50818 Heart_Valve_Repair FDA Activity_Kind C50819 Extubation FDA Activity_Kind C50820 Reinfusion FDA Activity_Kind C50822 Resuscitation FDA Activity_Kind C50824 Apicectomy FDA Activity_Kind C50825 Mitral_Valve_Replacement FDA Activity_Kind C50839 Established_Diagnosis FDA Activity_Kind C50841 Laceration_Of_Esophagus FDA Findings_and_Disorders_Kind C50888 Mitral_Insufficiency FDA Findings_and_Disorders_Kind C50901 Microcytic_Corneal_Edema FDA Findings_and_Disorders_Kind C50910 Osteopenia FDA Findings_and_Disorders_Kind C50911 Sudden_Cardiac_Death FDA Findings_and_Disorders_Kind C50913 Invalid_Data FDA NCI_Kind C50918 Endotoxin FDA Chemicals_and_Drugs_Kind C50921 Staphylococcus_Aureus FDA Organism_Kind C51282 Clinic FDA NCI_Kind C51804 Audiologist FDA NCI_Kind C51840 Pharmacist FDA NCI_Kind C51945 Ambulatory_Surgical_Facility FDA NCI_Kind C51957 Ambulatory_Surgical_Center FDA NCI_Kind C51959 Attorney FDA NCI_Kind C51960 Biomedical_Engineer FDA NCI_Kind C51963 Blood_Bank FDA NCI_Kind C51964 Bloodmobile FDA NCI_Kind C51966 Free-Standing_Cardiac_Catheterization_Laboratory FDA NCI_Kind C51967 Chemotherapy_Center FDA NCI_Kind C51968 Company_Representative FDA NCI_Kind C52181 _5-Hydroxytryptophan FDA Chemicals_and_Drugs_Kind C52198 Ropivicaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C52654 Dentist FDA NCI_Kind C52668 Intervention_Required FDA Properties_or_Attributes_Kind C53053 Type_of_Event FDA Properties_or_Attributes_Kind C53054 Product_Problem FDA NCI_Kind C53263 Other_Personal_Medical_History FDA Properties_or_Attributes_Kind C53265 Type_of_Device FDA Properties_or_Attributes_Kind C53272 Operator_of_Medical_Device FDA NCI_Kind C53273 Service_Personnel FDA NCI_Kind C53274 Device_Unattended FDA NCI_Kind C53287 Health_Care_Professional FDA NCI_Kind C53289 Other_Health_Care_Professional FDA NCI_Kind C53293 Dental_Hygienist FDA NCI_Kind C53408 Alfuzosin_Hydrochloride FDA Chemicals_and_Drugs_Kind C53417 Emergency_Medical_Technician FDA NCI_Kind C53418 Medical_Technologist FDA NCI_Kind C53419 Nuclear_Medicine_Technologist FDA NCI_Kind C53420 Paramedic FDA NCI_Kind C53421 Phlebotomist FDA NCI_Kind C53422 Physical_Therapist FDA NCI_Kind C53423 Physician_Assistant FDA NCI_Kind C53424 Radiologic_Technologist FDA NCI_Kind C53425 Respiratory_Therapist FDA NCI_Kind C53427 Other_Caregiver FDA NCI_Kind C53428 Dental_Assistant FDA NCI_Kind C53429 Home_Health_Aid FDA NCI_Kind C53430 Medical_Assistant FDA NCI_Kind C53431 Nursing_Assistant FDA NCI_Kind C53432 Patient_Family_Member_or_Friend FDA NCI_Kind C53433 Hospital_Service_Technician FDA NCI_Kind C53441 Service_and_Testing_Personnel FDA NCI_Kind C53442 Medical_Equipment_Company_Technician_or_Representative FDA NCI_Kind C53446 Physicist FDA NCI_Kind C53447 Octreotide_Acetate FDA Chemicals_and_Drugs_Kind C53448 Risk_Manager FDA NCI_Kind C53449 Device_Available_for_Evaluation FDA NCI_Kind C53489 Systematized_Nomenclature_of_Medicine CDISC NCI_Kind C53511 Intensive_Care_Unit FDA NCI_Kind C53516 Operating_Room FDA NCI_Kind C53528 Urgent_Care_Center FDA NCI_Kind C53532 Hospice FDA NCI_Kind C53563 Single-Use_Device_Reprocessed_and_Reused_on_Patient FDA Equipment_Kind C53568 Consumer FDA NCI_Kind C53593 Reason_for_Non-Evaluation FDA NCI_Kind C53602 Device_Labeled_for_Single_Use FDA Equipment_Kind C53610 Replacement FDA Activity_Kind C53614 Reprocessor FDA NCI_Kind C53616 Manufacturer FDA NCI_Kind C53619 Corrective_Action_Number FDA Properties_or_Attributes_Kind C54026 Device_Problem FDA NCI_Kind C54067 Health_Professional FDA NCI_Kind C54344 Limitation_Of_Use FDA NCI_Kind C54354 Pharmacokinetic_Effect_Consequences FDA Findings_and_Disorders_Kind C54383 Type_Of_Consequence FDA Properties_or_Attributes_Kind C54398 Intent_To_Treat FDA NCI_Kind C54404 Intent_For_Prophylaxis FDA NCI_Kind C54415 Intent_For_Diagnostic FDA NCI_Kind C54447 Individual_Case_Safety_Report_Terminology FDA NCI_Kind C54450 Patient_Problem_Codes_FDA_CDRH FDA NCI_Kind C54451 Medical_Device_Problem_Codes_FDA_CDRH FDA NCI_Kind C54452 Structured_Product_Labeling_Terminology FDA NCI_Kind C54453 Structured_Product_Labeling_Color_Terminology FDA NCI_Kind C54454 Structured_Product_Labeling_Shape_Terminology FDA NCI_Kind C54455 Structured_Product_Labeling_Drug_Route_of_Administration_Terminology FDA NCI_Kind C54456 Structured_Product_Labeling_Pharmaceutical_Dosage_Form_Terminology FDA NCI_Kind C54457 Structured_Product_Labeling_Package_Type_Terminology FDA NCI_Kind C54458 Structured_Product_Labeling_Potency_Terminology FDA NCI_Kind C54459 Structured_Product_Labeling_DEA_Schedule_Terminology FDA NCI_Kind C54577 Medical_Device_Component_Or_Accessory_Terminology_CDRH FDA NCI_Kind C54580 Type_of_Event_ICSR_Terminology FDA NCI_Kind C54583 Adverse_Event_Outcome_ICSR_Terminology FDA NCI_Kind C54584 Operator_of_Medical_Device_ICSR_Terminology FDA NCI_Kind C54585 Occupation_ICSR_Terminology FDA NCI_Kind C54587 Report_Source_ICSR_Terminology FDA NCI_Kind C54588 Type_Of_Report_ICSR_Terminology FDA NCI_Kind C54590 Location_Of_Event_Occurrence_ICSR_Terminology FDA NCI_Kind C54591 Type_of_Reportable_Event_ICSR_Terminology FDA NCI_Kind C54592 Type_Of_Follow-Up_ICSR_Terminology FDA NCI_Kind C54593 Reason_For_Non-Evaluation_ICSR_Terminology FDA NCI_Kind C54594 Type_Of_Remedial_Action_ICSR_Terminology FDA NCI_Kind C54595 Device_Usage_ICSR_Terminology FDA NCI_Kind C54596 Type_Of_Reporter_ICSR_Terminology FDA NCI_Kind C54598 Type_Of_Manufacturer_ICSR_Terminology FDA NCI_Kind C54599 Limitation_Of_Use_Structured_Product_Labeling_Terminology FDA NCI_Kind C54600 Pharmacokinetic_Effect_Consequences_Structured_Product_Labeling_Terminology FDA NCI_Kind C54602 Increased_Peak_Drug_Blood_Concentration FDA Findings_and_Disorders_Kind C54603 Increased_Drug_Half_Life FDA Findings_and_Disorders_Kind C54604 Increased_Time_To_Peak_Drug_Blood_Concentration FDA Findings_and_Disorders_Kind C54605 Increased_Drug_AUC FDA Findings_and_Disorders_Kind C54606 Decreased_Peak_Drug_Blood_Concentration FDA Findings_and_Disorders_Kind C54607 Decreased_Drug_Half_Life FDA Findings_and_Disorders_Kind C54608 Decreased_Time_To_Peak_Drug_Blood_Concentration FDA Findings_and_Disorders_Kind C54609 Decreased_Drug_AUC FDA Findings_and_Disorders_Kind C54610 Increased_Concomitant_Drug_Peak_Blood_Concentration FDA Findings_and_Disorders_Kind C54611 Increased_Concomitant_Drug_Half_Life FDA Findings_and_Disorders_Kind C54612 Increased_Time_To_Concomitant_Drug_Peak_Blood_Concentration FDA Findings_and_Disorders_Kind C54613 Increased_Concomitant_Drug_AUC FDA Findings_and_Disorders_Kind C54614 Decreased_Concomitant_Drug_AUC FDA Findings_and_Disorders_Kind C54615 Decreased_Concomitant_Drug_Peak_Blood_Concentration FDA Findings_and_Disorders_Kind C54617 Decreased_Time_To_Concomitant_Drug_Peak_Blood_Concentration FDA Findings_and_Disorders_Kind C54618 Structured_Product_Labeling_Type_Of_Drug_Interaction_Consequence_Terminology FDA NCI_Kind C54619 Structured_Product_Labeling_Medical_Product_Intent_Of_Use_Terminology FDA NCI_Kind C54708 Drug_Interaction FDA Biological_Process_Kind C54711 Atmosphere_Pressure CDISC Properties_or_Attributes_Kind C60654 Limitation_Of_Use_Based_On_Conditional_Approval FDA NCI_Kind C60655 Limitation_Of_Use_Based_On_Duration_Of_Use FDA NCI_Kind C60811 Pediatric_Death FDA Findings_and_Disorders_Kind C60891 Concentrate_Dosage_Form FDA Equipment_Kind C61318 Methazolamide FDA Chemicals_and_Drugs_Kind C61375 Tissue_Breakdown FDA Findings_and_Disorders_Kind C61439 Meloxicam FDA Chemicals_and_Drugs_Kind C61523 Abacavir_Base FDA Chemicals_and_Drugs_Kind C61525 Acebutolol_Base FDA Chemicals_and_Drugs_Kind C61527 Atorvastatin_Base FDA Chemicals_and_Drugs_Kind C61608 Clomipramine FDA Chemicals_and_Drugs_Kind C61610 Meclizine FDA Chemicals_and_Drugs_Kind C61612 Metformin FDA Chemicals_and_Drugs_Kind C61621 Acetarsone FDA Chemicals_and_Drugs_Kind C61623 Acetic_Acid FDA Chemicals_and_Drugs_Kind C61625 Alendronic_Acid FDA Chemicals_and_Drugs_Kind C61626 Alfentanil FDA Chemicals_and_Drugs_Kind C61627 Alfuzosin FDA Chemicals_and_Drugs_Kind C61628 Almotriptan_Malate FDA Chemicals_and_Drugs_Kind C61629 Alpha-D-Glucopyranose_Monohydrate FDA Chemicals_and_Drugs_Kind C61630 Alphaprodine_Hydrochloride FDA Chemicals_and_Drugs_Kind C61631 Aluminum_Stearate FDA Chemicals_and_Drugs_Kind C61632 Amantadine FDA Chemicals_and_Drugs_Kind C61634 Aminobenzoic_Acid FDA Chemicals_and_Drugs_Kind C61635 Amlodipine FDA Chemicals_and_Drugs_Kind C61636 Amphetamine_Aspartate FDA Chemicals_and_Drugs_Kind C61664 Cefotetan FDA Chemicals_and_Drugs_Kind C61697 Dantrolene FDA Chemicals_and_Drugs_Kind C61698 Dantrolene_Sodium FDA Chemicals_and_Drugs_Kind C61699 Deserpidine FDA Chemicals_and_Drugs_Kind C61700 Desipramine FDA Chemicals_and_Drugs_Kind C61701 Desmopressin FDA Chemicals_and_Drugs_Kind C61702 Desonide FDA Chemicals_and_Drugs_Kind C61703 Desvenlafaxine FDA Chemicals_and_Drugs_Kind C61704 Desvenlafaxine_Succinate FDA Chemicals_and_Drugs_Kind C61705 Dexbrompheniramine FDA Chemicals_and_Drugs_Kind C61706 Dexbrompheniramine_Maleate FDA Chemicals_and_Drugs_Kind C61707 Dexchlorpheniramine FDA Chemicals_and_Drugs_Kind C61708 Dextroamphetamine_Saccharate FDA Chemicals_and_Drugs_Kind C61709 DL-Limonene FDA Chemicals_and_Drugs_Kind C61710 DL-Liothyronine FDA Chemicals_and_Drugs_Kind C61711 DL-Propoxyphene FDA Chemicals_and_Drugs_Kind C61712 DL-5-Hydroxytryptophan FDA Chemicals_and_Drugs_Kind C61713 DL-Phenylalanine FDA Chemicals_and_Drugs_Kind C61714 D-Limonene FDA Chemicals_and_Drugs_Kind C61715 D-Phenylalanine FDA Chemicals_and_Drugs_Kind C61716 Dextrose_Anhydrous FDA Chemicals_and_Drugs_Kind C61717 Dextrose_Monohydrate FDA Chemicals_and_Drugs_Kind C61718 Sodium_Lactate_D FDA Chemicals_and_Drugs_Kind C61719 Dextrothyroxine FDA Chemicals_and_Drugs_Kind C61720 Dicyclomine FDA Chemicals_and_Drugs_Kind C61721 Diethylpropion FDA Chemicals_and_Drugs_Kind C61722 Diflorasone FDA Chemicals_and_Drugs_Kind C61723 Digitalin FDA Chemicals_and_Drugs_Kind C61724 Dihydrostreptomycin FDA Chemicals_and_Drugs_Kind C61725 Diltazem FDA Chemicals_and_Drugs_Kind C61726 Dimyristoyl_Lecithin FDA Chemicals_and_Drugs_Kind C61727 Dinoprostone FDA Chemicals_and_Drugs_Kind C61728 Diphenhydramine FDA Chemicals_and_Drugs_Kind C61729 Dipivefrin FDA Chemicals_and_Drugs_Kind C61730 Disopyramide FDA Chemicals_and_Drugs_Kind C61731 DL-Alanine FDA Chemicals_and_Drugs_Kind C61732 DL-Proline FDA Chemicals_and_Drugs_Kind C61733 Dobutamine FDA Chemicals_and_Drugs_Kind C61734 Docetaxel_Anhydrous FDA Chemicals_and_Drugs_Kind C61735 Dolasetron FDA Chemicals_and_Drugs_Kind C61736 Doxapram FDA Chemicals_and_Drugs_Kind C61737 Doxazosin FDA Chemicals_and_Drugs_Kind C61738 Doxylamine FDA Chemicals_and_Drugs_Kind C61739 D-Serine FDA Chemicals_and_Drugs_Kind C61740 Econazole FDA Chemicals_and_Drugs_Kind C61741 Edetate_Disodium FDA Chemicals_and_Drugs_Kind C61742 Edetic_Acid FDA Chemicals_and_Drugs_Kind C61743 Emedastine FDA Chemicals_and_Drugs_Kind C61744 Emedastine_Difumarate FDA Chemicals_and_Drugs_Kind C61745 Enclomiphene_Citrate FDA Chemicals_and_Drugs_Kind C61746 Entacapone FDA Chemicals_and_Drugs_Kind C61747 Epiandrosterone FDA Chemicals_and_Drugs_Kind C61748 Epoprostenol FDA Chemicals_and_Drugs_Kind C61749 Eprosartan FDA Chemicals_and_Drugs_Kind C61750 Erdosteine FDA Chemicals_and_Drugs_Kind C61751 Ergotamine FDA Chemicals_and_Drugs_Kind C61752 Ertapenem FDA Chemicals_and_Drugs_Kind C61753 Ertapenem_Sodium FDA Chemicals_and_Drugs_Kind C61754 Escitalopram FDA Chemicals_and_Drugs_Kind C61755 Ethambutol FDA Chemicals_and_Drugs_Kind C61756 Ethanolamine FDA Chemicals_and_Drugs_Kind C61757 Ethanolamine_Oleate FDA Chemicals_and_Drugs_Kind C61758 Ethchlorvynol FDA Chemicals_and_Drugs_Kind C61759 Fenoldopam FDA Chemicals_and_Drugs_Kind C61760 Fenoprofen FDA Chemicals_and_Drugs_Kind C61761 Fenoprofen_Calcium FDA Chemicals_and_Drugs_Kind C61762 Fentanyl_Hydrochloride FDA Chemicals_and_Drugs_Kind C61763 Ferrous_Fumarate FDA Chemicals_and_Drugs_Kind C61764 Fexofenadine FDA Chemicals_and_Drugs_Kind C61765 Flavoxate FDA Chemicals_and_Drugs_Kind C61766 Fluorescein FDA Chemicals_and_Drugs_Kind C61767 Fluticasone FDA Chemicals_and_Drugs_Kind C61768 Fluvastatin FDA Chemicals_and_Drugs_Kind C61769 Fluvoxamine FDA Chemicals_and_Drugs_Kind C61770 Fomivirsen_Sodium FDA Chemicals_and_Drugs_Kind C61771 Fosamprenavir_Calcium FDA Chemicals_and_Drugs_Kind C61772 Fosfomycin FDA Chemicals_and_Drugs_Kind C61773 Gamma-Hydroxybutyric_Acid FDA Chemicals_and_Drugs_Kind C61774 Ganirelix_Acetate FDA Chemicals_and_Drugs_Kind C61775 Gemifloxacin FDA Chemicals_and_Drugs_Kind C61776 Gentian_Violet FDA Chemicals_and_Drugs_Kind C61777 Gluconic_Acid FDA Chemicals_and_Drugs_Kind C61778 Glycol_Dimethacrylate FDA Chemicals_and_Drugs_Kind C61779 Guanfacine FDA Chemicals_and_Drugs_Kind C61780 Halazepam FDA Chemicals_and_Drugs_Kind C61781 Halobetasol FDA Chemicals_and_Drugs_Kind C61782 Heptanoic_Acid FDA Chemicals_and_Drugs_Kind C61783 Homatropine FDA Chemicals_and_Drugs_Kind C61784 Homatropine_Methylbromide FDA Chemicals_and_Drugs_Kind C61785 Hydrocortisone_Acetate FDA Chemicals_and_Drugs_Kind C61786 Hydrocortisone_Hemisuccinate FDA Chemicals_and_Drugs_Kind C61787 Hydroxyamphetamine FDA Chemicals_and_Drugs_Kind C61788 Imipramine_Pamoate FDA Chemicals_and_Drugs_Kind C61789 Inamrinone FDA Chemicals_and_Drugs_Kind C61790 Iobenguane_I-131 FDA Chemicals_and_Drugs_Kind C61791 Iodipamide FDA Chemicals_and_Drugs_Kind C61792 Iothalamic_Acid FDA Chemicals_and_Drugs_Kind C61793 Ioxaglic_Acid FDA Chemicals_and_Drugs_Kind C61794 Ipratropium_Cation FDA Chemicals_and_Drugs_Kind C61795 Isoxsuprine FDA Chemicals_and_Drugs_Kind C61796 Ivermectin FDA Chemicals_and_Drugs_Kind C61797 Ketamine FDA Chemicals_and_Drugs_Kind C61798 Ketorolac_Tromethamine FDA Chemicals_and_Drugs_Kind C61799 Ketotifen FDA Chemicals_and_Drugs_Kind C61800 Lanthanum FDA Chemicals_and_Drugs_Kind C61801 Lanthanum_Carbonate FDA Chemicals_and_Drugs_Kind C61802 Lanthanum_Ion FDA Chemicals_and_Drugs_Kind C61803 L-Carbidopa_Anhydrous FDA Chemicals_and_Drugs_Kind C61805 Levobupivacaine_Hydrochloride FDA Chemicals_and_Drugs_Kind C61806 Levocabastine FDA Chemicals_and_Drugs_Kind C61809 Levomenthol FDA Chemicals_and_Drugs_Kind C61810 Levorphanol FDA Chemicals_and_Drugs_Kind C61811 Lincomycin FDA Chemicals_and_Drugs_Kind C61812 Lithium_Citrate FDA Chemicals_and_Drugs_Kind C61813 Lodoxamide FDA Chemicals_and_Drugs_Kind C61814 Lomefloxacin FDA Chemicals_and_Drugs_Kind C61817 L-Tyrosine FDA Chemicals_and_Drugs_Kind C61832 Mercaptopurine_Anhydrous FDA Chemicals_and_Drugs_Kind C61833 Meropenem_Anhydrous FDA Chemicals_and_Drugs_Kind C61851 Mupirocin_Calcium FDA Chemicals_and_Drugs_Kind C61948 Sorafenib FDA Chemicals_and_Drugs_Kind C62002 Amiodarone_Base FDA Chemicals_and_Drugs_Kind C62005 Amitriptyline_Base FDA Chemicals_and_Drugs_Kind C62006 Amphetamine_Base FDA Chemicals_and_Drugs_Kind C62008 Arginine_Base FDA Chemicals_and_Drugs_Kind C62010 Bromocriptine_Base FDA Chemicals_and_Drugs_Kind C62011 Bupivacaine_Base FDA Chemicals_and_Drugs_Kind C62013 Buspirone_Base FDA Chemicals_and_Drugs_Kind C62021 Cephalothin_Base FDA Chemicals_and_Drugs_Kind C62024 Diphenoxylate_Base FDA Chemicals_and_Drugs_Kind C62026 Dorzolamide_Base FDA Chemicals_and_Drugs_Kind C62030 Flurazepam_Base FDA Chemicals_and_Drugs_Kind C62032 Hydralazine_Base FDA Chemicals_and_Drugs_Kind C62033 Hydrocodone_Base FDA Chemicals_and_Drugs_Kind C62035 Imatinib_Base FDA Chemicals_and_Drugs_Kind C62039 Imipramine_Base FDA Chemicals_and_Drugs_Kind C62041 Isoproterenol_Base FDA Chemicals_and_Drugs_Kind C62043 Levobunolol_Base FDA Chemicals_and_Drugs_Kind C62044 Methadone_Base FDA Chemicals_and_Drugs_Kind C62047 Mexiletine_Base FDA Chemicals_and_Drugs_Kind C62048 Miconazole_Base FDA Chemicals_and_Drugs_Kind C62049 Midazolam_Base FDA Chemicals_and_Drugs_Kind C62052 Moxifloxacin_Base FDA Chemicals_and_Drugs_Kind C62053 Nafcillin_Base FDA Chemicals_and_Drugs_Kind C62055 Naltrexone_Base FDA Chemicals_and_Drugs_Kind C62059 Norethindrone_Base FDA Chemicals_and_Drugs_Kind C62060 Nortriptyline_Base FDA Chemicals_and_Drugs_Kind C62061 Oseltamivir_Base FDA Chemicals_and_Drugs_Kind C62063 Oxacillin_Base FDA Chemicals_and_Drugs_Kind C62064 Penicillin_V_Base FDA Chemicals_and_Drugs_Kind C62065 Phenoxybenzamine_Base FDA Chemicals_and_Drugs_Kind C62066 Phentolamine_Base FDA Chemicals_and_Drugs_Kind C62067 Phenylephrine_Base FDA Chemicals_and_Drugs_Kind C62069 Piperacillin_Base FDA Chemicals_and_Drugs_Kind C62070 Pravastatin_Base FDA Chemicals_and_Drugs_Kind C62071 Primaquine_Base FDA Chemicals_and_Drugs_Kind C62074 Quinapril_Base FDA Chemicals_and_Drugs_Kind C62077 Sulfacetamide_Base FDA Chemicals_and_Drugs_Kind C62079 Tazobactam_Base FDA Chemicals_and_Drugs_Kind C62080 Levothyroxine FDA Chemicals_and_Drugs_Kind C62081 Thiethylperazine_Base FDA Chemicals_and_Drugs_Kind C62082 Tobramycin_Base FDA Chemicals_and_Drugs_Kind C62083 Tolterodine_Base FDA Chemicals_and_Drugs_Kind C62098 Norepinephrine_Base FDA Chemicals_and_Drugs_Kind C62596 FDA_Center_For_Devices_And_Radiological_Health_Terminology FDA NCI_Kind C62624 Oxidized_Glutathione FDA Chemicals_and_Drugs_Kind C63538 Dextropropoxyphene_Hydrochloride FDA Chemicals_and_Drugs_Kind